inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading gild fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap accountspayableandotheraccruedliabilitiescurrenthttp fasb org gaap accountspayableandotheraccruedliabilitiescurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap cumulativeeffectperiodofadoptionadjustmentmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap countrygild gaap minimummemberus gaap gaap machineryandequipmentmembersrt minimummemberus gaap maximummemberus gaap hivproductsatriplamembercountry europemembergild otherinternationalmembergild hivproductsatriplamembercountry europemembergild otherinternationalmembergild hivproductsatriplamembercountry europemembergild otherinternationalmembergild hivproductsbiktarvymembercountry hivproductsbiktarvymembersrt otherinternationalmembergild hivproductsbiktarvymembercountry hivproductsbiktarvymembersrt otherinternationalmembergild hivproductsbiktarvymembercountry hivproductsbiktarvymembersrt otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild hivproductsgenvoyamembercountry hivproductsgenvoyamembersrt hivproductsgenvoyamembergild hivproductsgenvoyamembercountry hivproductsgenvoyamembersrt hivproductsgenvoyamembergild hivproductsgenvoyamembercountry hivproductsgenvoyamembersrt hivproductsgenvoyamembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild hivproductsstribildmembercountry hivproductsstribildmembersrt otherinternationalmembergild hivproductsstribildmembercountry hivproductsstribildmembersrt otherinternationalmembergild hivproductsstribildmembercountry hivproductsstribildmembersrt otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild productsrevenuesharesymtuzamembercountry productsrevenuesharesymtuzamembersrt otherinternationalmembergild productsrevenuesharesymtuzamembercountry productsrevenuesharesymtuzamembersrt otherinternationalmembergild productsrevenuesharesymtuzamembercountry productsrevenuesharesymtuzamembersrt otherinternationalmembergild productsotherhivmembercountry productsotherhivmembersrt otherinternationalmembergild productsotherhivmembercountry productsotherhivmembersrt otherinternationalmembergild productsotherhivmembercountry productsotherhivmembersrt otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild hcvproductsledipasvirsofosbuvirmembercountry europemembergild otherinternationalmembergild hcvproductsledipasvirsofosbuvirmembercountry europemembergild otherinternationalmembergild hcvproductsledipasvirsofosbuvirmembercountry europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild otherhcvmembercountry otherhcvmembersrt otherinternationalmembergild otherhcvmembercountry otherhcvmembersrt otherinternationalmembergild otherhcvmembercountry otherhcvmembersrt otherinternationalmembergild hcvproductsalesmembercountry hcvproductsalesmembersrt hcvproductsalesmembergild hcvproductsalesmembercountry hcvproductsalesmembersrt hcvproductsalesmembergild hcvproductsalesmembercountry hcvproductsalesmembersrt hcvproductsalesmembergild hepatitisbvirushepatitisdeltavirusproductvemlidymembercountry hepatitisbvirushepatitisdeltavirusproductvemlidymembersrt hepatitisbvirushepatitisdeltavirusproductvemlidymembergild hepatitisbvirushepatitisdeltavirusproductvemlidymembercountry hepatitisbvirushepatitisdeltavirusproductvemlidymembersrt hepatitisbvirushepatitisdeltavirusproductvemlidymembergild hepatitisbvirushepatitisdeltavirusproductvemlidymembercountry hepatitisbvirushepatitisdeltavirusproductvemlidymembersrt hepatitisbvirushepatitisdeltavirusproductvemlidymembergild hepatitisbvirushepatitisdeltavirusproductvireadmembercountry europemembergild otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductvireadmembercountry europemembergild otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductvireadmembercountry europemembergild otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductothermembercountry hepatitisbvirushepatitisdeltavirusproductothermembersrt otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductothermembercountry hepatitisbvirushepatitisdeltavirusproductothermembersrt otherinternationalmembergild hepatitisbvirushepatitisdeltavirusproductothermembercountry hepatitisbvirushepatitisdeltavirusproductothermembersrt otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild celltherapyproductstecartusmembercountry celltherapyproductstecartusmembersrt otherinternationalmembergild celltherapyproductstecartusmembercountry celltherapyproductstecartusmembersrt otherinternationalmembergild celltherapyproductstecartusmembercountry celltherapyproductstecartusmembersrt otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild trodelvymembercountry europemembergild otherinternationalmembergild trodelvymembercountry europemembergild otherinternationalmembergild trodelvymembercountry europemembergild otherinternationalmembergild otherproductsambisomemembercountry otherproductsambisomemembersrt otherproductsambisomemembergild otherproductsambisomemembercountry otherproductsambisomemembersrt otherproductsambisomemembergild otherproductsambisomemembercountry otherproductsambisomemembersrt otherproductsambisomemembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild usgild europemembergild otherinternationalmembergild otherproductsranexamembercountry otherproductsranexamembersrt otherproductsranexamembergild otherproductsranexamembercountry otherproductsranexamembersrt otherproductsranexamembergild otherproductsranexamembercountry otherproductsranexamembersrt otherproductsranexamembergild otherproductszydeligmembercountry otherproductszydeligmembersrt otherproductszydeligmembergild otherproductszydeligmembercountry otherproductszydeligmembersrt otherproductszydeligmembergild otherproductszydeligmembercountry otherproductszydeligmembersrt otherproductszydeligmembergild otherproductsothermembercountry otherproductsothermembersrt otherproductsothermembergild otherproductsothermembercountry otherproductsothermembersrt otherproductsothermembergild otherproductsothermembercountry otherproductsothermembersrt otherproductsothermembergild otherproductstotalotherproductsalesmembercountry otherproductstotalotherproductsalesmembersrt otherinternationalmembergild otherproductstotalotherproductsalesmembercountry otherproductstotalotherproductsalesmembersrt otherinternationalmembergild otherproductstotalotherproductsalesmembercountry otherproductstotalotherproductsalesmembersrt otherinternationalmembergild gaap productmembercountry gaap productmembersrt otherinternationalmemberus gaap gaap productmembercountry gaap productmembersrt otherinternationalmemberus gaap gaap productmembercountry gaap productmembersrt otherinternationalmemberus gaap royaltycontractandothermembercountry royaltycontractandothermembersrt otherinternationalmembergild royaltycontractandothermembercountry royaltycontractandothermembersrt otherinternationalmembergild royaltycontractandothermembercountry royaltycontractandothermembersrt otherinternationalmembergild amerisourcebergencorpmemberus gaap customerconcentrationriskmemberus gaap amerisourcebergencorpmemberus gaap customerconcentrationriskmemberus gaap amerisourcebergencorpmemberus gaap customerconcentrationriskmemberus gaap cardinalhealthincmemberus gaap customerconcentrationriskmemberus gaap cardinalhealthincmemberus gaap customerconcentrationriskmemberus gaap cardinalhealthincmemberus gaap customerconcentrationriskmemberus gaap mckessoncorpmemberus gaap customerconcentrationriskmemberus gaap mckessoncorpmemberus gaap customerconcentrationriskmemberus gaap mckessoncorpmemberus gaap customerconcentrationriskmemberus gaap gaap gaap ustreasurysecuritiesmemberus gaap gaap ustreasurysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap ustreasurysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap ustreasurysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap ustreasurysecuritiesmemberus gaap gaap ustreasurysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap ustreasurysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap ustreasurysecuritiesmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap corporatedebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmembergild residentialmortgageandassetbackedsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmembergild residentialmortgageandassetbackedsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosuremembergild gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmembergild residentialmortgageandassetbackedsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmembergild residentialmortgageandassetbackedsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosuremembergild gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmembergild gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmembergild galapagosmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmembergild galapagosmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap equitysecuritiesmembergild gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmembergild gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmembergild galapagosmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmembergild galapagosmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap equitysecuritiesmembergild gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap arcusbiosciencesincmemberus gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap equitysecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap deferredcompensationplanmemberus gaap deferredcompensationplanmemberus gaap fairvaluemeasurementsrecurringmemberus gaap deferredcompensationplanmemberus gaap fairvaluemeasurementsrecurringmemberus gaap deferredcompensationplanmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap deferredcompensationplanmemberus gaap deferredcompensationplanmemberus gaap fairvaluemeasurementsrecurringmemberus gaap deferredcompensationplanmemberus gaap fairvaluemeasurementsrecurringmemberus gaap deferredcompensationplanmemberus gaap fairvaluemeasurementsrecurringmemberus gaap foreigncurrencyderivativecontractsmemberus gaap gaap foreigncurrencyderivativecontractsmemberus gaap fairvaluemeasurementsrecurringmemberus gaap foreigncurrencyderivativecontractsmemberus gaap fairvaluemeasurementsrecurringmemberus gaap foreigncurrencyderivativecontractsmemberus gaap fairvaluemeasurementsrecurringmemberus gaap foreigncurrencyderivativecontractsmemberus gaap gaap foreigncurrencyderivativecontractsmemberus gaap fairvaluemeasurementsrecurringmemberus gaap foreigncurrencyderivativecontractsmemberus gaap fairvaluemeasurementsrecurringmemberus gaap foreigncurrencyderivativecontractsmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmembergild myrgmbhmemberus gaap gaap fairvaluemeasurementsrecurringmembergild myrgmbhmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosuremembergild gaap gaap fairvaluemeasurementsrecurringmembergild gaap fairvaluemeasurementsrecurringmembergild myrgmbhmemberus gaap gaap fairvaluemeasurementsrecurringmembergild myrgmbhmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap estimateoffairvaluefairvaluedisclosuremembergild gaap cashandcashequivalentsmemberus gaap gaap cashandcashequivalentsmemberus gaap gaap prepaidexpensesandothercurrentassetsmemberus gaap gaap prepaidexpensesandothercurrentassetsmemberus gaap gaap equitysecuritiesmemberus gaap gaap equitysecuritiesmemberus gaap gaap gaap gileadfoundationmembergild gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap carryingreportedamountfairvaluedisclosurememberus gaap gaap fairvaluemeasurementsrecurringmembergild myrgmbhmemberus gaap gaap fairvaluemeasurementsnonrecurringmembergild immunomedicsincmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap fairvaluemeasurementsnonrecurringmembergild immunomedicsincmemberus gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap fairvaluemeasurementsnonrecurringmemberus gaap carryingreportedamountfairvaluedisclosuremembergild immunomedicsincmemberus gaap gaap fairvaluemeasurementsnonrecurringmemberus gaap carryingreportedamountfairvaluedisclosuremembergild immunomedicsincmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap othernoncurrentliabilitiesmemberus gaap gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap othernoncurrentliabilitiesmemberus gaap gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap maximummembergild hepcludexmembergild gaap inprocessresearchanddevelopmentmembergild hepcludexmembergild myrgmbhmemberus gaap hepcludexmembergild hepcludexmembergild hepcludexmembergild myrgmbhmemberus gaap immunomedicsincmemberus gaap mediumtermnotesmembergild immunomedicsincmembergild gaap inprocessresearchanddevelopmentmembergild immunomedicsincmemberus gaap immunomedicsincmembergild gaap immunomedicsincmemberus gaap gaap measurementinputriskfreeinterestratemembergild immunomedicsincmemberus gaap gaap inprocessresearchanddevelopmentmembergild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap mercksharpdohmecorplicenseandcollaborationagreementmembergild mercksharpdohmecorplicenseandcollaborationagreementmembergild injectableformulationproductmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcusstockpurchaseagreementmembergild arcusstockpurchaseagreementmembergild arcusstockpurchaseagreementmembergild arcusstockpurchaseagreementmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild arcuscollaborationagreementandstockpurchaseagreementsmembergild pionyrmergerandoptionagreementsmembergild pionyrmergerandoptionagreementsmembergild pionyrmergerandoptionagreementsmembergild pionyrmergerandoptionagreementsmembergild pionyrmergerandoptionagreementsmembergild pionyrimmunotherapeuticsincmembergild pionyrimmunotherapeuticsincmembergild pionyrimmunotherapeuticsincmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild tizonamergerandoptionagreementsmembergild maximummembergild tizonamergerandoptionagreementsmembergild developmentagreementmembergild tangotherapeuticsincmembergild tangotherapeuticsincmembersrt maximummembergild jouncetherapeuticsincmembergild jouncetherapeuticsincmembergild jouncetherapeuticsincmembergild jouncetherapeuticsincmembergild filgotiniblicenseandcollaborationagreementwithgalapagosmembergild eurxbrli galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagossubscriptionagreementmembergild galapagoscollaborationagreementmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmemberus gaap londoninterbankofferedratelibormembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmemberus gaap londoninterbankofferedratelibormembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap mediumtermnotesmembergild gaap mediumtermnotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap gaap gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap gaap mediumtermnotesmembergild gaap seniornotesmembergild gaap gaap seniornotesmembergild gaap seniornotesmembergild gaap gaap gaap seniornotesmembergild minimummemberus gaap seniornotesmembergild gaap seniornotesmembergild gaap mediumtermnotesmembergild gaap mediumtermnotesmembergild gaap mediumtermnotesmembergild gaap lineofcreditmemberus gaap revolvingcreditfacilitymembergild gaap lineofcreditmemberus gaap revolvingcreditfacilitymembergild gaap lineofcreditmembergild gaap gaap lineofcreditmembergild gaap gaap lineofcreditmembergild gaap gaap lineofcreditmembergild gaap gaap scenarioforecastmembergild gaap subsequenteventmembergild lawsuitgild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap commonstockmembergild gaap commonstockmembergild gaap commonstockmembergild gaap employeestockoptionmembersrt gaap employeestockoptionmembersrt gaap gaap gaap gaap gaap minimummemberus gaap maximummemberus gaap minimummemberus gaap maximummemberus gaap minimummemberus gaap maximummemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap restrictedstockandperformanceshareawardsmembergild restrictedstockandperformanceshareawardsmembergild restrictedstockandperformanceshareawardsmembergild fairvalueatvestingdatemembergild fairvalueatvestingdatemembergild fairvalueatvestingdatemembergild gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap united state security and exchange commissionwashington form mark one annual report pursuant to section or of the security exchange act of the fiscal year ended december transition report pursuant to section or of the security exchange act of for the transition period from to commission file no gilead science inc exact name of registrant specified in it charter state or other jurisdiction of incorporation or organization irs employer identification no lakeside drive foster city california address of principal executive office including zip code registrant telephone number including area code security registered pursuant to section of the exchange act title of each classtrading symbol name of each exchange on which registeredcommon stock par value per sharegildthe nasdaq global select marketsecurities registered pursuant to section of the exchange act noneindicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or section of the exchange act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the exchange act the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control over financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no the aggregate market value of the voting and non voting common equity held by non affiliate of the registrant based upon the closing price of it common stock on the nasdaq global select market on june wa billion the number of share outstanding of the registrant common stock on february wa incorporated by reference specified portion of the registrant proxy statement which will be filed with the commission pursuant to regulation in connection with the registrant annual meeting of stockholder to be held on may are incorporated by reference into part iii of this report based on closing price of per share on june excludes share of the registrant common stock held by executive officer director and any stockholder whose ownership exceeds of registrant common stock outstanding at june exclusion of such share not be construed to indicate that any such person posse the power direct or indirect to direct or cause the direction of the management or policy of the registrant or that such person is controlled by or under common control with the registrant gilead science inc form annual reporttable of contentspart item staff safety ii item for registrant common equity related stockholder matter and issuer purchase of equity reserved discussion and analysis of financial condition and result of and qualitative disclosure about market statement and supplementary in and disagreement with accountant on accounting and financial and regarding foreign jurisdiction that prevent iii item executive officer and corporate ownership of certain beneficial owner and management and related stockholder relationship and related transaction and director accountant fee and iv item and financial statement or have right to various trademark copyright and trade name used in business including the following gilead gilead science ambisome atripla biktarvy cayston complera descovy descovy for prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada for prep tybost veklury vemlidy viread vosevi yescarta and zydelig this report also refers to trademark service mark and trade name of other company this annual report on form including the section entitled management discussion and analysis of financial condition and result of operation contains forward looking statement regarding future event and our future result that are subject to the safe harbor created under the security act of amended the security act and the security exchange act of amended the exchange act word such expect anticipate target goal project hope intend plan believe seek estimate continue may could should might forecast and variation of such word and similar expression are intended to identify such forward looking statement in addition any statement other statement of historical fact are forward looking statement including statement regarding overall trend operating cost and revenue trend liquidity and capital need plan and expectation with respect to product product candidate corporate strategy business and operation financial projection and the use of capital collaboration and licensing arrangement ongoing litigation and investigation matter statement regarding the anticipated future impact on our business of the ongoing coronavirus disease covid and related public health measure and other statement of expectation belief future plan and strategy anticipated event or trend and similar expression have based these forward looking statement on our current expectation about future event these statement are not guarantee of future performance and involve risk uncertainty and assumption that are difficult to predict our actual result may differ materially from those suggested by these forward looking statement for various reason including those identified in part item of this annual report on form under the heading risk factor given these risk and uncertainty you are cautioned not to place undue reliance on forward looking statement the forward looking statement included in this report are made only of the date hereof unless otherwise specified except required under federal security law and the rule and regulation of the security and exchange commission sec we not undertake and specifically decline any obligation to update any of these statement or to publicly announce the result of any revision to any forward looking statement the distribution of this report whether result of new information future event change in assumption or otherwise in evaluating our business you should carefully consider the risk described in the section entitled risk factor under part item of this annual report on form any of the risk contained herein could materially and adversely affect our business result of operation and financial condition item businessgilead science inc gilead we our or is biopharmaceutical company that ha pursued and achieved breakthrough in medicine for more than three decade with the goal of creating healthier world for all people we are committed to advancing innovative medicine to prevent and treat life threatening disease including hiv viral hepatitis and cancer we operate in more than country worldwide with headquarters in foster city california our businessproductsour innovative medicine represent advancement by offering first in class treatment greater efficacy enhanced mode of delivery more convenient treatment regimen improved resistance profile and reduced side effect our focus on innovation ha allowed to deliver marketed product across multiple therapeutic area in our primary revenue generating product and the approved indication in the united state follows hiv aid biktarvy is an oral formulation dosed once day for the treatment of hiv infection in certain patient biktarvy is single tablet regimen of fixed dose combination of our antiretroviral medication bictegravir emtricitabine and tenofovir alafenamide taf genvoya is an oral formulation dosed once day for the treatment of hiv infection in certain patient genvoya is single tablet regimen of fixed dose combination of our antiretroviral medicine elvitegravir cobicistat emtricitabine and taf descovy is an oral formulation indicated in combination with other antiretroviral agent for the treatment of hiv infection in certain patient descovy is fixed dose combination of our antiretroviral medication emtricitabine and taf descovy is also approved by food and drug administration fda for pre exposure prophylaxis prep indication to reduce the risk of sexually acquired hiv infection in certain at risk patient odefsey is an oral formulation dosed once day for the treatment of hiv infection in certain patient odefsey is single tablet regimen of fixed dose combination of our antiretroviral medication emtricitabine and taf and rilpivirine marketed by janssen science ireland unlimited company one of the janssen pharmaceutical company of johnson johnson janssen truvada is an oral formulation indicated in combination with other antiretroviral agent for the treatment of hiv infection in certain patient truvada is fixed dose combination of our antiretroviral medication tenofovir disoproxil fumarate tdf and emtricitabine truvada is also approved by fda for prep indication to reduce the risk of sexually acquired hiv infection in certain at risk patient complera eviplera is an oral formulation dosed once day for the treatment of hiv infection in certain patient the product marketed in the united state complera and in europe eviplera is single tablet regimen of fixed dose combination of our antiretroviral medication tdf and emtricitabine and janssen rilpivirine hydrochloride stribild is an oral formulation dosed once day for the treatment of hiv infection in certain patient stribild is single tablet regimen of fixed dose combination of our antiretroviral medication elvitegravir cobicistat tdf and emtricitabine atripla is an oral formulation indicated complete regimen for the treatment of hiv infection in certain patient atripla is fixed dose combination of our antiretroviral medication tdf and emtricitabine and bristol myers squibb company bm efavirenz covid veklury remdesivir an injection for intravenous use is nucleotide analog rna polymerase inhibitor indicated for the treatment of coronavirus disease covid in certain adult and child year of age and older and weighing at least pound kg are hospitalized or ii not hospitalized and have mild to moderate covid and are at high risk for progression to severe covid including hospitalization or death this indication received expedited approval by fda in january disease epclusa is an oral formulation of once daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis virus hcv infection in adult and certain pediatric patient with genotype or without cirrhosis or with compensated cirrhosis or ii with decompensated cirrhosis for use in combination with ribavirin in addition we have an authorized generic version of epclusa distributed by our separate subsidiary asegua therapeutic llc harvoni is an oral formulation of once daily single tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic hcv infection in adult with genotype or without cirrhosis or with compensated cirrhosis ii adult with genotype with decompensated cirrhosis in combination with ribavirin iii adult with genotype or who are liver transplant recipient without cirrhosis or with compensated cirrhosis in combination with ribavirin or iv certain pediatric patient with genotype or without cirrhosis or with compensated cirrhosis in addition we have an authorized generic version of harvoni distributed by our separate subsidiary asegua therapeutic llc vosevi is an oral formulation of once daily single tablet regimen of sofosbuvir velpatasvir and voxilaprevir for the treatment of chronic hcv infection in adult with genotype or previously treated with an inhibitor containing regimen or ii with genotype or previously treated with sofosbuvir containing regimen without an inhibitor vemlidy is an oral formulation of taf dosed once day for the treatment of chronic hepatitis virus hbv infection in adult with compensated liver disease viread is an oral formulation of tdf dosed once day for the treatment of chronic hbv infection in adult and certain pediatric patient hematology oncology cell therapy yescarta axicabtagene ciloleucel suspension for intravenous infusion is chimeric antigen receptor car cell therapy for the treatment of adult patient with relapsed or refractory large cell lymphoma after two or more line of systemic therapy including diffuse large cell lymphoma dlbcl not otherwise specified primary mediastinal large cell lymphoma high grade cell lymphoma and dlbcl arising from follicular lymphoma and ii adult patient with relapsed or refractory follicular lymphoma fl after two or more line of systemic therapy this indication is approved under accelerated approval by fda and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial tecartus brexucabtagene autoleucel suspension for intravenous infusion is car cell therapy for the treatment of adult patient with relapsed or refractory mantle cell lymphoma mcl and ii adult patient with relapsed or refractory cell precursor acute lymphoblastic leukemia all trodelvy sacituzumab govitecan hziy an injection for intravenous use is trop directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patient with unresectable locally advanced or metastatic triple negative breast cancer tnbc who have received two or more prior systemic therapy at least one of them for metastatic disease and ii adult patient with locally advanced or metastatic urothelial cancer who have previously received platinum containing chemotherapy and either programmed death receptor pd or programmed death ligand pd inhibitor this indication is approved under accelerated approval by fda and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial zydelig idelalisib is an oral formulation of kinase inhibitor for the treatment of patient with relapsed chronic lymphocytic leukemia in combination with rituximab for rituximab alone would be considered appropriate therapy due to other co morbidity other letairis ambrisentan is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension pah who group to improve exercise capacity and delay clinical worsening or ii in combination with tadalafil to reduce the risk of disease progression and hospitalization for worsening pah and to improve exercise ability ranexa ranolazine is an oral formulation of an extended release tablet of an antianginal for the treatment of chronic angina ambisome amphotericin liposome for injection is proprietary liposomal formulation of amphotericin an antifungal agent for the treatment of serious invasive fungal infection caused by various fungal specie in adult information about our revenue generating product including the amount of revenue contributed by the product listed see note revenue of the note to consolidated financial statement included in part ii item of this annual report on form revenue share and other revenueswe also generate revenue from other activity including revenue share from combination product royalty for outbound license of our intellectual property and other payment received from our collaboration with third party partner for example pursuant to our collaboration with janssen we receive revenue share from cobicistat emtricitabine and taf that are component of symtuza darunavir cobicistat emtricitabine taf fixed dose combination product commercialized by janssen we include our revenue share from symtuza in our product sale for description of our collaboration with janssen and other partner see note collaboration and other arrangement of the note to consolidated financial statement included in part ii item of this annual report on form commercialization and distributionwe have and international commercial sale operation with marketing subsidiary in more than country our product are marketed through our commercial team and or in conjunction with third party distributor and corporate partner our commercial team promote our product through direct field contact with physician hospital clinic and other healthcare provider we generally grant our third party distributor the exclusive right to promote our product in territory for specified period of time of our agreement with these distributor provide for collaborative effort the distributor and gilead in obtaining and maintaining regulatory approval for the product in the specified territory we sell and distribute most of our product in the united state exclusively through the wholesale channel during the year ended december approximately of our product sale in the united state and approximately of our total worldwide revenue were to three large wholesaler amerisourcebergen corporation cardinal health inc and mckesson corporation we sell and distribute our product in europe and country outside the united state the product is approved either through our commercial team third party distributor or corporate partner competitionwe operate in highly competitive environment we face significant competition from global pharmaceutical and biotechnology company specialized pharmaceutical firm and generic drug manufacturer our product compete with other commercially available product based primarily on efficacy safety tolerability acceptance by doctor ease of patient compliance ease of use price insurance and other reimbursement coverage distribution and marketing our product mature pricing pressure from private insurer and government payer often result in reduction of the net product price further new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected research and developmentour research and development mission is to discover and develop transformational therapy in area of high unmet medical need our product development effort are focused primarily in viral disease inflammatory disease and oncology our team of research scientist is engaged in the discovery and development of new molecule and technology that we hope will lead to the approval of innovative medicine and therapy that will advance the current standard of care and address unmet medical need we intend to continue committing significant resource to internal opportunity and external business development activity to drive innovation and growth of our business the development of product candidate and investigational therapy in our pipeline is subject to various risk and uncertainty these risk and uncertainty include our ability to enroll patient in clinical trial the possibility of unfavorable result of our clinical trial the need to modify or delay our clinical trial including on account of clinical hold placed by regulatory authority or to perform additional trial and the risk of failing to obtain regulatory approval result our product candidate and investigational therapy may never be successfully commercialized drug development is inherently risky and many product candidate and investigational therapy fail during the development process in we continued to invest in and advance our pipeline across our therapeutic area below is summary of our product candidate that were in phase or registrational phase clinical trial or pending marketing authorization review by fda or european medicine agency ema of the end of candidate in viral diseasesproduct candidatesdescriptionregulatory filingslenacapavira new drug application and marketing authorization application have been filed with fda and ema respectively for lenacapavir an hiv capsid inhibitor component of long acting regimen for the treatment of hiv infection in heavily treatment experienced people living with hiv it ha been granted breakthrough therapy designation by fda for this indication bulevirtidea biologics license application ha been filed with fda for bulevirtide for the treatment of chronic hepatitis delta virus hdv infection it ha been granted both orphan drug and breakthrough therapy designation by fda for this indication in europe hepcludex bulevirtide ha been granted conditional marketing authorization by the european commission and priority medicine prime scheme eligibility by the ema the first approved treatment in adult with chronic hdv infection with compensated liver disease phase is evaluated for an hiv prep indication program timeline is pending resolution of clinical hold placed by fda on study evaluating injectable lenacapavir product candidate in inflammatory diseasesproduct candidatedescriptionphase an fxr agonist is being evaluated for the treatment of primary sclerosing cholangitis filgotinibfilgotinib inhibitor is being evaluated for the treatment of crohn disease product candidate in oncologyproduct candidatesdescriptionregulatory filingsyescarta axicabtagene ciloleucel supplemental biologics license application and type ii variation marketing authorization application have been filed with fda and ema respectively for axicabtagene ciloleucel car cell therapy for the treatment of second line dlbcl type ii variation marketing authorization application ha been filed with ema for axicabtagene ciloleucel for the treatment of relapsed or refractory fl yescarta ha received accelerated approval by fda for the treatment of adult patient with relapsed or refractory fl after two or more line of systemic therapy tecartus brexucabtagene autoleucel type ii variation marketing authorization application ha been filed with ema for brexucabtagene autoleucel car cell therapy for the treatment of adult all tecartus ha received fda approval for the treatment of adult patient with relapsed or refractory cell precursor all phase govitecan hziysacituzumab govitecan hziy trop directed antibody and topoisomerase inhibitor conjugate is being evaluated for hormone receptor positive hr human epidermal growth factor receptor negative metastatic breast cancer and ii non small cell lung cancer nsclc second line or third line treatment magrolimabmagrolimab an anti is being evaluated for higher risk myelodysplastic syndrome md first line treatment and ii acute myeloid leukemia aml first line treatment program timeline are pending resolution of partial clinical hold placed by fda on study evaluating magrolimab zimberelimab zimberelimab an anti pd monoclonal antibody is being evaluated for nsclc first line treatment domvanalimab domvanalimab an fc silent anti tigit antibody is being evaluated for nsclc first line treatment registrational phase autoleucelbrexucabtagene autoleucel is being evaluated for the treatment of pediatric all in collaboration with arcus bioscience inc arcus see note collaboration and other arrangement of the note to consolidated financial statement included in part ii item of this annual report on form for additional information regarding this collaboration in we also received regulatory approval or authorization from fda and the european commission to expand the indication of our product including productregulatory approval or authorizationbiktarvyfda approved new low dose tablet dosage form of biktarvy for pediatric patient weighing at least kg to le than kg who are virologically suppressed or new to antiretroviral therapy epclusafda approved an expansion of the pediatric indication of epclusa for the treatment of chronic hcv infection to include pediatric patient year of age and older regardless of hcv genotype or liver disease severity vekluryeuropean commission approved variation to the conditional marketing authorization for veklury to include adult who do not require supplemental oxygen and are at an increased risk of progressing to severe covid yescartafda granted accelerated approval of yescarta for the treatment of adult patient with relapsed or refractory fl tecartusfda approved tecartus for the treatment of adult patient with relapsed or refractory cell precursor all trodelvyfda granted full approval of trodelvy for adult patient with unresectable locally advanced or metastatic tnbc fda granted accelerated approval of trodelvy for use in adult patient with locally advanced or metastatic uc european commission granted marketing authorization for trodelvy monotherapy indicated for the treatment of adult patient with unresectable or metastatic tnbc who have received two or more prior systemic therapy at least one of them for advanced disease in addition we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic area through acquisition in licensing and strategic collaboration for example in october we entered into clinical trial collaboration with merck sharp dohme corp subsidiary of merck co inc merck to evaluate trodelvy in combination with merck keytruda in patient with first line metastatic tnbc in november we expanded our research collaboration with arcus and exercised our option to three program in arcus clinical stage portfolio including domvanalimab which is in phase and study in nsclc our strategic business development activity reflects our commitment to focus on transformative science build sustainable and diverse portfolio and position for the near medium and long term growth of our business patent and proprietary rightsu and european patent expirationwe have number of and foreign patent patent application and right to patent related to our compound product and technology but we can not be certain that issued patent will be enforceable or provide adequate protection or that pending patent application will result in issued patent the following table show the estimated expiration date including patent term extension supplementary protection certificate and or pediatric exclusivity where granted in the united state and the european union for the primary typically compound patent for our key product candidate described above for our product candidate that are fixed dose combination of single tablet regimen the estimated patent expiration date provided corresponds to the latest expiring compound patent for one of the active ingredient in the single tablet regimen product candidatespatent expirationu viral disease disease axicabtagene brexucabtagene sacituzumab govitecan the composition of matter patent ha expired in the european union in the european union and the united state patent application are pending relating to proprietary manufacturing process of kite gilead company kite an application for patent term extension wa filed in the united state that if granted would extend the expiration date to at least regulatory exclusivity in the united state expires in in collaboration with arcus the following table show the actual or estimated expiration date including patent term extension supplementary protection certificate and or pediatric exclusivity where granted in the united state and the european union for the primary typically compound patent for our principal product for our product that are fixed dose combination or single tablet regimen the estimated patent expiration date provided correspond to the latest expiring compound patent for one of the active ingredient in the single tablet regimen productspatent expirationu estimated expiration date do not include any potential additional exclusivity patent term extension supplementary protection certificate or pediatric exclusivity that ha not yet been granted ______________________________ in gilead and lupin limited reached an agreement to settle patent litigation matter related to ranexa application for patent term extension are pending in the united state and or spcs are pending in one or more country in the european union for these product the composition of matter patent ha expired in the european union in the european union and the united state patent application are pending relating to proprietary manufacturing process of kite in gilead and mylan pharmaceutical reached an agreement to settle the patent litigation concerning patent that protect cobicistat in our stribild and genvoya product an application for patent term extension wa filed in the united state that if granted would extend the expiration date to at least regulatory exclusivity in the united state expires in protection and certain challenge patent and other proprietary right are important to our business if we have properly drafted and enforceable patent it can be more difficult for our competitor to use our technology to create competitive product and more difficult for our competitor to obtain patent that prevents from using technology we create part of our business strategy we actively seek patent protection both in the united state and internationally and file additional patent application when appropriate to cover improvement in our compound product and technology patent covering certain of the active pharmaceutical ingredient api of most of our hiv product well cell therapy product are held by third party we acquired exclusive right to these patent in the agreement we have with these party we may obtain patent for certain product many year marketing approval is obtained patent have limited life that may begin to run prior to the commercial sale of the related product the commercial value of the patent may be limited however we may be able to apply for patent term extension or supplementary protection certificate in country for example extension for the patent or supplementary protection certificate on many of our product have been granted in the united state and in number of european country compensating in part for delay in obtaining marketing approval similar patent term extension may be available for other product we are developing but we can not be certain we will obtain them in some country it is also important that we do not infringe the valid patent of third party if we infringe the valid patent of third party our reputation may be harmed and we may be required to pay significant monetary damage we may be prevented from commercializing product or we may be required to obtain license from these third party we may not be able to obtain alternative technology or any required license on reasonable term or at all if we fail to obtain these license or alternative technology we may be unable to develop or commercialize some or all of our product for example we are aware of patent and patent application owned by other party that such party may claim to cover the use of sofosbuvir axicabtagene ciloleucel brexucabtagene autoleucel tenofovir disoproxil tenofovir alafenamide and bictegravir because patent application are confidential for period of time patent is issued we may not know if our competitor have filed patent application for technology covered by our pending application or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent application competitor may have filed patent application or received patent and may obtain additional patent and proprietary right that block or compete with our product in addition if competitor file patent application covering our technology we may have to participate in litigation post grant proceeding before the patent and trademark office or other proceeding to determine the right to patent or validity of any patent granted such litigation and proceeding are unpredictable and expensive and could divert management attention from other operation such that even if we are ultimately successful we may be adversely impacted patent relating to pharmaceutical biopharmaceutical and biotechnology product compound and process such those that cover our existing compound product and process and those that we will likely file in the future do not always provide complete or adequate protection future litigation or other proceeding regarding the enforcement or validity of our existing patent or any future patent could result in the invalidation of our patent or substantially reduce protection from time to time certain individual or entity may challenge our patent our pending patent application and the patent application filed by our collaborative partner may not result in the issuance of any patent or may result in patent that do not provide adequate protection result we may not be able to prevent third party from developing compound or product that are closely related to those which we have developed or are developing in addition certain country do not provide effective enforcement of our patent and third party manufacturer may be able to sell generic version of our product in those country for description of our significant pending legal proceeding see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form see also item risk factor our success depends to significant degree on our ability to obtain and defend our patent and other intellectual property right both domestically and internationally and to operate without infringing upon the patent or other proprietary right of third party secretswe also rely on unpatented trade secret and improvement unpatented internal know and technological innovation for example great deal of our liposomal manufacturing expertise which is key component of our liposomal technology is not covered by patent but is instead protected trade secret we protect these right mainly through confidentiality agreement with our corporate partner employee consultant and vendor these agreement provide that all confidential information developed or made known to an individual during the course of their relationship with will be kept confidential and will not be used or disclosed to third party except in specified circumstance in the case of employee the agreement provide that all invention made by an individual employed by will be our exclusive property we can not be certain that these party will comply with these confidentiality agreement that we have adequate remedy for any breach or that our trade secret internal know how or technological innovation will not otherwise become known or be independently discovered by our competitor under some of our agreement invention become jointly owned by and our corporate partner and in other case become the exclusive property of one party in certain circumstance it can be difficult to determine who owns particular invention and dispute could arise regarding those invention if our trade secret or confidential information become known or independently discovered by competitor or if we enter into dispute over ownership of invention our business and result of operation could be adversely affected manufacturing and raw materialsour product are manufactured either at our own facility or by third party contract manufacturer we depend on third party to perform manufacturing activity for the majority of our api and drug product for most of our product including our hiv and hcv product we use multiple third party contract manufacturer that we have primary and back supplier and manufacturing site for our cell therapy product we have established clinical and commercial manufacturing facility for cell processing activity for our future product we continue to develop additional manufacturing capability and establish additional third party supplier to manufacture sufficient quantity of our product candidate to undertake clinical trial and to manufacture sufficient quantity of any product that is approved for commercial sale our manufacturing facility we own or lease manufacturing facility to manufacture and distribute certain product and api for clinical and or commercial us these facility include foster city california we conduct process chemistry research and formulation development activity manufacture api and drug product for our clinical trial and oversee our third party contract manufacturer san dimas and la verne california we manufacture ambisome and also package and label the majority of our commercial product for distribution to the america and pacific rim oceanside california we utilize the facility for clinical manufacturing and process development of our biologics candidate el segundo california we utilize the facility for clinical and commercial manufacturing and processing of our cell therapy product frederick maryland we utilize the facility for clinical manufacturing and processing of our cell therapy product morris plain new jersey we utilize the facility for manufacturing for monoclonal antibody intermediate and process optimization of our antibody drug conjugate product cork and dublin ireland we utilize the cork facility for commercial manufacturing packaging and labeling of our product we also perform quality control testing labeling packaging and final release of many of our product at the cork facility which are distributed to the european union and other international market through our facility in dublin we utilize our other facility in central dublin drug development hub for our pediatric program where we perform clinical development safety quality biostatistics and data science regulatory and compliance function edmonton canada we conduct process chemistry research and scale up activity for our clinical development candidate manufacture api for both investigational and commercial product and conduct chemical development activity to improve existing commercial manufacturing process hoofddorp netherlands we utilize the facility for commercial manufacturing and processing of our cell therapy product party manufacturerswe believe the technology we use to manufacture our product is proprietary for product manufactured by our third party contract manufacturer we have disclosed all necessary aspect of this technology to enable them to manufacture the product for we have agreement with these third party manufacturer that are intended to restrict them from using or revealing this technology but we can not be certain that these third party manufacturer will comply with these restriction for more information about our third party manufacturer see item risk factor we may face manufacturing difficulty delay or interruption including at our third party manufacturer and corporate partner regulation of manufacturing processthe manufacturing process for pharmaceutical product is highly regulated and regulator may shut manufacturing facility that they observe do not comply with regulation we our third party manufacturer and our corporate partner are subject to current good manufacturing practice gmp which are extensive regulation governing manufacturing process stability testing record keeping and quality standard defined by fda and the ema similar regulation are in effect in other jurisdiction our manufacturing operation are subject to routine inspection by regulatory agency for our cell therapy product we are required by fda to comply with the risk evaluation and mitigation strategy program which includes educating and certifying medical personnel regarding the therapy procedure and the potential side effect profile of our therapy such the potential adverse side effect related to cytokine release syndrome and neurologic toxicity additionally we are required to maintain complex chain of identity and custody with respect to patient material such material move to the manufacturing facility through the manufacturing process and back to the patient access to raw material we need access to certain raw material to conduct our clinical trial and manufacture our product these raw material are generally available from multiple source purchased worldwide and normally available in quantity adequate to meet the need of our business we attempt to manage the risk associated with our supply chain by inventory management relationship management and evaluation of alternative source when feasible for more information see item risk factor we may not be able to obtain material or supply necessary to conduct clinical trial or to manufacture and sell our product which could limit our ability to generate revenue human capitalgilead success depends on the work of it dedicated employee who embrace shared sense of purpose and culture of excellence our human capital objective is to make gilead the employer of choice for the best talent in our industry gilead key priority for human capital management include inclusion and diversity health and safety total reward employee development and engagement the compensation and talent committee of our board of director oversees our overall human capital management inclusion diversityinclusion is gilead core value and we believe building an inclusive and diverse workforce is critical to enabling gilead mission our global inclusion and diversity council is responsible for governance of these matter tracking progress on our goal and promoting culture of inclusion the global inclusion and diversity council is chaired by our chairman and chief executive officer and includes member of our leadership team in we introduced our advancing black leadership strategy multi year initiative that outline our commitment to create internal and external pipeline for diverse talent and to build awareness capability and accountability among our people manager part of this strategy we set clear target for representation within our overall workforce and executive population including goal to increase the percentage of female black and hispanic employee with well defined annual target through gilead also implemented multiple program to train manager on inclusion and diversity topic and created strategy and initiative focused on attracting developing and retaining diverse talent and driving an inclusive culture in our workplace which organizational leader were required to regularly review starting in in addition our employee resource group erg support diverse employee and aim to raise awareness of different culture within the workplace cultivate diversity business strength and support gilead talent acquisition strategy to source attract and recruit diverse candidate executive sponsor and leader of our erg contribute to the advancement of our inclusion and diversity commitment through service on our global inclusion and diversity council we believe gilead inclusive and diverse workforce is the foundation for innovation and productivity gilead commitment to equal employment opportunity furthers it effort to cultivate and celebrate an equitable culture of belonging of december gilead approximately employee and gilead global workforce wa approximately female and male additionally woman represented of gilead leadership defined vice president level and above in the united state based on our employee voluntary self identification our workforce wa white asian hispanic black and other and safetygilead is committed to providing workplace for it employee that promotes health safety wellness and productivity we have workplace safety training and security program together with various compliance protocol to support this commitment we routinely train and educate our employee on workplace safety and security in response to the covid pandemic most gilead site required flexible location employee to work from home while employee who needed to be physically present for their position such laboratory technician continued to work at gilead site in the fourth quarter of gilead transitioned to return to site phase for our flexible location employee during the pandemic we implemented job site enhancement and risk protocol including health screening covid testing and vaccine requirement reconfiguration of work and common space to allow for physical distancing in our effort to support the safe occupancy of our site gilead also maintains robust contact tracing and notification process for any employee who report covid infection we continue to monitor the state of the pandemic and we remain committed to maintaining work environment that promotes the health safety and productivity of our workforce total rewardsgilead compensation and benefit program are designed to help attract develop and retain the industry most talented workforce our total reward program which varies by country includes competitive base salary and incentive compensation stock award an employee stock purchase plan saving plan with company match that vest immediately health and welfare and other valuable benefit such flexible work arrangement flexible spending account paid time off family leave family care resource fertility adoption and surrogacy assistance student loan repayment and tuition assistance employee assistance program global wellbeing reimbursement and tuition assistance among many others each year we reassess our total reward package to confirm whether it offer benefit and incentive that align with our total reward philosophy we are pay for performance company and are committed to addressing pay equity our employee salary are informed by market based range and are assessed annually through performance and career development review our policy is that compensation decision are made without regard to personal characteristic such gender race color national or ethnic origin age disability sexual orientation gender identity or expression genetic information religion or veteran status we also conduct an annual pay equity review of employee compensation in an effort to strive to make our pay practice gender and race neutral employee development and engagementemployee development and engagement maximizes the potential and performance of each member of our workforce and is critical to achieving our business goal gilead offer number of internal and external professional management and leadership development training program to help our employee develop technical cross functional and leadership skill and tool to grow their career in addition employee can receive reimbursement for tuition expense incurred while pursuing undergraduate graduate or certificate course at an accredited college or university we strive to be the employer of choice in our industry our listening strategy gather input from our employee to shape our engagement strategy and program and measure our progress in addition to ongoing internal and external data collection we conducted large scale review of the employee experience in with an employee survey the result of this survey played key role in determining the direction of our culture well the company broader response to the continuing covid pandemic including the meaningful benefit we provided to employee and our approach to flexible work arrangement we believe our flexible work program position to be competitive for talent and support employee well being while also creating the collaborative environment and connection that fuel innovation environmental social and governance esg investing in corporate responsibility is core to our business strategy and reflects our value of accountability inclusion teamwork excellence and integrity this is in service to our mission to advance global health by providing innovative therapeutic in area of unmet need in way that is socially responsible and environmentally sustainable gilead esg program reflect this commitment to our stakeholder esg strategy and performance are overseen by the nominating and corporate governance committee of it board of director and managed by corporate responsibility committee comprised of leader from key department across our company the corporate responsibility committee is responsible for reviewing material esg issue and integrating them into our overall business strategy and operation additional information about this program and esg highlight are available in gilead year in review under gilead website at www gilead com news and press annual report year in review our esg goal are aspirational and may change statement regarding these goal and related initiative are not guarantee or promise that they will be met of operationsour worldwide product sale do not reflect any significant degree of seasonality in end user demand however in the united state fluctuation in wholesaler inventory level impact our product sale we typically observe strong wholesaler and sub wholesaler purchase of our product in the fourth quarter resulting in inventory draw down by wholesaler and sub wholesaler in the subsequent first quarter several other factor including government budget annual grant cycle for federal and state fund the covid pandemic and other buying pattern also could impact the product sale recorded in particular quarter for more information see item risk factor we face challenge in accurately forecasting sale because of the difficulty in predicting demand for our product and fluctuation in purchasing pattern or wholesaler inventory government regulationour operation and activity are subject to extensive regulation by numerous government authority in the united state the european union and other country including law and regulation governing the testing manufacture safety efficacy labeling storage record keeping approval advertising and promotion of our product result of these regulation product development and product approval process are very expensive and time consuming which ha significant impact on our capital expenditure and result of operation the regulatory requirement applicable to drug development and approval are subject to change any legal and regulatory change may impact our operation in the future country regulatory agency such fda in the united state and the ema and european commission for the european union well the national authority of the european union member state must approve drug before it can be sold in the respective country or country the general process for drug approval in the united state is summarized below many other country including country in the european union and the european union under centralized procedure have similar regulatory structure preclinical testingbefore we can test drug candidate in human we must study the drug in laboratory experiment and in animal to generate data to support the drug candidate potential benefit and safety we submit this data to fda in an investigational new drug ind application seeking it approval to test the compound in human clinical trialsif fda accepts the ind the drug candidate can be studied in human clinical trial to determine if the drug candidate is safe and effective these clinical trial involve three separate phase that often overlap can take many year and are very expensive these three phase which are subject to considerable regulation are follows phase the drug candidate is given to small number of healthy human control subject or patient suffering or at risk from the indicated disease to test for safety dose tolerance pharmacokinetics metabolism distribution and excretion phase the drug candidate is given to limited patient population to determine the effect of the drug candidate in treating or preventing the disease the best dose of the drug candidate and the possible side effect and safety risk of the drug candidate it is not uncommon for drug candidate that appears promising in phase clinical trial to fail in the more rigorous and extensive phase clinical trial phase if drug candidate appears to be effective and have an appropriate safety profile in phase clinical trial phase clinical trial are commenced to confirm those result phase clinical trial are conducted over longer term involve significantly larger population are conducted at numerous site in different geographic region and are carefully designed to provide reliable and conclusive data regarding the safety and benefit of drug candidate it is not uncommon for drug candidate that appears promising in phase clinical trial to fail in the more rigorous and extensive phase clinical trial fda approval processwhen we believe that the data from our clinical trial show an acceptable benefit risk profile we submit the appropriate filing usually in the form of new drug application biologics license application or supplemental application with fda seeking approval to sell the drug candidate for particular use at fda discretion fda may hold public hearing where an independent advisory committee of expert advisor asks additional question and make recommendation regarding the drug candidate this committee make recommendation to fda that is not binding but is generally followed by fda if fda agrees that the drug ha met the required level of safety and efficacy for particular use it will approve the application and allow to sell the drug in the united state for that use it is not unusual however for fda to decline to approve an application because it belief that the drug candidate is not safe enough or efficacious enough doe not have an appropriate benefit risk profile or because it doe not believe that the data submitted is reliable or conclusive any point in this process the development of drug candidate can be stopped for number of reason including safety concern lack of treatment benefit or manufacturing issue we can not be certain that any clinical trial that we are currently conducting or any that we conduct in the future will be completed successfully or within any specified time period we may choose or fda may require to delay or suspend our clinical trial at any time if it appears that patient are being exposed to an unacceptable health risk or if the drug candidate doe not appear to have sufficient treatment benefit even after approving drug fda may also require phase non registrational study to explore scientific question to further characterize safety and efficacy during commercial use of our drug fda may also require to provide additional data or information improve our manufacturing process procedure or facility or may require extensive surveillance to monitor the safety or benefit of our product candidate if it determines that our filing doe not contain adequate evidence of the safety and benefit of the drug in addition even if fda approves drug it could limit the us of the drug fda can withdraw approval if it doe not believe that we are complying with regulatory standard or if concern about the safety or efficacy are uncovered or occur after approval in addition to obtaining fda approval for each drug we obtain fda approval of the manufacturing facility for any drug we sell including those of company who manufacture our drug for all of these facility are subject to periodic inspection by fda fda must also approve foreign establishment that manufacture product to be sold in the united state and these facility are subject to periodic regulatory inspection our manufacturing facility located in california also must be licensed by the state of california in compliance with local regulatory requirement our manufacturing facility in canada ireland and netherlands also must obtain local license and permit in compliance with local regulatory requirement fda may employ one of several tool to facilitate and expedite the development and review of drug including fast track designation breakthrough therapy designation accelerated approval and priority review designation fast track designation is designed to facilitate the development and review of drug that treat serious condition and fill an unmet medical need breakthrough therapy designation is designed to expedite the development and review of drug that treat serious condition and preliminary clinical evidence demonstrates substantial improvement over available therapy accelerated approval of drug may be granted by fda where the drug treat serious condition fill an unmet medical need and ha been studied for safety and efficacy priority review designation mean fda goal is to take action on an application within six month of filing fda may grant priority review designation to drug that would provide significant improvement in the safety or effectiveness of treatment diagnosis or prevention of serious condition european union regulatory system and approval processin the european union eu our product are subject to variety of eu and eu member state regulation governing clinical trial commercial sale and distribution we are required to obtain marketing authorization in the eu before we can market our medicinal product on the relevant market the conduct of clinical trial in the eu is governed by among others directive ec and directive ec and the eu ich good clinical practice rule these impose legal and regulatory obligation that are similar to those provided in applicable law the conduct of clinical trial in the eu must be approved by the competent authority of each eu member state in which the clinical trial take place and positive opinion must be obtained from the relevant ethic committee in the relevant member state in the eu legislator adopted regulation eu no to replace directive ec and to introduce coordinated procedure for authorization of clinical trial this regulation entered into application in january marketing authorization holder manufacturer importer wholesaler and distributor of medicinal product placed on the market in the eu are required to comply with number of regulatory requirement including pharmacovigilance gmp compliance and the requirement to obtain manufacturing import and or distribution license issued by the competent authority of the eu member state failure to comply with these requirement may lead to the imposition of civil criminal or administrative sanction including suspension of marketing or manufacturing authorization pricing and reimbursementsuccessful commercialization of our product depends in part on the availability of third party payer reimbursement for the cost of such product and related treatment and medical service in the market where we sell our product government health authority private health insurer and other organization generally provide reimbursement in the united state the european union and other significant or potentially significant market for our product and product candidate government authority and third party payer are increasingly attempting to limit or regulate the price of medical product and service significant portion of our sale of the majority of our product are subject to substantial discount from their list price including rebate we may be required to pay to medicaid agency or discount we may be required to pay to covered entity result the price increase we implement from time to time on certain product may have limited effect on our net product sale in certain market in addition standard reimbursement structure may not adequately reimburse for innovative therapy our product mature pricing pressure from private insurer and government payer often result in reduction of the net product price further new branded or generic product are introduced into major market our ability to maintain pricing and market share may be affected for more information see item risk factor our existing product are subject to reimbursement pressure from government agency and other third party required rebate and other discount on our product and other pricing pressure and we face challenge in accurately forecasting sale because of the difficulty in predicting demand for our product and fluctuation in purchasing pattern or wholesaler inventory health care fraud and abuse law anti bribery lawswe are subject to various federal and state law pertaining to health care fraud and abuse including anti kickback law and false claim law anti kickback law make it illegal for prescription drug manufacturer to knowingly and willingly solicit offer receive or pay any remuneration in exchange for or to induce the referral of business reimbursed by federal healthcare program including the purchase or prescription of particular drug false claim law generally prohibit anyone from knowingly presenting or causing to be presented false or fraudulent claim for payment by federal and certain state payer including medicare and medicaid or knowingly making using or causing to be made or used false record or statement material to false or fraudulent claim in addition the fda regulates written and verbal communication about our product in addition to federal law state also have consumer protection and false claim law due to the breadth of the statutory provision and the attention being given to them by law enforcement authority our sale marketing patient support medical clinical and public affair activity may be subject to scrutiny under these law for example recently there ha been enhanced scrutiny by government enforcement authority of company sponsored patient assistance program including co pay assistance program and manufacturer donation to third party charity that provide such assistance reimbursement support offering clinical education program and promotional speaker program similarly in europe interaction between pharmaceutical company and physician are subject to strict law regulation industry self regulation code of conduct and physician code of professional conduct applicable including the eu member state anti corruption law and the uk bribery act in addition the foreign corrupt practice act and similar worldwide anti bribery law generally prohibit company and their intermediary from making improper payment for the purpose of obtaining or retaining business our policy mandate compliance with these anti bribery law we operate in part of the world that have experienced governmental corruption to some degree in certain circumstance strict compliance with anti bribery law may conflict with local custom and practice or may require to interact with doctor and hospital some of which may be state controlled in manner that is different than local custom despite our training and compliance program our internal control policy and procedure may not protect from unlawful act committed by our employee or agent violation of fraud and abuse law or anti bribery law may be punishable by criminal and or civil sanction including fine and civil monetary penalty well the possibility of exclusion from federal health care program including medicare and medicaid violation can also lead to the imposition of corporate integrity agreement or similar government oversight program even if we disagree with the government perspective that we have violated any rule or guidance any similar violation by our competitor could also negatively impact the reputation of our industry and increase governmental and public scrutiny over our business and our product healthcare reformthe federal and state government continue to propose and pas legislation designed to regulate the healthcare industry including legislation that seek to indirectly or directly regulate pharmaceutical drug pricing for more information see item risk factor we are impacted by evolving law regulation and legislative or regulatory action applicable to the health care industry environmentwe are subject to number of law and regulation that require compliance with federal state and local regulation for the protection of the environment the regulatory landscape continues to evolve and we anticipate additional regulation in the future law and regulation are implemented and under consideration to mitigate the effect of climate change mainly caused by greenhouse gas emission our business is not energy intensive therefore we do not anticipate being subject to cap and trade system or other mitigation measure that would materially impact our capital expenditure operation or competitive position informationwe are subject to the information requirement of the security exchange act of exchange act therefore we file periodic report proxy and information statement and other information with the sec the sec maintains website www sec gov that contains report proxy and information statement and other information regarding issuer that file electronically with the sec our website is www gilead com through link on the investor page of our website under the sec filing section we make available the following filing free of charge soon reasonably practicable after they are electronically filed with or furnished to the sec our annual report on form quarterly report on form current report on form and any amendment to those report filed or furnished pursuant to section or of the exchange act website reference are provided throughout this document for convenience the content on the referenced website doe not constitute part of and is not incorporated by reference into this annual report on form risk factorsin evaluating our business you should carefully consider the following discussion of material risk event and uncertainty that make an investment in speculative or risky in addition to the other information in this annual report on form manifestation of any of the following risk and uncertainty could in circumstance we may or may not be able to accurately predict materially and adversely affect our business and operation growth reputation including the commercial or scientific reputation of our product prospect product pipeline and sale operating and financial result financial condition cash flow liquidity and stock price we note these factor for investor permitted by the private security litigation reform act of it is not possible to predict or identify all such factor our operation could also be affected by factor event or uncertainty that are not presently known to or that we currently do not consider to present significant risk to our operation therefore you should not consider the following risk to be complete statement of all the potential risk or uncertainty that we face product and commercialization riskscertain of our product subject to additional or heightened risk hiv product we receive substantial portion of our revenue from sale of our product for the treatment and prevention of hiv infection during sale of our hiv product accounted for approximately of our total product sale we may be unable to sustain or increase sale of our hiv product for any number of reason including market share gain by competitive product including generic or the inability to introduce new hiv medication necessary to remain competitive in such case we may need to scale back our operation including our future drug development and spending on research and development effort for example many of our hiv product contain tenofovir alafenamide taf which belongs to the nucleoside class of antiviral therapeutic and any change to the treatment paradigm for hiv may cause nucleoside based therapeutic to fall of favor veklurywe face risk related to our supply and distribution of veklury which wa approved by the food and drug administration fda in october treatment for patient hospitalized with coronavirus disease covid and in january treatment for non hospitalized adult and adolescent patient who are at high risk of progression to severe covid including hospitalization or death while the utilization of veklury ha largely tracked rate of covid hospitalization we are unable to accurately predict our revenue or supply need over the short and long term due to the dynamic nature of the pandemic including the availability uptake and effectiveness of vaccine and alternative treatment for covid fluctuating hospital utilization rate the emergence of new variant and timing of surge in infection if we do not accurately forecast demand or manufacture veklury at level sufficient to meet demand then we may experience product shortage or build excess inventory that may be written off we also remain subject to significant public attention and scrutiny over the complex decision made regarding clinical data supply allocation distribution and pricing of veklury all of which affect our corporate reputation cell therapyadvancing novel and personalized therapy such yescarta or tecartus which are chimeric antigen receptor car cell therapy creates significant challenge including educating and certifying medical personnel regarding the procedure and the potential side effect such cytokine release syndrome and neurologic toxicity in compliance with the risk evaluation and mitigation strategy program required by fda securing sufficient supply of other medication to manage side effect such tocilizumab and corticosteroid which may not be available in sufficient quantity may not adequately control the side effect and or may have detrimental impact on the efficacy of cell therapy developing and maintaining robust and reliable process for engineering patient cell in our facility and infusing them back into the patient and conditioning patient with chemotherapy in advance of administering our therapy which may increase the risk of adverse side effect use of engineered cell potential cancer treatment is recent development and may not be broadly accepted by physician patient hospital cancer treatment center payer and others in the medical community while fda ha approved some cell therapy including yescarta and tecartus we must continue to demonstrate to the medical community the potential advantage of cell therapy compared to existing and future therapeutic for challenge related to the reimbursement of yescarta and tecartus see also our existing product are subject to reimbursement pressure from government agency and other third party required rebate and other discount on our product and other pricing pressure we rely on third party site to collect patient white blood cell known apheresis center well shipper courier and hospital for the logistical collection of patient white blood cell and ultimate delivery of yescarta or tecartus to patient these vendor may encounter disruption or difficulty that could result in product loss and regulatory action apheresis center may also choose not to participate in our quality certification process or we may be unable to complete such certification in timely manner or at all which could delay or constrain our manufacturing and commercialization effort we operate new automated manufacturing facility in frederick maryland the facility is pending fda approval for commercial manufacturing and even if we obtain such approval we have not manufactured our product in an automated facility on commercial scale result we may not be able to produce or otherwise obtain an amount of supply sufficient to satisfy demand for our product if we are unable to meet product demand we will have difficulty meeting sale forecast for product that we plan to manufacture at this facility our success depends on developing and commercializing new product or expanding the indication for existing product if we are unable to launch commercially successful new product or new indication for existing product our business will be adversely impacted the launch of commercially successful product is necessary to grow our business cover our substantial expense and offset revenue loss when existing product lose market share due to factor such competition and loss of patent exclusivity there are many difficulty and uncertainty inherent in drug development and the introduction of new product the product development cycle is characterized by significant investment of resource long lead time and unpredictable outcome due to the nature of developing medicine for human use we expend significant time and resource on our product pipeline without any assurance that we will recoup our investment or that our effort will be commercially successful high rate of failure is inherent in the discovery and development of new product and failure can occur at any point in the process including late in the process after substantial investment we face challenge in accurately forecasting sale because of the difficulty in predicting demand for our product and fluctuation in purchasing pattern or wholesaler inventory we may be unable to accurately predict demand for our product including the uptake of new product demand depends on number of factor for example product demand may be adversely affected if physician do not see the benefit of our product additionally the non retail sector in the united state which includes government institution including state aid drug assistance program the department of veteran affair correctional facility and large health maintenance organization tends to be le consistent in term of buying pattern and often cause quarter over quarter fluctuation that do not necessarily mirror patient demand for our product federal and state budget pressure well the annual grant cycle for federal and state fund may cause purchasing pattern to not reflect patient demand for our product we expect to continue to experience fluctuation in the purchasing pattern of our non retail customer in light of the budget crisis faced by many european country we have observed variation in purchasing pattern induced by cost containment measure in europe we believe these measure have caused some government agency and other purchaser to reduce inventory of our product in the distribution channel and we may continue to see this trend in the future we sell and distribute most of our product in the united state exclusively through the wholesale channel for the year ended december approximately of our product sale in the united state were to three wholesaler amerisourcebergen corporation cardinal health inc and mckesson corporation the wholesaler with whom we have entered into inventory management agreement make estimate to determine end user demand and may not be completely effective in matching their inventory level to actual end user demand result change in inventory level held by those wholesaler can cause our operating result to fluctuate unexpectedly if our sale to these wholesaler do not match end user demand in addition inventory is held at retail pharmacy and other non wholesaler location with whom we have no inventory management agreement and no control over buying pattern adverse change in economic condition increased competition or other factor may cause retail pharmacy to reduce their inventory of our product which would reduce their order from wholesaler and consequently the wholesaler order from even if end user demand ha not changed in addition we have observed that strong wholesaler and sub wholesaler purchase of our product in the fourth quarter typically result in inventory draw down by wholesaler and sub wholesaler in the subsequent first quarter inventory in the distribution channel fluctuates from quarter to quarter we may continue to see fluctuation in our earnings and mismatch between prescription demand for our product and our revenue face significant competition from global pharmaceutical and biotechnology company specialized pharmaceutical firm and generic drug manufacturer new branded or generic product entering major market affect our ability to maintain pricing and market share our product compete with other available product based primarily on efficacy safety tolerability acceptance by doctor ease of patient compliance ease of use price insurance and other reimbursement coverage distribution and marketing number of company are pursuing the development of technology which are competitive with our existing product or research program these competing company include large pharmaceutical and biotechnology company and specialized pharmaceutical firm acting either independently or together with other such company furthermore academic institution government agency and other public and private organization conducting research may seek patent protection or may establish collaborative arrangement for competitive product or program we may be adversely impacted if any of these competitor gain market share result of new technology commercialization strategy or otherwise our existing product are subject to reimbursement pressure from government agency and other third party required rebate and other discount on our product and other pricing pressure product reimbursementssuccessful commercialization of our product depends in part on the availability of third party payer reimbursement for the cost of such product and related treatment and medical service in the market where we sell our product government health authority private health insurer and other organization generally provide reimbursement our product mature pricing pressure from private insurer and government payer often result in reduction of the net product price legislative and regulatory action affecting government prescription drug procurement and reimbursement program occur relatively frequently for example in september fda issued final rule implementing pathway for the importation of certain prescription drug from canada this rule is subject to ongoing litigation we may be adversely impacted by any such legislative and regulatory action though it is difficult to predict the impact if any on the use and reimbursement of our product product pricing discount and rebatesin the united state the european union eu and other significant or potentially significant market for our product and product candidate government authority and third party payer are increasingly attempting to limit or regulate the price of medical product and service in the united state the volume of drug pricing related bill ha dramatically increased in recent year for example congress ha enacted law requiring manufacturer refund on certain amount of discarded drug from single use vial beginning in and eliminating the existing cap on medicaid rebate amount beginning in congress ha also proposed bill to require the department of health and human service to negotiate price for certain drug impose an inflation based rebate on medicare part and drug when list price for drug grow faster than inflation and increase manufacturer contribution in some or all of the medicare part benefit phase in addition many state legislature are considering or have already passed into law legislation that seek to indirectly or directly regulate pharmaceutical drug pricing such requiring manufacturer to publicly report proprietary pricing information creating review board for price to state agency and encouraging the use of generic drug such initiative and legislation may cause added pricing pressure on our product and the resulting impact on our business is uncertain many country outside the united state including the eu member state have established complex and lengthy procedure to obtain price approval and coverage reimbursement and periodically review their pricing and reimbursement decision the outcome of this review can not be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal product in the eu member state reduction in the pricing of our medicinal product in one member state could affect the price in other member state and have negative impact on our financial result substantial portion of our product sale is subject to significant discount from list price including rebate that we may be required to pay state medicaid agency and discount provided to covered entity change to the program or the medicaid program at the federal or state level could have material adverse effect on our business for example in december center for medicare medicaid service cm issued final rule that will make certain change to the calculation of rebate under the medicaid drug rebate program among other change effective january the final rule will change the requirement for excluding manufacturer co pay coupon from the medicaid best price these change are subject to ongoing litigation if these change go into effect they could substantially increase our medicaid rebate obligation and decrease the price we charge covered entity the continued growth of the program also limit the price we may charge on an increasing percentage of sale addition standard reimbursement structure may not adequately reimburse for innovative therapy for example beginning in fiscal year cm established new severity adjusted diagnosis related group drg for medicare inpatient reimbursement of car product such yescarta and tecartus while the new drg ha significantly higher base payment amount than the prior drg the payment available may not be sufficient to reimburse some hospital for their cost of care for patient receiving yescarta and tecartus when reimbursement is not aligned well to account for treatment cost medicare beneficiary may be denied access this misalignment could impact the willingness of some hospital to offer the therapy and of doctor to recommend the therapy additionally in the eu there are barrier to reimbursement in individual country that could limit the uptake of yescarta and tecartus in addition we estimate the rebate we will be required to pay in connection with sale during particular quarter based on claim data from prior quarter in the united state actual rebate claim are typically made by payer one to three quarter in arrears actual claim and payment may vary significantly from our estimate we may experience adverse impact resulting from the importation of our product from lower price market or the distribution of illegally diverted or counterfeit version of our product price for our product are based on local market economics and competition and sometimes differ from country to country our sale in country with relatively higher price may be reduced if product can be imported and resold into those country from lower price market for example sale could also be affected if fda permit importation of drug from canada we have entered into agreement with generic drug manufacturer well licensing agreement with the medicine patent pool united nation backed public health organization which allows generic drug manufacturer to manufacture generic version of certain of our product for distribution in certain low and middle income country we may be adversely affected if any generic version of our product whether or not produced and or distributed under these agreement are exported to the united state europe or market with higher price in the eu we are required to permit product purchased in one eu member state to be sold in another member state purchase of our product in country where our selling price are relatively low for resale in country in which our selling price are relatively high can affect the inventory level held by our wholesaler and can cause the relative sale level in the various country to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter additionally diverted product may be used in country where they have not been approved and patient may source the diverted product outside the legitimate supply chain these diverted product may be handled shipped and stored inappropriately which may affect the efficacy of the product and could harm patient and adversely impact we are also aware of the existence of various supplier around the world that source our product and generic version of our product without gilead authorization and sell them for use in country where those product have not been approved result patient may be at risk of taking unapproved medication that may not be they purport to be may not have the potency they claim to have or may contain harmful substance which could adversely impact further third party have illegally distributed and sold and may continue to illegally distribute and sell illegally diverted and counterfeit version of our medicine which do not meet the rigorous quality standard of our manufacturing and supply chain for example part of an ongoing investigation in coordination with the marshal and local law enforcement we recently executed court ordered seizure at location across eight state and seized thousand of bottle of gilead labeled medication with counterfeit supply chain documentation including bottle labeled biktarvy and descovy our investigation revealed that pharmaceutical distributor that are not authorized by gilead to sell gilead medicine sold to independent pharmacy nationwide purported genuine gilead medicine sourced from an illegal counterfeiting scheme illegally diverted and counterfeit medicine pose serious risk to patient health and safety our action to stop or prevent the distribution and sale of illegally diverted and counterfeit version of our medicine around the world may be costly and unsuccessful which may adversely affect our reputation and business including our product revenue and financial result product development and supply chain riskswe face risk in our clinical trial including the potential for unfavorable result delay in anticipated timeline and disruption we are required to demonstrate the safety and efficacy of product candidate that we develop for each intended use through extensive preclinical study and clinical trial the result from preclinical and early clinical study do not always accurately predict result in later large scale clinical trial even successfully completed large scale clinical trial may not result in marketable product face numerous risk and uncertainty with our clinical trial that could result in delay or prevent completion of the development and approval of our product candidate these risk and uncertainty include challenge in clinical trial protocol design our ability to enroll patient in clinical trial and the possibility of unfavorable or inadequate trial result to support further development of our product candidate including failure to meet trial primary endpoint safety issue arising from our clinical trial and the need to modify or delay our clinical trial or to perform additional trial for example we recently announced clinical hold placed by fda on clinical trial evaluating injectable lenacapavir lenacapavir in combination with islatravir and magrolimab including in combination with azacitidine result we may be unable to successfully complete our clinical trial on our anticipated timeline or at all based on trial result it is possible that fda and other regulatory authority may not approve our product candidate or that any market approval may include significant limitation on the product use in addition clinical trial involving our commercial product could raise new safety issue for our existing product which could adversely impact our business further we may make strategic decision to discontinue development of our product candidate if for example we believe commercialization will be difficult relative to other opportunity in our pipeline therefore our product candidate may never be successfully commercialized and we may be unable to recoup the significant and clinical trial expense incurred in we anticipate the continued expansion of our clinical pipeline which includes multiple planned phase study initiation in oncology and virology we expect to expend significant time and resource on our clinical trial activity without any assurance that we will recoup our investment or that our effort will be commercially successful there are also risk associated with the use of third party in our clinical trial activity we extensively outsource our clinical trial activity and usually perform only small portion of the start up activity in house we rely on independent third party contract research organization cro to perform most of our clinical study including document preparation site identification screening and preparation pre study visit training program management patient enrollment ongoing monitoring site management and bioanalytical analysis many important aspect of the service performed for by the cro are out of our direct control if there is any dispute or disruption in our relationship with our cro our clinical trial may be delayed moreover in our regulatory submission we rely on the quality and validity of the clinical work performed by third party cro if any of our cro process methodology or result were determined to be invalid or inadequate our own clinical data and result and related regulatory approval may be adversely affected we may face manufacturing difficulty delay or interruption including at our third party manufacturer and corporate partner our product which are manufactured at our own facility or by third party manufacturer and corporate partner are the result of complex highly regulated manufacturing process we depend on third party manufacturer and corporate partner to perform manufacturing activity effectively and on timely basis for the majority of our active pharmaceutical ingredient and drug product these third party are independent entity subject to their own unique operational and financial risk that are out of our control we and our third party manufacturer and corporate partner are subject to good manufacturing practice gmp which are extensive regulation governing manufacturing process stability testing record keeping and quality standard defined by fda and the european medicine agency ema well comparable regulation in other jurisdiction manufacturing operation are also subject to routine inspection by regulatory agency any adverse development affecting or resulting from our manufacturing operation or the operation of our third party manufacturer and corporate partner may result in shipment delay inventory shortage lot failure product withdrawal or recall or other interruption in the commercial supply of our product we may also need to take inventory write offs and incur other charge and expense for product that fail to meet specification and quality standard undertake costly remediation effort or seek more costly manufacturing alternative such development could increase our manufacturing cost cause to lose revenue or market share and damage our reputation in addition manufacturing issue may cause delay in our clinical trial and application for regulatory approval for example if we are unable to remedy any deficiency cited by fda or other regulatory agency in their inspection our existing product and the timing of regulatory approval of product candidate in development could be adversely affected further there is risk that regulatory agency in other country where marketing application are pending will undertake similar additional review or apply heightened standard of review which could delay the regulatory approval for product in those country our business may be adversely affected if approval of any of our product candidate were delayed or if production of our product were interrupted we may not be able to obtain material or supply necessary to conduct clinical trial or to manufacture and sell our product which could limit our ability to generate revenue we need access to certain supply and product to conduct our clinical trial and to manufacture and sell our product if we are unable to purchase sufficient quantity of these material or find suitable alternative material in timely manner our development effort for our product candidate may be delayed or our ability to manufacture and sell our product could be limited of key component and material must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval and significant delay can occur if the qualification of new supplier is required even after manufacturer is qualified by the regulatory authority the manufacturer must continue to expend time money and effort in the area of production and quality control to maintain full compliance with gmp manufacturer are subject to regular periodic inspection by regulatory authority following initial approval if result of these inspection regulatory authority determines that the equipment facility laboratory or process do not comply with applicable regulation and condition of product approval the regulatory authority may suspend the manufacturing operation if the manufacturing operation of any of the single supplier for our product are suspended we may be unable to generate sufficient quantity of commercial or clinical supply of product to meet market demand in addition if delivery of material from our supplier are interrupted for any reason we may be unable to ship certain of our product for commercial supply or to supply our product candidate in development for clinical trial also some of our product and the material that we utilize in our operation are manufactured by only one supplier or at only one facility which we may not be able to replace in timely manner and on commercially reasonable term or at all problem with any of the single supplier or facility we depend on including in the event of disaster such an earthquake equipment failure or other difficulty may negatively impact our development and commercialization effort significant portion of the raw material and intermediate used to manufacture our antiviral product are supplied by third party manufacturer and corporate partner outside of the united state result any political or economic factor in specific country or region including any change in or interpretation of trade regulation compliance requirement or tax legislation that would limit or prevent third party outside of the united state from supplying these material could adversely affect our ability to manufacture and supply our antiviral product to meet market need and have material and adverse effect on our operating result if we were to encounter any of these difficulty our ability to conduct clinical trial on product candidate and to manufacture and sell our product could be impaired regulatory and other legal risksour operation depend on compliance with complex fda and comparable international regulation failure to obtain broad approval on timely basis or to maintain compliance could delay or halt commercialization of our product the product we develop must be approved for marketing and sale by regulatory authority and once approved are subject to extensive regulation by fda ema and comparable regulatory agency in other country we have filed and anticipate that we will file for marketing approval in additional country and for additional indication and product over the next several year these and any future marketing application we file may not be approved by the regulatory authority on timely basis or at all even if marketing approval is granted for these product there may be significant limitation on their use we can not state with certainty when or whether any of our product candidate under development will be approved or launched whether we will be able to develop license or acquire additional product candidate or product or whether any product once launched will be commercially successful further how we manufacture and sell our product is subject to extensive regulation and review for example under fda rule we are often required to conduct post approval clinical study to ass known serious risk signal of serious risk or to identify an unexpected serious risk in certain circumstance we may be required to implement risk evaluation and mitigation strategy program for our product which could include medication guide patient package insert communication plan to healthcare provider restriction on distribution or use of product and other element fda deems necessary to assure safe use of the drug discovery of previously unknown problem with our marketed product or product candidate including serious safety resistance or drug interaction issue or problem with our manufacturing safety reporting or promotional activity may result in regulatory approval being delayed denied or granted with significant restriction on our product including limitation on or the withdrawal of the product from the market failure to comply with these or other requirement imposed by fda could result in significant civil monetary penalty fine suspension of regulatory approval product recall seizure of product and criminal prosecution are impacted by evolving law regulation and legislative or regulatory action applicable to the health care industry the health care industry is subject to various federal state and international law and regulation pertaining to drug reimbursement rebate price reporting health care fraud and abuse and data privacy and security in the united state these law include anti kickback and false claim law law and regulation relating to the medicare and medicaid program and other federal and state program the medicaid rebate statute law that regulate written and verbal communication about our product individual state law relating to pricing and sale and marketing practice the health insurance portability and accountability act and other federal and state law relating to the privacy and security of health information actual or alleged violation of these law or any related regulation may be punishable by criminal and or civil sanction including in some instance substantial fine civil monetary penalty exclusion from participation in federal and state health care program including medicare medicaid and department of veteran affair and department of defense health program action executive overseeing our business and significant remediation measure negative publicity or other consequence these law and regulation are broad in scope and subject to changing and evolving interpretation which could require to incur substantial cost associated with compliance or to alter one or more of our sale or marketing practice the resulting impact on our business is uncertain and could be material in addition government price reporting and payment regulation are complex and we are continually assessing the method by which we calculate and report pricing in accordance with these obligation our methodology for calculation are inherently subjective and may be subject to review and challenge by various government agency which may disagree with our interpretation if the government disagrees with our reported calculation we may need to restate previously reported data and could be subject to additional financial and legal liability there also continues to be enhanced scrutiny of company sponsored patient assistance program including co pay assistance program and manufacturer donation to third party charity that provide such assistance there ha also been enhanced scrutiny by government on reimbursement and other patient support offering clinical education program and promotional speaker program if we or our agent and vendor are deemed to have failed to comply with law regulation or government guidance in any of these area we could be subject to criminal or civil sanction any similar violation by our competitor could also negatively impact our industry reputation and increase scrutiny over our business and our product for description of our government investigation and related litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form we are subject to risk if significant safety issue arise for our marketed product or our product candidate additional study are conducted subsequent to obtaining marketing approval for our product and our product are used over longer period of time by many patient including patient with underlying health problem or patient taking other medicine we expect to continue finding new issue related to safety resistance or drug interaction any such issue may require change to our product label such additional warning contraindication or even narrowed indication or to halt sale of product regulatory authority have been moving towards more active and transparent pharmacovigilance and are making greater amount of stand alone safety information and clinical trial data directly available to the public through website and other mean such periodic safety update report summary risk management plan summary and various adverse event data safety information without the appropriate context and expertise may be misinterpreted and lead to misperception or legal action our success depends to significant degree on our ability to obtain and defend our patent and other intellectual property right both domestically and internationally and to operate without infringing upon the patent or other proprietary right of third party patent and other proprietary right are very important to our business part of our business strategy we actively seek patent protection both in the united state and internationally and file additional patent application when appropriate to cover improvement in our compound product and technology our success depends to significant degree on our ability to obtain patent and license to patent right preserve trade secret and internal know how defend against infringement of our patent and effort to invalidate them and operate without infringing on the intellectual property of others patent application are confidential for period of time before patent is issued we may not know if our competitor have filed patent application for technology covered by our pending application or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent application if competitor file patent application covering our technology we may have to participate in litigation post grant proceeding before the patent and trademark office or other proceeding to determine the right to patent or validity of any patent granted such litigation and proceeding are unpredictable and expensive and could divert management attention from other operation such that even if we are ultimately successful we may be adversely impacted generic manufacturer have sought and may continue to seek fda approval to market generic version of our product through an abbreviated new drug application anda the application process typically used by manufacturer seeking approval of generic drug for description of our anda litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form the entry of generic version of our product ha and may in the future lead to market share and price erosion if we are found to infringe the valid patent of third party we may be required to pay significant monetary damage or we may be prevented from commercializing product or may be required to obtain license from these third party we may not be able to obtain alternative technology or any required license on commercially reasonable term or at all if we fail to obtain these license or alternative technology we may be unable to develop or commercialize some or all of our product for example we are aware of patent and patent application owned by third party that such party may claim cover the use of sofosbuvir axicabtagene ciloleucel or bictegravir well certain us of combination of emtricitabine ftc and tenofovir disoproxil fumarate tdf or taf for description of our pending patent litigation see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form furthermore we also rely on unpatented trade secret and improvement unpatented internal know how and technological innovation for example great deal of our liposomal manufacturing expertise which is key component of our liposomal technology is not covered by patent but is instead protected trade secret we protect these right mainly through confidentiality agreement with our corporate partner employee consultant and vendor we can not be certain that these party will comply with these confidentiality agreement that we have adequate remedy for any breach or that our trade secret internal know how or technological innovation will not otherwise become known or be independently discovered by our competitor under some of our agreement invention become jointly owned by and our corporate partner and in other case become the exclusive property of one party in certain circumstance it can be difficult to determine who owns particular invention and dispute could arise regarding those invention we could be adversely affected if our trade secret internal know how technological innovation or confidential information become known or independently discovered by competitor or if we enter into dispute over ownership of invention we face potentially significant liability and increased expense from litigation and government investigation relating to our product and operation we are involved in number of litigation investigation and other dispute related matter that require to expend substantial internal and financial resource these matter could require to pay significant monetary amount including royalty payment for past and future sale for example on february we reached an agreement with viiv healthcare company and related party collectively viiv for global resolution of all pending or potential claim related to our sale of biktarvy pursuant to which viiv granted gilead broad worldwide license and covenant not to sue relating to any past present or future development or commercialization of bictegravir and gilead agreed to make one time payment of billion and an ongoing royalty at rate of on future sale of biktarvy and the bictegravir component of bictegravir containing product in the united state until october we expect these matter will continue to require high level of internal and financial resource for the foreseeable future these matter have reduced and are expected to continue to reduce our earnings and require significant management attention in addition the testing manufacturing marketing and use of our commercial product well product candidate in development involve substantial risk of product liability claim these claim may be made directly by consumer healthcare provider pharmaceutical company or others we have limited insurance for product liability that may arise and claim may exceed our coverage for description of our litigation investigation and other dispute related matter see note commitment and contingency of the note to consolidated financial statement included in part ii item of this annual report on form the outcome of such legal proceeding or any other legal proceeding that may be brought against the investigation or any other investigation that may be initiated and any other dispute related matter are inherently uncertain and adverse development or outcome can result in significant expense monetary damage penalty or injunctive relief against risksour business ha been and may in the future be adversely affected by outbreak of epidemic pandemic or contagious disease including the ongoing covid outbreak actual or threatened outbreak of epidemic pandemic or contagious disease such covid may significantly disrupt our global operation and adversely affect our business financial condition and result of operation for example the covid pandemic ha caused significant volatility and uncertainty in and international market and ha resulted in increased risk and adverse impact to our operation including described below in addition to the development discussed in part ii item management discussion and analysis of financial condition and result of operation we are monitoring number of risk related to the pandemic including the following supply chain the pandemic could result in disruption to our global supply chain and distribution in the future for example quarantine shelter in place and other governmental order and policy travel restriction airline capacity and route reduction safety guideline and health impact of the pandemic could impact the availability or productivity of product and personnel at manufacturer distributor freight carrier and other necessary component of our supply chain in addition there may be unfavorable change in the availability or cost of raw material intermediate and other material necessary for production which may result in higher cost disruption in our supply chain and interruption in our distribution capability clinical trial the pandemic ha adversely affected and may continue to adversely affect certain of our clinical trial including our ability to initiate and complete our clinical trial within the anticipated timeline for ongoing trial clinical trial site have imposed restriction on patient visit to limit risk of possible covid exposure and we may experience issue with participant compliance with clinical trial protocol result of quarantine travel restriction and interruption to healthcare service there is also risk that closure at clinical site may be necessary the pandemic and related guidance and restriction continue to evolve for the foregoing reason we have experienced delay with new subject enrollment for most clinical trial during the course of the pandemic and may continue to experience overall delay in our clinical trial there is also the risk of biased data collection if only certain clinical trial site remain open result of these challenge our anticipated filing and marketing timeline for certain product may be adversely impacted regulatory review the operation of fda ema or other regulatory agency may be adversely affected we may also experience delay in necessary interaction with regulatory authority around the world including with respect to any anticipated filing which together with other factor resulting from the pandemic may adversely impact our ability to launch new commercial product access to healthcare provider the pandemic ha limited patient ability or willingness to access and seek care from healthcare provider and initiate or continue therapy which ha resulted in lower demand for our product during the course of the pandemic particularly with respect to hepatitis virus hcv treatment and hiv treatment and prevention for example we have observed lower level of patient visit and testing volume in hcv resulting in fewer patient start in addition at time during the pandemic we have seen lower level of screening and diagnosis for hiv resulting in fewer treatment initiation well higher level of discontinuation resulting in reduction in prescription refill with increased level of unemployment at time during the pandemic we have also experienced shift in payer mix towards more government funded coverage and the uninsured segment our field personnel have also had reduced access to healthcare personnel during the pandemic including fewer in person interaction which ha adversely impacted and may continue to adversely impact our commercial activity employee we face risk related to the health safety morale and productivity of our employee including the safe occupancy of our site during the pandemic in the fourth quarter of we transitioned to return to site phase for our flexible location employee our job site enhancement and risk protocol which include health screening and covid testing and vaccine requirement do not guarantee that we can maintain the continued safe occupancy of our site and may adversely impact employee recruitment and retention on site employee testing positive for covid could lead to mandatory quarantine and potential site shutdown financial the pandemic ha had and may continue to have an adverse financial impact in the short term and potentially beyond in particular our hcv and hiv business have been and continue to be adversely impacted for example we have observed reduction in the overall hcv treatment hiv treatment and hiv pre exposure prophylaxis prep volume at time during the pandemic and it is uncertain when these volume will all return to pre pandemic level we may continue to experience fluctuating revenue infection rate rise and fall and pandemic restriction are periodically tightened and eased we have also experienced and may continue to experience volatility in our short term revenue due to fluctuation in inventory channel purchase during the pandemic we could also have additional unexpected expense related to the pandemic which could negatively affect our result of operation these factor together with the overall uncertainty and disruption caused by the pandemic could result in increased volatility and decreased predictability in our result of operation and volatility in our stock price the pandemic ha also amplified many of the other risk described throughout the risk factor section of this annual report on form the extent to which the pandemic impact our business and result will depend on future development which are uncertain and can not be predicted with confidence including any potential future wave of the pandemic new variant of the virus that impact the severity and duration of the pandemic the development distribution effectiveness and public acceptance of vaccine and any other ongoing and future action taken to contain the pandemic we face risk associated with our global operation our global operation are accompanied by certain financial political economic and other risk including those listed below foreign currency exchange for the year ended december approximately of our product sale were outside the united state because significant percentage of our product sale is denominated in foreign currency primarily the euro we face exposure to adverse movement in foreign currency exchange rate overall we are net receiver of foreign currency and therefore we benefit from weaker dollar and are adversely affected by stronger dollar our hedging program doe not eliminate our exposure to currency fluctuation we may be adversely impacted if the dollar appreciates significantly against certain currency and our hedging program doe not sufficiently offset the effect of such appreciation interest rate and inflation we hold interest generating asset and interest bearing liability including our available for sale debt security and our senior unsecured note and credit facility fluctuation in the interest rate could expose to increased financial risk in addition change in the inflation rate could also adversely impact our business and financial result anti bribery we are subject to the foreign corrupt practice act and similar worldwide anti bribery law that govern our international operation with respect to payment to government official our international operation are heavily regulated and require significant interaction with foreign official we operate in part of the world that have experienced governmental corruption to some degree in certain circumstance strict compliance with anti bribery law may conflict with local custom and practice or may require to interact with doctor and hospital some of which may be state controlled in manner that is different than local custom it is possible that certain of our practice may be challenged under these law in addition our internal control policy and procedure may not protect from reckless or criminal act committed by our employee and agent enforcement activity under anti bribery law could subject to administrative and legal proceeding and action which could result in civil and criminal sanction including monetary penalty and exclusion from healthcare program other risk inherent in conducting global business include restrictive government action against our intellectual property and other foreign asset such nationalization expropriation the imposition of compulsory license or similar action including waiver of intellectual property protection protective economic policy taken by foreign government such trade protection measure and import and export licensing requirement which may result in the imposition of trade sanction or similar restriction by the united state or other government business interruption stemming from natural or man made disaster such climate change earthquake hurricane flooding fire extreme heat drought or actual or threatened public health emergency or effort taken by third party to prevent or mitigate such disaster such public safety power shutoffs and facility shutdown for which we may be uninsured or inadequately insured for example our corporate headquarters in foster city and certain and manufacturing facility are located in california seismically active region in the event of major earthquake we may not carry adequate earthquake insurance and significant recovery time could be required to resume operation political instability or disruption in geographic region where we operate regardless of cause including war terrorism social unrest and political change aspiration goal and disclosure related to environmental social and governance esg matter expose to numerous risk including risk to our reputation and stock price institutional and individual investor are increasingly using esg screening criterion to determine whether gilead qualifies for inclusion in their investment portfolio we are frequently asked by investor and other stakeholder to set ambitious esg goal and provide new and more robust disclosure on goal progress toward goal and other matter of interest to esg stakeholder in response we have adapted the tracking and reporting of our corporate responsibility program to various evolving esg framework and we have established and announced goal and other objective related to esg matter these goal statement reflect our current plan and aspiration and are not guarantee that we will be able to achieve them our effort to accomplish and accurately report on these goal and objective present numerous operational reputational financial legal and other risk any of which could have material negative impact including on our reputation and stock price our ability to achieve any goal or objective including with respect to environmental and diversity initiative is subject to numerous risk many of which are outside of our control example of such risk include the availability and cost of low or non carbon based energy source and technology evolving regulatory requirement affecting esg standard or disclosure the availability of supplier that can meet our sustainability diversity and other standard our ability to recruit develop and retain diverse talent in our labor market and the impact of our organic growth and acquisition or disposition of business or operation the standard for tracking and reporting on esg matter are relatively new have not been harmonized and continue to evolve our selection of disclosure framework that seek to align with various reporting standard may change from time to time and may result in lack of consistent or meaningful comparative data from period to period in addition our process and control may not always comply with evolving standard for identifying measuring and reporting esg metric our interpretation of reporting standard may differ from those of others and such standard may change over time any of which could result in significant revision to our goal or reported progress in achieving such goal if our esg practice do not meet evolving investor or other stakeholder expectation and standard then our reputation our ability to attract or retain employee and our attractiveness an investment business partner or acquiror could be negatively impacted similarly our failure or perceived failure to pursue or fulfill our goal target and objective or to satisfy various reporting standard within the timeline we announce or at all could also have similar negative impact and expose to government enforcement action and private litigation we depend on relationship with third party for sale and marketing performance technology development logistics and commercialization of product failure to maintain these relationship poor performance by these company or dispute with these third party could negatively impact our business we rely on number of collaborative relationship with third party for our sale and marketing performance in certain territory for example we have collaboration arrangement with janssen science ireland uc for odefsey complera eviplera and symtuza in some country we rely on international distributor for sale of certain of our product some of these relationship also involve the clinical development of these product by our partner reliance on collaborative relationship pose number of risk including the risk that we are unable to control the resource our corporate partner devote to our program or product dispute may arise with respect to the ownership of right to technology developed with our corporate partner disagreement with our corporate partner could cause delay in or termination of the research development or commercialization of product candidate or result in litigation or arbitration contract with our corporate partner may fail to provide significant protection or may fail to be effectively enforced if one of these partner fails to perform our corporate partner have considerable discretion in electing whether to pursue the development of any additional product and may pursue alternative technology or product either on their own or in collaboration with our competitor our corporate partner with marketing right may choose to pursue competing technology or to devote fewer resource to the marketing of our product than they do to product of their own development and our distributor and our corporate partner may be unable to pay given these risk there is great deal of uncertainty regarding the success of our current and future collaborative effort if these effort fail our product development or commercialization of new product could be delayed or revenue from product could decline to the specialized and technical nature of our business the failure to attract develop and retain highly qualified personnel could adversely impact our future success will depend in large part on our continued ability to attract develop and retain highly qualified scientific technical and management personnel well personnel with expertise in clinical testing governmental regulation and commercialization our ability to do so also depends in part on how well we maintain strong workplace culture that is attractive to employee in addition competition for qualified personnel in the biopharmaceutical field is intense and there is limited pool of qualified potential employee to recruit we face competition for personnel from other company university public and private research institution government entity and other organization additionally change to immigration and work authorization law and regulation could make it more difficult for employee to work in or transfer to one of the jurisdiction in which we operate significant cybersecurity incident could give rise to legal liability and regulatory action under data protection and privacy law and adversely affect our business and operation we are dependent upon information technology system infrastructure and data including our kite konnect platform which is critical to maintain chain of identity and chain of custody of yescarta and tecartus the multitude and complexity of our computer system make them inherently vulnerable to service interruption or destruction malicious intrusion and ransomware attack likewise data privacy or security breach by employee or others can result in the exposure of sensitive data including our intellectual property or trade secret or the personal information of our employee patient customer or other business partner to unauthorized person or to the public cybersecurity incident are increasing in their frequency sophistication and intensity including during the covid pandemic cybersecurity incident include for example the deployment of harmful malware ransomware denial of service social engineering and other mean to affect service reliability and threaten data confidentiality integrity and availability our business and technology partner face similar risk and any security breach of their system could adversely affect our security posture like many company we have experienced cybersecurity incident including data breach and service interruption when cybersecurity incident occur we respond and address them in accordance with applicable governmental regulation and other legal requirement including our cybersecurity protocol there can be no assurance that our effort in response to cybersecurity incident well our investment to protect our information technology infrastructure and data will shield from significant loss and potential liability or prevent any future interruption or breach of our system such cybersecurity incident can cause the loss of critical or sensitive information including personal information and could give rise to legal liability and regulatory action under data protection and privacy law regulator globally are also imposing new data privacy and security requirement including new and greater monetary fine for privacy violation for example the general data protection regulation gdpr established regulation regarding the handling of personal data and non compliance with the gdpr may result in monetary penalty of up to four percent of worldwide revenue in addition new domestic data privacy and security law such the california consumer privacy act and the california privacy right act and other law that have been or may be passed similarly introduce requirement with respect to personal information and non compliance with such law may result in liability through private action subject to statutorily defined damage in the event of certain data breach and enforcement other change or new law or regulation associated with the enhanced protection of personal information including in some case healthcare data or other personal information could greatly increase our cost of providing our product and service or even prevent from offering certain service in jurisdiction in which we operate and financial riskswe are subject to risk associated with engaging in business acquisition licensing arrangement collaboration option equity investment asset divestiture and other strategic transaction we have engaged in and may in the future engage in such transaction part of our business strategy we may not identify suitable transaction in the future and if we do we may not complete such transaction in timely manner on cost effective basis or at all and may not realize the expected benefit if we are successful in making an acquisition or closing licensing arrangement or collaboration the product intellectual property and technology that are acquired or licensed may not be successful or may require significantly greater resource and investment than anticipated part of our annual impairment testing of our goodwill and other indefinite lived intangible asset in the fourth quarter and earlier if impairment indicator exist required under generally accepted accounting principle we may need to recognize impairment charge if the product intellectual property and technology that are acquired or licensed are not successful for option structured deal there is no assurance that we will elect to exercise our option right and it is possible that disagreement uncertainty or other circumstance may arise including with respect to whether our option right have been appropriately triggered which may hinder our ability to realize the expected benefit for equity investment in our strategic transaction such in connection with our collaboration with arcus bioscience inc and galapagos nv the value of our equity investment may fluctuate and decline in value if we are not successful in the execution or implementation of these transaction our financial condition cash flow and result of operation may be adversely affected and our stock price could decline we have paid substantial amount of cash and incurred additional debt to finance our strategic transaction additional indebtedness and lower cash balance could result in downgrade of our credit rating limit our ability to borrow additional fund or refinance existing debt on favorable term increase our vulnerability to adverse economic or industry condition and reduce our financial flexibility to continue with our capital investment stock repurchase and dividend payment for example result of the cash used and the debt issued in connection with our acquisition of immunomedics inc in global rating downgraded our credit rating we may be adversely impacted by any failure to overcome these additional risk change in our effective income tax rate could reduce our earnings we are subject to income tax in the united state and various foreign jurisdiction due to economic and political condition various country are actively considering and have made change to existing tax law and we can not predict the form or timing of such change our effective tax rate are affected by change in the mix of earnings in country with differing statutory tax rate change in the valuation of deferred tax asset and liability the introduction of new tax and change in tax law regulation administrative practice and interpretation including in the united state germany and ireland we are also subject to the examination of our tax return and other tax matter by the internal revenue service and tax authority in various foreign jurisdiction there are differing interpretation of tax law and regulation and result significant dispute may arise with these tax authority involving issue of the timing and amount of deduction and allocation of income among various tax jurisdiction we may be adversely affected by the resolution of one or more of these exposure in any reporting period item unresolved staff comment not applicable item property our corporate headquarters are located in foster city california where we house our administrative manufacturing and activity we also have facility in emeryville oceanside and santa monica california seattle washington morris plain new jersey frederick maryland edmonton canada and dublin ireland our principal manufacturing facility are in el segundo la verne oceanside and san dimas california edmonton canada cork ireland and hoofddorp netherlands for more information about our manufacturing facility see item business our manufacturing facility our global operation include office in europe north america asia south america africa australia and the middle east we believe that our existing property including both owned and leased site are adequate and suitable for the conduct of our business we believe our capital resource are sufficient to purchase lease or construct any additional facility required to meet our expected long term growth need legal proceeding for description of our significant pending legal proceeding see note commitment and contingency legal proceeding of the note to consolidated financial statement included in part ii item of this annual report on form item mine safety disclosure not applicable ii item market for registrant common equity related stockholder matter and issuer purchase of equity security our common stock is traded on the nasdaq global select market under the symbol gild of february we had approximately stockholder of record of our common stock performance graph the following graph compare our cumulative total stockholder return for the past five year to two index the standard poor stock index index and the nasdaq biotechnology index nbi index the stockholder return shown on the graph below is not necessarily indicative of future performance and we do not make or endorse any prediction to future stockholder return comparison of cumulative total return on investment for the past five year ______________________________________________________ this section is not soliciting material is not deemed filed with the security and exchange commission sec and is not to be incorporated by reference in any of our filing under the security act of amended the security act or the security exchange act of exchange act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing show the cumulative return on investment assuming an investment of in our common stock the nbi index and the index on december and assuming that all dividend were reinvested compensation plan informationthe following table provides certain information with respect to our equity compensation plan in effect of december in million except per share amount number of common share to be issued upon exercise of outstanding option warrant and right weighted average exercise price of outstanding option warrant and right number of common share remaining available for future issuance under equity compensation plan excluding security reflected in column plan category equity compensation plan approved by security holder equity incentive plan employee stock purchase plan total equity compensation plan approved by security equity compensation plan not approved by security holder ______________________________________________________ doe not take into account million restricted stock unit performance share award or unit and phantom share which have no exercise price and were granted under our and equity incentive plan includes award and share previously issuable under the immunomedics inc amended and restated long term incentive plan the immunomedics plan which wa assumed in connection with our acquisition of immunomedics inc and subsequently merged into the equity incentive plan under our employee stock purchase plan participant are permitted to purchase our common stock at discount on certain date through payroll deduction within pre determined purchase period accordingly these number are not determinable includes award and share issuable under the forty seven inc equity incentive plan which wa assumed in connection with our acquisition of forty seven inc forty seven and subsequently amended and restated our equity incentive plan material feature of the gilead science inc equity incentive planthe forty seven inc equity incentive plan wa originally established by forty seven in june in connection with gilead acquisition of forty seven in april gilead assumed the forty seven inc equity incentive plan and amended and restated it the gilead science inc equity incentive plan the plan the plan is intended to help the gilead secure and retain the service of eligible award recipient provide incentive for such person to exert maximum effort for the success of gilead and any affiliate and provide mean by which the eligible recipient may benefit from increase in value of gilead common stock from and after april only employee and consultant of forty seven of immediately prior to such date and employee and consultant of gilead hired on or following such date are eligible to receive grant of new award under the plan the plan provides for the award of incentive stock option and non qualified stock option each of which must generally have an exercise price equal to at least the fair market value of our common stock on the date of grant stock appreciation right restricted stock award restricted stock unit award performance stock award other stock award and performance cash award of april the aggregate number of share of common stock issuable under the plan from and after such date wa from and after april gilead ha granted restricted stock unit performance share award or unit and stock option under the plan and these are the only type of equity award outstanding under the plan of december million share of gilead common stock remained available for issuance under the plan issuer purchase of equity security in the first quarter of our board of director authorized billion stock repurchase program the program under which repurchase may be made in the open market or in privately negotiated transaction we made repurchase under the program starting in april in the first quarter of our board of director authorized new billion stock repurchase program the program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction during we repurchased and retired million share of our common stock for million through open market transaction under the program of december the remaining authorized repurchase amount from both program wa billion table below summarizes our stock repurchase activity for the three month ended december total numberof sharespurchased in thousand averageprice paidper share in dollar total number ofshares purchasedas part of publiclyannounced program in thousand maximum fairvalue of sharesthat may yet bepurchased underthe program in million october october november november december december ______________________________________________________ the difference between the total number of share purchased and the total number of share purchased part of publicly announced program is due to share of common stock withheld by from employee restricted stock award in order to satisfy applicable tax withholding obligation dividendsfor the year ended december and we paid quarterly dividend we expect to continue to pay quarterly dividend although the amount and timing of any future dividend are subject to declaration by our board of director additional information is included in item management discussion and analysis of financial condition and result of operation to the consolidated financial statement item reserved item management discussion and analysis of financial condition and result of operationsthe following management discussion and analysis of financial condition and result of operation md is intended to help the reader understand our result of operation and financial condition md is provided supplement to and should be read in conjunction with our audited consolidated financial statement and the accompanying note to consolidated financial statement and other disclosure included in this annual report on form including the disclosure under part item risk factor additional information related to the comparison of our result of operation between the year and is included in item management discussion and analysis of financial condition and result of operation of our form filed with the security and exchange commission the sec our consolidated financial statement have been prepared in accordance with generally accepted accounting principle and are presented in dollar management overviewgilead science inc gilead we our or is biopharmaceutical company that ha pursued and achieved breakthrough in medicine for more than three decade with the goal of creating healthier world for all people we are committed to advancing innovative medicine to prevent and treat life threatening disease including hiv viral hepatitis and cancer we operate in more than country worldwide with headquarters in foster city california our portfolio of marketed product includes ambisome atripla biktarvy cayston complera descovy descovy for prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada for prep tybost veklury vemlidy viread vosevi yescarta and zydelig the approval status of hepcludex and jyseleca vary worldwide and hepcludex and jyseleca are not approved in the united state we also sell and distribute authorized generic version of epclusa and harvoni in the united state through our separate subsidiary asegua therapeutic llc in addition we sell and distribute certain product through our corporate partner under collaborative agreement business highlight we delivered strong financial performance in veklury continued to play critical role in addressing the coronavirus disease covid pandemic veklury performance helped mitigate the impact of covid on other part of the business including on our hiv and chronic hepatitis virus hcv franchise and the impact of the october loss of exclusivity of truvada and atripla in the united state despite these transitory headwind underlying demand for our virology portfolio remained strong led by the continued growth of our biktarvy franchise we also received increased contribution from our oncology franchise experiencing growth in trodelvy well our cell therapy franchise continued to expand and strengthen both our commercial portfolio and clinical pipeline across therapeutic focus area to drive future growth potential during we announced an additional six filing for regulatory approval in addition to investing in our internal pipeline program we also continued to enter into and leverage our existing strategic collaboration and partnership including opting into four additional pipeline asset from our collaboration with arcus bioscience inc arcus to further develop the foundation for more sustainable and diversified business viral disease in october food and drug administration fda approved new low dose tablet dosage form of biktarvy for pediatric patient weighing at least kg to le than kg who are virologically suppressed or new to antiretroviral therapy in august our marketing authorization application for lenacapavir an investigational long acting hiv capsid inhibitor wa fully validated and is under evaluation with the european medicine agency ema in june fda granted approval of new oral pellet formulation of epclusa expanding the pediatric indication to treat child young year of age with chronic hcv in june we submitted new drug application to fda for lenacapavir an investigational long acting agent in development for the treatment of hiv in people with limited therapy option in march we entered into an agreement with merck sharp dohme corp merck subsidiary of merck co inc to jointly develop and commercialize long acting investigational treatment in hiv that combine gilead investigational capsid inhibitor lenacapavir and merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir in march we completed the acquisition of myr gmbh myr the acquisition provides with hepcludex which is conditionally approved by ema for the treatment of chronic hepatitis delta virus hdv in adult with compensated liver disease covid in january fda granted expedited approval for veklury for the treatment of non hospitalized adult and adolescent patient who are at high risk of progression to severe covid including hospitalization or death in december the european commission granted approval to expand the indication for veklury for use in the earlier stage of the disease in adult patient who do not require supplemental oxygen and are at increased risk of progressing to severe covid in april we announced that we will provide assistance and support for expansion of local manufacturing capacity of remdesivir in india and will donate the active pharmaceutical ingredient and ii donate minimum of vial of veklury remdesivir to the government of india oncologycell therapy in january fda approved an update to the prescribing information for yescarta to include the use of prophylactic corticosteroid across all approved indication yescarta is now the first and only chimeric antigen receptor car cell therapy with information in the label to help physician manage and potentially prevent treatment side effect in october fda approved tecartus for the treatment of adult patient with relapsed or refractory cell precursor acute lymphoblastic leukemia all tecartus is the first and only car cell therapy approved for adult with all in september kite gilead company kite submitted supplemental biologics license application to fda for yescarta to expand it current indication to include the treatment of adult with relapsed or refractory large cell lymphoma lbcl in the second line setting in august kite and appia bio inc entered into collaboration and license agreement to research and develop hematopoietic stem cell derived cell therapy directed toward hematological malignancy in june kite entered into research collaboration and license agreement with shoreline bioscience inc to develop novel allogeneic cell therapy across variety of cancer target in june fosun kite biotechnology co ltd joint venture between kite and shanghai fosun pharmaceutical group co ltd received approval from the china national medical product administration for axicabtagene ciloleucel for the treatment of adult patient with relapsed or refractory lbcl in china in march fda granted accelerated approval of yescarta for the treatment of adult patient with relapsed or refractory follicular lymphoma fl in january we entered into clinical trial collaboration agreement with merck to evaluate trodelvy in combination with merck anti programmed death receptor pd therapy keytruda in first line setting for patient with non small cell lung cancer nsclc in november the european commission granted marketing authorization for trodelvy for treatment of metastatic triple negative breast cancer tnbc in adult patient with unresectable or metastatic tnbc who have received two or more prior systemic therapy at least one of them for advanced disease in november we exercised option to three program in the clinical stage portfolio of arcus including anti tigit molecule domvanalimab and well clinical candidate etrumadenant dual adenosine receptor antagonist and quemliclustat small molecule inhibitor the transaction closed in december in october we entered into clinical trial collaboration and supply agreement with merck to evaluate the efficacy of trodelvy in combination with keytruda first line treatment for patient with locally advanced or metastatic tnbc in september health canada approved trodelvy for the treatment of adult patient with unresectable locally advanced or metastatic tnbc who have received two or more therapy at least one of them for metastatic disease canada joined australia great britain switzerland and the united state among the country that have approved trodelvy for use under project orbis global collaborative review program for high impact oncology marketing application across participating country in april fda granted accelerated approval of trodelvy for use in adult patient with locally advanced or metastatic urothelial cancer uc new indication in april fda granted full approval of trodelvy for adult patient with unresectable locally advanced or metastatic tnbc ______________________________________________________ we announced and discussed these update in further detail in press release available on our website at www gilead com reader are also encouraged to review all other press release available on our website mentioned above the content on the referenced website doe not constitute part of and is not incorporated by reference into this annual report on form financial highlight in million except percentage and per share amount revenue net income attributable to gilead nmnet income per share attributable to gilead common stockholder diluted nm________________________________nm not meaningfultotal revenue increased by to billion in compared to billion in primarily due to increased sale of veklury our fda approved treatment for hospitalized patient with covid the increase also reflects the continued growth of biktarvy in all geography and the continued uptake of trodelvy cell therapy and chronic hepatitis virus hbv and hdv product the increase were partially offset by the decrease in truvada and atripla sale in the united state expected primarily due to the continued generic competition following the october loss of exclusivity in the united state net income attributable to gilead wa billion or diluted earnings per share in compared to million or diluted earnings per share in the increase wa primarily due to lower acquired in process research and development ipr charge revenue growth and lower unrealized loss from our equity investment partially offset by billion charge for settlement related to bictegravir litigation and charge of million related to the arcus collaboration opt in our acquired ipr expense in were billion primarily related to our acquisition of forty seven well collaboration and other investment that we entered into during the year with arcus pionyr immunotherapeutics inc pionyr tango therapeutic inc tango tizona therapeutic inc tizona and jounce therapeutic inc jounce strategy and outlook purpose is to deliver life changing medication to patient in need through scientific breakthrough innovation and strong operational execution our strategic ambition are to bring transformative therapy to patient by ii be the biotech employer and partner of choice and iii deliver shareholder value in sustainable and responsible manner our strategic priority reflect how we will deliver those ambition expand internal and external innovation ii strengthen portfolio strategy and decision making iii increase patient benefit and access and iv continue to evolve our culture we will continue to focus on executing our strategy to expand and diversify our commercial portfolio and clinical pipeline across our three therapeutic focus area virology oncology and inflammation specifically we plan to significantly increase clinical development study across our novel oncology portfolio while maintaining our leadership in antiviral medication through our work in hiv hepatitis the covid pandemic and emerging virus our collaboration with arcus provides additional opportunity for to further develop the foundation for more sustainable and diversified business beyond expanding our product and pipeline we also continue to focus on our employee the evolution of our culture and our effort to promote racial equity and social justice additionally we expect to maintain rigorous focus on disciplined expense management while the covid pandemic continues to impact our business and broader market dynamic we expect revenue growth of between in product sale excluding veklury compared to our hiv product sale will continue to recover from the covid pandemic and demonstrate year over year growth the financial impact of the truvada and atripla loss of exclusivity will be largely behind starting in the second quarter of we also expect our oncology business including cell therapy and trodelvy to contribute to our growth veklury sale are generated in highly dynamic and complex global environment which continues to evolve result veklury sale are subject to significant volatility and uncertainty future product demand will depend on the nature of the covid pandemic including duration infection rate hospitalization and availability and adoption of alternative therapy and vaccine while we anticipate year over year decline in veklury product sale we expect veklury to continue to play key role in the pandemic and contribute meaningfully to our revenue in more heavily weighted towards the beginning of the year our ability to deliver on our strategy is subject to number of uncertainty including but not limited to the effect of the covid pandemic which remains unpredictable the uncertainty regarding the amount and timing of future veklury sale the continuation of an uncertain global macroeconomic environment our ability to realize the potential benefit of our acquisition collaboration or licensing arrangement our ability to initiate progress or complete clinical trial within currently anticipated timeframes including result of any current or future hold on clinical trial the possibility of unfavorable result from new and ongoing clinical trial our ability to submit new drug application for new product candidate or expanded indication in the currently anticipated timeline our ability to receive regulatory approval in timely manner or at all market share and price erosion caused by the introduction of generic loss of exclusivity of our product higher than anticipated effect of the loss of exclusivity from truvada and atripla slower than anticipated growth in biktarvy trodelvy vemlidy and cell therapy product inaccuracy in our patient start estimate additional pricing pressure from payer and competitor an increase in discount chargebacks and rebate due to ongoing contract and future negotiation with commercial and government payer potential government action that could have the effect of lowering price larger than anticipated shift in payer mix to more highly discounted payer segment and volatility in foreign currency exchange rate result of operationsrevenuesthe following table summarizes the period over period change in our revenue year ended december ended december in million except percentage europeother internationaltotalu europeother internationaltotalchangeproduct sale hiv hbv cell total product royalty contract and other total revenue ________________________________nm not saleshivhiv product sale decreased by to billion in compared to billion in due to the anticipated decline in sale volume of our truvada emtricitabine ftc and tenofovir disoproxil fumarate tdf based product driven by the continued generic competition following the october loss of exclusivity of truvada and atripla in the united state truvada and atripla product sale were billion lower in compared to the decrease wa also impacted by lower sale of genvoya driven by decrease in volume worldwide primarily due to patient switching to biktarvy these decline were partially offset by an increase in biktarvy product sale worldwide driven by higher demand higher net average selling price driven by favorable change in estimate of government rebate and discount in the united state we expect that our hiv business will continue to recover from the covid pandemic in we also expect the impact of the truvada and atripla loss of exclusivity will be largely behind starting in the second quarter of vekluryveklury product sale were billion in compared to billion in veklury became commercially available in the third quarter of resulting in partial year of sale in the increase wa also attributable to higher hospital demand worldwide sale of veklury are generally affected by covid related rate of infection hospitalization and vaccination well the availability uptake and effectiveness of alternative treatment for covid result future sale of veklury are difficult to predict hcvhcv product sale decreased by to billion in compared to billion in primarily due to lower demand driven by fewer patient start worldwide due to the impact of the covid pandemic the slight increase in hcv sale in europe in wa due to favorable change in estimate of government rebate which offset the revenue decrease associated with lower demand hbv hdvhbv and hdv product sale increased by to million in compared to million in primarily due to higher vemlidy product sale due to higher demand in all geography partially offset by lower viread product sale in other international location hepcludex sale in were million launch activity continued across europe following our first quarter acquisition of myr cell therapycell therapy product sale which include yescarta and tecartus increased by to million in compared to million in the growth wa primarily due to the july launch of tecartus in the united state for the treatment of adult patient with relapsed or refractory mantle cell lymphoma mcl and the december launch of tecartus for mcl in europe resulting in partial year of sale in the increase wa also driven by continued higher demand for yescarta worldwide for lbcl and volume growth related to approval of yescarta for fl in the united state in trodelvytrodelvy product sale increased to million in compared to million in we obtained trodelvy through the fourth quarter acquisition of immunomedics resulting in partial year of sale in in addition revenue include continued uptake of trodelvy following the full regulatory approval for metastatic tnbc in the united state and europe and accelerated approval for metastatic uc in the united state other product salesother product sale which include ambisome cayston jyseleca letairis ranexa and zydelig were billion in and remained flat compared to ambisome sale volume increased due to higher demand in geography outside the united state the increase wa mostly offset by lower letairis sale in the united state anticipated due to continued generic competition following the loss of exclusivity in gross to net deductionswe record product sale net of estimated government and other rebate and chargebacks cash discount for prompt payment distributor fee sale return and other related cost these deduction totaled billion or of gross product sale in compared to billion or of gross product sale in the reduction is driven by change in product mix primarily due to higher veklury sale in of the billion in billion or of gross product sale wa related to government and other rebate and chargebacks and billion wa related to cash discount for prompt payment distributor fee sale return and other related cost currency exchange impactof our total product sale and were generated outside the united state in and respectively we generally face exposure to movement in foreign currency exchange rate primarily in the euro we use foreign currency exchange contract to hedge portion of our foreign currency exposure foreign currency exchange net of hedge had favorable impact on our total product sale of million in based on comparison using foreign currency exchange rate from largely driven by euro based product sale following table summarizes the period over period change in our product sale year ended december ended december in million except percentage europeother internationaltotalu europeother internationaltotalchangehiv productsdescovy ftc taf based productsbiktarvy revenue share symtuza total descovy ftc taf based truvada ftc tdf based complera total truvada ftc tdf based other hiv total hcv productsledipasvir sofosbuvir sofosbuvir velpatasvir other hcv total hbv hdv other hbv hdv nmtotal hbv cell therapy total cell therapy nmother other total other total product _______________________________nm not meaningful represents our revenue from cobicistat emtricitabine ftc and tenofovir alafenamide taf in symtuza darunavir ftc taf fixed dose combination product commercialized by janssen science ireland unlimited company includes emtriva and tybost amount consist of sale of harvoni and the authorized generic version of harvoni sold by our separate subsidiary asegua therapeutic llc amount consist of sale of epclusa and the authorized generic version of epclusa sold by our separate subsidiary asegua therapeutic llc includes vosevi and sovaldi includes hepcludex and hepsera includes cayston and jyseleca and expensesthe following table summarizes the period over period change in our cost and expense in million except percentage of good sold product gross bpsresearch and development expense acquired ipr expense selling general and administrative sg expense product gross marginin product gross margin decreased to compared to in primarily due to billion charge for settlement related to bictegravir litigation well an increase of million in acquisition related expense from amortization of finite lived intangible asset and recognition of inventory step up charge primarily driven by our acquisition of immunomedics and myr product gross margin wa also impacted by higher inventory write down charge and change in product mix the increase were partially offset by lower royalty expense due to lower sale of product containing emtricitabine and elvitegravir and the reversal of previously recorded million litigation accrual following favorable court decision related to axicabtagene ciloleucel research and development expensesr expense consist primarily of clinical study performed by contract research organization material and supply payment under collaborative and other arrangement including milestone payment license and fee expense reimbursement to the collaboration partner personnel cost including salary benefit and stock based compensation expense and overhead allocation consisting of various support and infrastructure cost we manage our expense by identifying the activity we anticipate will be performed during given period and then prioritizing effort based on scientific data probability of technical and regulatory successful development market potential available human and capital resource and other consideration we continually review our project based on unmet medical need and necessary reallocate resource among our internal portfolio and external opportunity that we believe will best support the long term growth of our business in expense increased by million compared to primarily due to the arcus collaboration opt in charge of million well higher investment in trodelvy and magrolimab clinical activity these increase were partially offset by decline of approximately million in external expense related to wind down or completion of certain remdesivir clinical study ii million million charge recorded in in connection with the agreement to amend the existing arrangement with galapagos for the commercialization and development of jyseleca and iii lower stock based compensation expense expense for included accelerated stock based compensation expense of million related to our acquisition of immunomedics and forty seven acquired in process research and development expensesacquired ipr expense reflect ipr impairment well the initial cost of externally developed ipr project acquired directly in transaction other than business combination that do not have an alternative future use including upfront payment related to various collaboration and the initial cost of right to ipr project acquired ipr expense of million in were related to licensing collaboration investment and other arrangement we entered into during the year acquired ipr expense of billion in were primarily related to our acquisition of forty seven well collaboration and other investment we entered into during the year with arcus pionyr tango tizona and jounce selling general and administrative expense sg expense relate to sale and marketing finance human resource legal and other administrative activity including information technology investment sg expense consist primarily of personnel cost facility and overhead cost outside marketing advertising and legal expense and other general and administrative cost sg expense also include the branded prescription drug bpd fee in the united state we along with other pharmaceutical manufacturer of branded drug product are required to pay portion of the bpd fee which is estimated based on select government sale during the prior year percentage of total industry government sale sg expense increased by million compared to primarily due to an expense of million related to the donation of certain equity security at fair value to the gilead foundation california nonprofit organization the foundation and increased commercial activity including higher promotional and marketing activity primarily driven by trodelvy sg expense for included accelerated stock based compensation expense of million related to our acquisition of immunomedics and forty seven and charge of million related to department of justice investigation which wa settled in the third quarter of interest expense and other income expense netthe following table summarizes the period over period change in our interest expense and other income expense net in million except percentage expense other income expense net interest expense for increased by million or compared to primarily due to an increase in borrowing related to the fourth quarter acquisition of immunomedics partially offset by lower interest expense due to debt maturity and repayment the change in other income expense net for compared to primarily reflects lower unrealized loss from fair value adjustment of our investment in equity security largely driven by our investment in galapagos partially offset by lower interest income change in the fair value of equity security resulted in net unrealized loss of million and billion for the year ended december and respectively income tax the following table summarizes the period over period change in our income tax expense benefit in million except percentage before income tax income tax expense effective tax our effective tax rate decreased in compared to primarily due to billion acquired ipr charge recorded in connection with our acquisition of forty seven and million of certain other acquired ipr charge in that were non deductible for tax purpose liquidity and capital resourcesour cash cash equivalent and marketable debt security were billion and billion of december and respectively cash flowsthe following table summarizes our cash flow activity in million cash provided by used in operating activity investing activity financing activity operating activitiescash provided by operating activity represents the cash receipt and disbursement related to all of our activity other than investing and financing activity operating cash flow is derived by adjusting our net income for non cash item and change in operating asset and liability cash provided by operating activity increased by billion to billion in compared to the increase wa primarily due to revenue growth from sale of veklury well higher collection of receivables in activitiescash used in investing activity primarily consists of purchase sale and maturity of our marketable debt security capital expenditure acquisition including ipr net of cash acquired purchase of equity security and other investment cash used in investing activity wa billion in compared to billion in the decrease in cash used in investing activity wa primarily due to decrease in cash outflow related to acquisition including ipr net of cash acquired we made billion payment in the first quarter of for our acquisition of myr compared to the billion and billion payment made in related to our acquisition of forty seven and immunomedics respectively the decrease wa partially offset by net cash generated by investing activity in related to proceeds from sale and maturity of marketable debt security used to partially fund these acquisition financing activitiescash used in financing activity for the year ended december wa billion compared to cash provided by financing activity of million in in we utilized cash for billion of debt repayment billion of dividend payment and million of common stock repurchase in we obtained billion in proceeds from debt financing net of issuance cost to fund our fourth quarter acquisition of immunomedics partially offset by cash utilized for billion of dividend payment billion of debt repayment and billion of common stock repurchase debt and credit facilitiesa summary of our borrowing under various financing arrangement is included in note debt and credit facility of the note to consolidated financial statement included in item of this annual report on form we may choose to repay certain of our long term debt obligation prior to maturity date based on our assessment of current and long term liquidity and capital requirement senior unsecured note and term loan in we repaid billion of debt consisting of billion senior unsecured note and billion on our senior unsecured term loan facility we repaid billion of senior unsecured note due april in the first quarter of and billion of senior unsecured note due december in the third quarter of additionally we repaid million of senior unsecured note due upon maturity in september in october we exercised our option to call million of senior unsecured floating rate note and million of senior unsecured note both final maturity date of september these two early repayment totaling billion principal amount were made in the fourth quarter of in december we exercised our option to call million of senior unsecured note having final maturity of march the note were repaid in february no new debt wa issued in we are required to comply with certain covenant under our note indenture governing our senior unsecured note of december and we were not in violation of any covenant liability related to future royaltiesin connection with our acquisition of immunomedics we assumed liability related to funding arrangement which wa originally entered into by immunomedics and rpi finance trust prior to our acquisition of immunomedics the liability related to future royalty wa primarily included in long term debt net on our consolidated balance sheet see note acquisition of the note to consolidated financial statement included in item of this annual report on form for additional information credit facilityin june we terminated our billion five year revolving credit facility maturing in may the revolving credit facility and entered into new billion five year revolving credit facility maturing in june the revolving credit facility the revolving credit facility can be used for working capital requirement and for general corporate purpose including without limitation acquisition of december and there were no amount outstanding under the revolving credit facility the revolving credit facility contains customary representation warranty affirmative and negative covenant and event of default of december we were in compliance with all covenant capital return programthe detail of our stock repurchase program and dividend are included in note stockholder equity of the note to consolidated financial statement included in item of this annual report on form stock repurchase programsin the first quarter of our board of director authorized billion stock repurchase program the program under which repurchase may be made in the open market or in privately negotiated transaction we started repurchase under the program in april the first quarter of our board of director authorized new billion stock repurchase program the program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction we purchased million and million share of our common stock under the program for million and billion in and respectively of december the remaining authorized repurchase amount from both program wa billion dividendswe declared and paid quarterly cash dividend for an aggregate amount of billion or per share of our common stock and billion or per share of our common stock in and respectively on february we announced that our board of director declared quarterly cash dividend increase of from to per share of our common stock with payment date of march to all stockholder of record of the close of business on march future dividend are subject to declaration by our board of director capital resourceswe believe our existing capital resource supplemented by cash flow generated from our operation will be adequate to satisfy our capital need for the foreseeable future our future capital requirement will depend on many factor including but not limited to the following the commercial performance of our current and future product the progress and scope of our effort including preclinical study and clinical trial the cost timing and outcome of regulatory review the expansion of our sale and marketing capability the possibility of acquiring additional manufacturing capability or office facility the possibility of acquiring other company or new product debt service requirement the establishment of additional collaborative relationship with other company and cost associated with the defense settlement and adverse result of government investigation and litigation we may in the future require additional funding which could be in the form of proceeds from equity or debt financing if such funding is required we can not guarantee that it will be available to on favorable term if at all material cash requirementswe continually evaluate our liquidity and capital resource including our access to external capital to ensure that we can adequately and efficiently finance our operation of december our material cash requirement consisted primarily of the repayment of outstanding borrowing the remaining obligation for the one time repatriation transition tax from the tax cut and job act our settlement related to bictegravir litigation purchase of inventory operating lease obligation capital expenditure and milestone and other payment related to our collaborative agreement see note collaboration and other arrangement debt and credit facility lease commitment and contingency and income tax of the note to consolidated financial statement included in item of this annual report on form for additional information we anticipate our cash requirement related to capital expenditure will increase in compared to the prior year we work to expand our site infrastructure and capability critical accounting policy estimate and judgmentsthe discussion and analysis of our financial condition and result of operation is based on our consolidated financial statement included in item of this annual report on form which have been prepared in accordance with generally accepted accounting principle the preparation of these financial statement requires to make estimate and judgment that affect the reported amount of asset liability revenue and expense and related disclosure on an ongoing basis we evaluate and base our estimate on historical experience and on various other market specific and other relevant assumption that we believe to be reasonable under the circumstance the result of which form the basis for making judgment about the carrying value of asset and liability that are not readily apparent from other source actual result may differ significantly from these estimate we believe the following critical accounting policy reflect the more significant judgment and estimate used in the preparation of our consolidated financial statement and other rebate and chargebacks revenue from product sale are recognized net of estimated government and other rebate and chargebacks cash discount for prompt payment distributor fee sale return provision and other related deduction these deduction to product sale are referred to gross to net deduction and are estimated and recorded in the period in which the related product sale occur revenue from product sale net of these deduction are recorded only to the extent significant reversal of the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deduction is subsequently resolved government and other rebate and chargebacks are subject to complex estimation process which requires significant judgment by management in part due to the lag between the date of the product sale and the date the related rebate or chargeback claim are settled government and other rebate and chargebacks include amount payable to payer and healthcare provider under various program and may vary by product by payer and by individual payer plan for qualified program that can purchase our product through wholesaler or other distributor at lower contractual price the wholesaler or distributor charge back to the difference between their acquisition cost and the lower contractual price rebate and chargebacks are estimated primarily based on product sale and expected payer mix and discount rate which require significant estimate and judgment additionally in developing our estimate of government and other rebate and chargebacks we consider the following historical and estimated payer mix statutory discount requirement and contractual term historical claim experience and processing time lag estimated patient population known market event or trend market research channel inventory data obtained from our major wholesaler and other pertinent internal or external information the following table summarizes the consolidated activity and ending balance in our government and other rebate and chargebacks account in million balance at beginning of yeardecrease increase to product salespaymentsbalance at end of yearyear ended december activity related to sale activity related to sale prior to total year ended december activity related to sale activity related to sale prior to total product sale in include the impact of million for change in estimate related to our product sale primarily in the united state in we had assumed higher rebate claim from government payer segment resulting in part from the covid pandemic and it anticipated impact which not materialize we ass and update our estimate each reporting period to reflect actual claim and other current information we believe the methodology that we use to estimate our government and other rebate and chargebacks is reasonable and appropriate given the current fact and circumstance however actual result may differ significantly from our estimate historically our actual government and other rebate and chargebacks claimed for prior period have varied by le than from our estimate government and other chargebacks that are payable to our direct customer are classified reduction of account receivable in our consolidated balance sheet and totaled million and million of december and respectively see note other financial information of the note to consolidated financial statement included in item of this annual report on form for additional information government and other rebate that are payable to third party payer and healthcare provider are generally recorded in accrued government and other rebate on our consolidated balance sheet and totaled billion and billion of december and respectively and valuation of intangibleswe make certain judgment to determine whether transaction should be accounted for acquisition of asset or business combination if it is determined that substantially all of the fair value of gross asset acquired in transaction is concentrated in single asset or group of similar asset the transaction is treated an acquisition of asset we evaluate the input process and output associated with the acquired set of activity and asset if the asset in transaction include an input and substantive process that together significantly contribute to the ability to create output the transaction is treated an acquisition of business we account for business combination using the acquisition method of accounting which requires that asset acquired and liability assumed generally be recorded at their fair value of the acquisition date excess of consideration over the fair value of net asset acquired is recorded goodwill estimating fair value requires to make significant judgment and assumption we perform impairment testing of goodwill annually or more frequently if event or change in circumstance indicate that it is more likely than not that the asset is impaired in transaction accounted for acquisition of asset no goodwill is recorded and contingent consideration such payment upon achievement of various developmental regulatory and commercial milestone generally is not recognized at the acquisition date in an asset acquisition upfront payment allocated to ipr project at the acquisition date are expensed unless there is an alternative future use in addition product development milestone are expensed upon achievement valuation of intangible asset we have acquired and expect to continue to acquire intangible asset through asset acquisition or business combination the identifiable intangible asset are measured at their respective fair value of the acquisition date intangible asset acquired through business combination are subject to potential adjustment within the measurement period which may be up to one year from the acquisition date the fair value of the intangible asset are generally determined using probability weighted income approach that discount expected future cash flow to present value the estimated net cash flow are discounted using discount rate that is based on the estimated weighted average cost of capital for company with profile similar to our profile and represents the rate that market participant would use to value the intangible asset the discounted cash flow model used in valuing these intangible asset require the use of significant estimate and assumption including but not limited to identification of product candidate with sufficient substance requiring separate recognition estimate of projected future cash flow including revenue and operating profit related to the product or product candidate the probability of technical and regulatory success for unapproved product candidate considering their stage of development the time and resource needed to complete the development and approval of product candidate appropriate discount rate the life of the potential commercialized product and associated risk including the inherent difficulty and uncertainty in developing product candidate such obtaining fda and other regulatory approval and risk related to the viability of and potential alternative treatment in any future target market we believe the fair value used to record intangible asset acquired are based upon reasonable estimate and assumption given the fact and circumstance of the related valuation date impairment and amortization of intangible assetsintangible asset related to ipr project acquired in business combination are capitalized indefinite lived intangible asset until the completion or abandonment of the associated effort during the period the asset are considered indefinite lived they are not amortized when development is successfully completed which generally occurs when regulatory approval is obtained the associated asset are deemed finite lived and amortized over their respective estimated useful life beginning at that point in time primarily on straight line basis indefinite lived intangible asset composed of ipr project acquired in business combination that lack regulatory approval at the time of acquisition are tested for impairment annually whenever event or change in circumstance indicate that it is more likely than not that the asset are impaired and upon regulatory approval estimate of fair value result from complex series of judgment about future event and uncertainty and make assumption at point in time acquisition date or subsequent impairment assessment date change in estimate and assumption including the timing of product launch pricing reduction failure to obtain anticipated regulatory approval deterioration in and global financial market or other unanticipated event and circumstance may decrease the projected cash flow or increase the discount rate and could potentially result in an impairment charge the eventual realized value of the acquired ipr project may vary from it fair value at the date of acquisition if the carrying value of an intangible asset exceeds it estimated fair value an impairment charge is recorded to write down the intangible asset to it estimated fair value for example in we recognized an million impairment charge related to ipr project primarily for the treatment of indolent cell non hodgkin lymphoma due to change in estimated market opportunity high rate of failure is inherent in the discovery and development of new product intangible asset are also periodically reviewed for change in fact or circumstance resulting in reduction to the estimated useful life of the asset requiring the acceleration of amortization see note goodwill and intangible asset of the note to consolidated financial statement included in item of this annual report on form for additional information legal contingencieswe are party to various legal action the most significant of these are described in note commitment and contingency of the note to consolidated financial statement included in item of this annual report on form it is not possible to determine the outcome of these matter we recognize accrual for such action to the extent that we conclude that loss is both probable and reasonably estimable we accrue for the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that material loss is reasonably possible we disclose the possible loss or range of loss or that the amount of loss can not be estimated at this time significant judgment is required in both the determination of probability and the determination to whether an exposure is reasonably estimable because of the inherent uncertainty and unpredictability related to these matter accrual are based on what we believe to be the best information available at the time of our assessment including the legal fact and circumstance of the case status of the proceeding applicable law and the view of legal counsel upon the final resolution of such matter it is possible that there may be loss in excess of the amount recorded and such amount could have material adverse effect on our result of operation cash flow or financial position we periodically reassess these matter when additional information becomes available and adjust our estimate and assumption when fact and circumstance indicate the need for any change in the fourth quarter of we recorded an accrual of billion in accrued and other current liability on our consolidated balance sheet for the settlement related to bictegravir litigation see note commitment and contingency of the note to consolidated financial statement included in item of this annual report on form for additional information income taxeswe estimate our income tax provision including deferred tax asset and liability based on significant management judgment we evaluate the realization of our deferred tax asset each reporting period we record valuation allowance to reduce our deferred tax asset to the amount that are more likely than not to be realized we consider future taxable income ongoing tax planning strategy and our historical financial performance in assessing the need for valuation allowance if we expect to realize deferred tax asset for which we have previously recorded valuation allowance we will reduce the valuation allowance in the period in which such determination is first made we are subject to income tax in the united state and various foreign jurisdiction including ireland due to economic and political condition various country are actively considering or have made change to existing tax law we can not predict the form or timing of potential legislative change that could have material adverse impact on our result of operation in addition significant judgment is required in determining our worldwide provision for income tax we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authority based on the technical merit of the position the tax benefit recognized in the consolidated financial statement for particular tax position is based on the largest benefit that is more likely than not to be realized the amount of unrecognized tax benefit utb is adjusted appropriate for change in fact and circumstance such significant amendment to existing tax law new regulation or interpretation by tax authority new information obtained during tax examination or resolution of an examination we recognize both accrued interest and penalty where appropriate related to utb in income tax expense benefit on our consolidated statement of income recent accounting pronouncementsthere have been no new accounting pronouncement issued adopted during the year ended december that are of significance to quantitative and qualitative disclosure about market riskwe are exposed to market risk that may result from change in foreign currency exchange rate interest rate credit risk and market price to reduce certain of these risk we enter into various type of foreign currency or interest rate derivative hedging transaction follow investment guideline and monitor outstanding receivables part of our risk management program foreign currency exchange risk we have operation in more than country worldwide result our financial result could be significantly affected by factor such change in foreign currency exchange rate or weak economic condition in the foreign market in which we distribute our product our operating result are exposed to change in foreign currency exchange rate between the dollar and various foreign currency the most significant of which is the euro when the dollar strengthens against these currency the relative value of sale made in the respective foreign currency decrease conversely when the dollar weakens against these currency the relative value of such sale increase overall we are net receiver of foreign currency and therefore we benefit from weaker dollar and are adversely affected by stronger dollar approximately of our product sale were denominated in foreign currency during to partially mitigate the impact of change in currency exchange rate on net cash flow from our foreign currency denominated sale we may enter into foreign currency exchange forward or option contract we also hedge certain monetary asset and liability denominated in foreign currency which reduces but doe not eliminate our exposure to currency fluctuation between the date transaction is recorded and the date that cash is collected or paid in general the market risk of these contract are offset by corresponding gain and loss on the transaction being hedged of december and we had open foreign currency forward contract with notional amount of billion and billion respectively hypothetical adverse movement in foreign currency exchange rate compared with the dollar relative to exchange rate of december and would have resulted in reduction in fair value of these contract of approximately million and million respectively and if realized would have negatively affected earnings over the remaining life of the contract the analysis doe not consider the impact that hypothetical change in foreign currency exchange rate would have on anticipated transaction that these foreign currency sensitive instrument were designed to offset interest rate risk our portfolio of available for sale debt security and our senior unsecured note create an exposure to interest rate risk with respect to our investment portfolio we adhere to an investment policy that requires to limit amount invested in security based on credit rating maturity industry group and investment type and issuer except for security issued by the government the goal of our investment policy in order of priority are follows safety and preservation of principal and diversification of risk liquidity of investment sufficient to meet cash flow requirement and competitive after tax rate of return the following table summarizes the expected maturity and average interest rate of our interest generating asset and interest bearing liability of december expected maturity total fair value in million except percentage available for sale debt security average interest liability senior unsecured fixed rate note including current portion average interest _______________________________ amount represent principal balance in addition to the senior unsecured fixed rate note we have billion five year revolving credit facility that matures in june there were no amount outstanding under the five year revolving credit facility of december see note debt and credit facility of the note to consolidated financial statement included in item of this annual report on form for additional information price risk we hold share of common stock of certain publicly traded biotechnology company primarily in connection with license and collaboration agreement these equity security are measured at fair value with any change in fair value recognized in earnings the fair value of these equity security wa approximately billion and billion of december and respectively change in fair value of these equity security are impacted by the volatility of the stock market and change in general economic condition among other factor hypothetical increase or decrease in the stock price of these equity security would have increased or decreased their fair value of december and by approximately million and million respectively financial statement and supplementary data gilead science inc index to consolidated financial statement and supplementary datayears ended december and contentsreport of independent registered public accounting firm pcaob id consolidated financial statement consolidated balance statement of statement of comprehensive income loss statement of stockholder statement of cash to consolidated financial of independent registered public accounting firm to the stockholder and the board of director of gilead science inc opinion on the financial statementswe have audited the accompanying consolidated balance sheet of gilead science inc the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note collectively referred to the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinion these financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate government and commercial rebatesdescription of the matteras more fully described in note the company estimate reduction to it revenue for amount payable to payer and healthcare provider in the united state under various government and commercial rebate program in the period that the related sale occur rebate may vary by product payer and individual payer plan some of which may not be known at the point of sale estimated reduction to revenue are based on product sale historical and expected payer mix discount rate and various other estimated and actual data adjusted for current period expectation auditing the company estimated reduction to revenue for rebate wa complex and involved significant judgment particularly in assessing the reasonableness of estimated payer mix applied to sale during the period this estimate relies heavily on historical data that is adjusted for change in payer mix expectation over time we addressed the matter in our auditwe evaluated and tested the design and operating effectiveness of the company internal control over management estimation and review of reduction from revenue for rebate program including control to ass the payer mix assumption we also tested the completeness and accuracy of data utilized in the control and the accuracy of calculation supporting management estimate to test management estimation methodology for determining the payer mix our audit procedure included among others analytically evaluating management estimate evaluating evidence contrary to the estimated amount performing sensitivity analysis on the rate used in the estimate and performing comparison of actual payment related to amount accrued during the current and prior year valuation of in process research and development intangible asset acquired from immunomedics inc description of the matterat december the company in process research and development ipr intangible asset acquired in connection with the acquisition of immunomedics inc were billion discussed in note intangible asset with indefinite useful life related to purchased ipr project are measured at their respective fair value of the acquisition date and are considered indefinite lived until the completion or abandonment of the associated effort the company test indefinite lived intangible asset for impairment on an annual basis and in between annual test if they become aware of any event or change that would indicate the fair value of the asset are below their carrying amount auditing the impairment test of the ipr intangible asset acquired from immunomedics wa complex due to the significant judgment required in estimating their fair value in particular the fair value estimate required the use of valuation methodology that were sensitive to significant assumption discount rate probability of technical and regulatory success addressable patient population treatment duration and projected market share which were affected by expected future market or economic condition how we addressed the matter in our auditwe evaluated and tested the design and operating effectiveness of the company internal control over the determination of the estimated fair value of the ipr intangible asset acquired from immunomedics for example we tested control over management review of the valuation methodology and the significant assumption used to develop the fair value estimate we also tested management control to validate that the data used in the fair value estimate were complete and accurate to test the estimated fair value of the company ipr intangible asset acquired from immunomedics our audit procedure among others included evaluating the company use of appropriate valuation methodology with assistance from valuation specialist evaluating sensitivity analysis to determine which assumption had the greatest impact on the overall determination of value and testing the completeness and accuracy of the underlying data our audit procedure over the most significant assumption included comparing the assumption to current industry market and economic trend to historical result of the company business and other guideline company within the industry and to other relevant factor for example we evaluated the probability of technical and regulatory success by considering the phase of development of the clinical project and the company history of obtaining regulatory approval in addition we evaluated the expected addressable patient population by comparing the company estimate to external industry forecast ernst young llpwe have served the company auditor since san jose california february science inc consolidated balance sheetsdecember in million except per share amount asset cash and cash equivalent short term marketable debt account receivable prepaid and other current total current property plant and equipment long term marketable debt intangible asset other long term total asset liability and stockholder equity current liability account payable accrued government and other accrued and other current current portion of long term debt and other obligation total current long term debt long term income tax deferred tax other long term commitment and contingency note stockholder equity preferred stock par value per share share authorized none outstanding common stock par value per share authorized share issued and outstanding of december and additional paid in capital accumulated other comprehensive income loss retained total gilead stockholder noncontrolling interest total stockholder total liability and stockholder equity see accompanying note science inc consolidated statement of income year ended december in million except per share amount product sale royalty contract and other total cost and expense cost of good research and development acquired in process research and development selling general and administrative total cost and income from interest expense other income expense net income before income income tax expense benefit net net loss attributable to noncontrolling net income attributable to gilead net income per share attributable to gilead common stockholder basic share used in per share calculation net income per share attributable to gilead common stockholder diluted share used in per share calculation see accompanying note science inc consolidated statement of comprehensive income loss year ended december in million income other comprehensive income loss net foreign currency translation gain loss net of tax available for sale debt security net unrealized gain loss net of tax reclassification to net income net of tax net change cash flow hedge net unrealized gain loss net of tax reclassification to net income net of tax net other comprehensive income loss comprehensive income loss comprehensive loss attributable to noncontrolling comprehensive income loss attributable to gilead see accompanying note science inc consolidated statement of stockholder equity in million except per share amount gilead stockholder equity noncontrollinginteresttotalstockholders equitycommon stock additionalpaid incapitalaccumulatedothercomprehensive income loss retainedearningssharesamountbalance of december cumulative effect from the adoption of new accounting standard net income loss other comprehensive income net of tax issuance under employee stock purchase issuance under equity incentive stock based compensation repurchase of common stock dividend declared per share balance of december cumulative effect from the adoption of new accounting standard change in noncontrolling interest net income loss other comprehensive income loss net of tax issuance under employee stock purchase issuance under equity incentive stock based compensation repurchase of common stock dividend declared per share balance of december net income loss other comprehensive income loss net of tax issuance under employee stock purchase issuance under equity incentive stock based compensation repurchase of common stock dividend declared per share balance of december see accompanying note science inc consolidated statement of cash flow year ended december in million activity net income adjustment to reconcile net income to net cash provided by operating activity depreciation amortization stock based compensation deferred income tax net gain loss from equity acquired in process research and development in process research and development impairment write down for slow moving and excess raw material and work in process change in operating asset and liability account receivable prepaid expense and other account payable income tax payable accrued net cash provided by operating investing activity purchase of marketable debt security proceeds from sale of marketable debt proceeds from maturity of marketable debt acquisition including in process research and development net of cash acquired purchase of equity security capital expenditure other net cash used in by investing activity financing activity proceeds from debt financing net of issuance cost proceeds from issuance of common repurchase of common stock repayment of debt and other obligation payment of dividend other net cash used in provided by financing activity effect of exchange rate change on cash and cash equivalent net change in cash and cash equivalent cash and cash equivalent at beginning of cash and cash equivalent at end of period supplemental disclosure of cash flow information interest paid net of amount capitalized income tax paid see accompanying note science inc note to consolidated financial organization and summary of significant accounting policiesoverviewgilead science inc gilead we our or is biopharmaceutical company that ha pursued and achieved breakthrough in medicine for more than three decade with the goal of creating healthier world for all people we are committed to advancing innovative medicine to prevent and treat life threatening disease including hiv viral hepatitis and cancer we operate in more than country worldwide with headquarters in foster city california our portfolio of marketed product includes ambisome atripla biktarvy cayston complera descovy descovy for prep emtriva epclusa eviplera genvoya harvoni hepcludex bulevirtide hepsera jyseleca filgotinib letairis odefsey ranexa sovaldi stribild tecartus trodelvy truvada truvada for prep tybost veklury vemlidy viread vosevi yescarta and zydelig the approval status of hepcludex and jyseleca vary worldwide and hepcludex and jyseleca are not approved in the united state we also sell and distribute authorized generic version of epclusa and harvoni in the united state through our separate subsidiary asegua therapeutic llc in addition we sell and distribute certain product through our corporate partner under collaborative agreement basis of presentationthe accompanying consolidated financial statement include the account of gilead our wholly owned subsidiary and certain variable interest entity for which we are the primary beneficiary all intercompany transaction have been eliminated for consolidated entity where we own or are exposed to le than of the economics we record net income or loss attributable to noncontrolling interest in our consolidated statement of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party we ass whether we are the primary beneficiary of variable interest entity vie at the inception of the arrangement and at each reporting date this assessment is based on our power to direct the activity of the vie that most significantly impact the vie economic performance and our obligation to absorb loss or the right to receive benefit from the vie that could potentially be significant to the vie we did not have any material vies of december certain reclassification have been made to prior period in the consolidated financial statement and accompanying note to conform with the current presentation beginning acquired in process research and development ipr expense are reported separately from research and development expense on our consolidated statement of income our consolidated statement of income for the year ended december wa conformed to separately present acquired ipr expense segment informationwe have one operating segment which primarily focus on the discovery development and commercialization of innovative medicine in area of unmet medical need our chief executive officer the chief operating decision maker codm manages and allocates resource to the operation of our company on an entity wide basis managing and allocating resource on an entity wide basis enables our codm to ass the overall level of resource available and how to best deploy these resource across function and research and development project based on unmet medical need and necessary reallocate resource among our internal portfolio and external opportunity to best support the long term growth of our business see note revenue for summary of disaggregated revenue by product and geographic region significant accounting policy estimate and judgment the preparation of these consolidated financial statement in accordance with generally accepted accounting principle requires to make estimate and judgment that affect the reported amount of asset liability revenue and expense and related disclosure on an ongoing basis we evaluate our significant accounting policy and estimate we base our estimate on historical experience and on various market specific and other relevant assumption that we believe to be reasonable under the circumstance the result of which form the basis for making judgment about the carrying value of asset and liability that are not readily apparent from other source estimate are assessed each period and updated to reflect current information such the economic consideration related to the impact that the coronavirus disease covid could have on our significant accounting estimate actual result may differ significantly from these estimate recognition product saleswe recognize revenue from product sale when control of the product transfer generally upon shipment or delivery to the customer or in certain case upon the corresponding sale by our customer to third party the revenue are recognized net of estimated government and other rebate and chargebacks cash discount for prompt payment distributor fee sale return provision and other related deduction these deduction to product sale are referred to gross to net deduction and are estimated and recorded in the period in which the related product sale occur our payment term to customer generally range from to day however payment term differ by jurisdiction by customer and in some instance by type of product revenue from product sale net of gross to net deduction are recorded only to the extent significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deduction is subsequently resolved tax assessed by governmental authority and collected from customer are excluded from product sale if we expect at contract inception that the period between the transfer of control and corresponding payment from the customer will be one year or le we do not adjust the amount of consideration for the effect of financing component gross to net deduction rebate and chargebacksgovernment and other rebate and chargebacks include amount payable to payer and healthcare provider under various program and may vary by product by payer and individual payer plan rebate and chargebacks are based on contractual arrangement or statutory requirement which may vary by product payer and individual payer plan for qualified program that can purchase our product through wholesaler or other distributor at lower contractual price the wholesaler or distributor charge back to the difference between their acquisition cost and the lower contractual price rebate and chargebacks are estimated primarily based on product sale and expected payer mix and discount rate which require significant estimate and judgment additionally in developing our estimate we consider historical and estimated payer mix statutory discount requirement and contractual term historical claim experience and processing time lag estimated patient population known market event or trend market research channel inventory data obtained from our major wholesaler and other pertinent internal or external information we ass and update our estimate each reporting period to reflect actual claim and other current information government and other chargebacks that are payable to our direct customer are generally classified reduction of account receivable on our consolidated balance sheet government and other rebate that are payable to third party payer and healthcare provider are recorded in accrued government and other rebate on our consolidated balance sheet cash discountswe estimate cash discount based on contractual term historical customer payment pattern and our expectation regarding future customer payment pattern distributor feesunder our inventory management agreement with our significant wholesaler we pay the wholesaler fee primarily for compliance with certain contractually determined covenant such the maintenance of agreed upon inventory level these distributor fee are based on contractually determined fixed percentage of sale allowance for sale returnsallowances are made for estimated sale return by our customer and are recorded in the period the related revenue is recognized we typically permit return if the product is damaged defective or otherwise can not be used by the customer in the united state we typically permit return six month prior to and up to one year after the product expiration date outside the united state return are only allowed in certain country on limited basis our estimate of sale return are based primarily on analysis of our historical product return pattern industry information reporting the return rate for similar product and contractual agreement term we also take into consideration known or expected change in the marketplace specific to each product shipping and handlingshipping and handling activity are considered to be fulfillment activity and not considered to be separate performance obligation royalty contract and other revenuesroyalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sale by our corporate partner occur and development expensesr expense consist primarily of clinical study performed by contract research organization cro material and supply payment under collaborative and other arrangement including milestone payment license and fee expense reimbursement to the collaboration partner personnel cost including salary benefit and stock based compensation expense and overhead allocation consisting of various support and infrastructure cost milestone payment made to third party collaborator are expensed incurred up to the point of regulatory approval milestone payment made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product from time to time we enter into development and collaboration agreement in which we share expense with collaborative partner we record payment received from our collaborative partner for their share of the development cost reduction of expense we charge cost including clinical study cost to expense when incurred clinical study cost are significant component of expense most of our clinical study are performed by third party cro we monitor level of performance under each significant contract including the extent of patient enrollment and other activity through communication with our cro we accrue cost for clinical study performed by cro over the service period specified in the contract and adjust our estimate if required based upon our ongoing review of the level of effort and cost actually incurred by the cro all of our material cro contract are terminable by upon written notice and we are generally only liable for actual service completed by the cro and certain non cancelable expense incurred at any point of termination payment we make for service prior to the service being rendered are recorded prepaid asset in our consolidated balance sheet and are expensed the service are provided acquired in process research and development expensesacquired ipr expense reflect ipr impairment well the initial cost of externally developed ipr project acquired directly in transaction other than business combination that do not have an alternative future use including upfront payment related to various collaboration and the initial cost of right to ipr project the acquired ipr is expensed on acquisition date future cost to develop these ipr project are recorded in research and development expense on our consolidated statement of income incurred selling general and administrative expensesselling general and administrative sg expense relate to sale and marketing finance human resource legal and other administrative activity sg expense consist primarily of personnel cost facility and overhead cost outside marketing advertising and legal expense and other general and administrative cost sg expense also include the branded prescription drug bpd fee in the united state we along with other pharmaceutical manufacturer of branded drug product are required to pay portion of the bpd fee which is estimated based on select government sale during the prior year percentage of total industry government sale we expense the cost of advertising including promotional expense incurred advertising expense were million million and million for the year ended december and respectively cash and cash equivalent we consider highly liquid investment with insignificant interest rate risk and an original maturity of three month or le on the purchase date to be cash equivalent marketable and non marketable securitiesmarketable debt securitieswe determine the appropriate classification of our marketable debt security at the time of purchase and reevaluate such designation at each balance sheet date all of our marketable debt security are considered available for sale and carried at estimated fair value and reported in cash equivalent short term marketable debt security or long term marketable debt security unrealized gain and loss on available for sale debt security are excluded from net income and reported in accumulated other comprehensive income loss aoci separate component of stockholder equity other income expense net includes interest amortization of purchase premium and discount realized gain and loss on sale of security and expected credit loss if any the cost of security sold is based on the specific identification method we regularly review our investment for decline in fair value below their amortized cost basis to determine whether the impairment is due to credit related factor or noncredit related factor our review includes the creditworthiness of the security issuer the severity of the unrealized loss whether we have the intent to sell the security and whether it is more likely than not that we will be required to sell the security before the recovery of their amortized cost base when we determine that portion of the unrealized loss is due to an expected credit loss we recognize the loss amount in other income expense net with corresponding allowance against the carrying value of the security we hold the portion of the unrealized loss related to factor other than credit loss is recognized in aoci and non marketable equity securitiesinvestments in equity security other than equity method investment are recorded at fair market value if fair value is readily determinable and unrealized gain and loss are included in other income expense net on our consolidated statement of income for investment in entity over which we have significant influence but do not meet the requirement for consolidation and have not elected the fair value option we use the equity method of accounting with our share of the underlying income or loss of such entity reported in other income expense net on our consolidated statement of income we have elected the fair value option to account for our equity investment in arcus bioscience inc arcus and galapagos nv galapagos over which we have significant influence we believe the fair value option best reflects the underlying economics of these investment see note collaboration and other arrangement for additional information equity security without readily determinable fair value are recorded using the measurement alternative of cost le impairment if any adjusted for observable price change in orderly transaction for identical or similar investment of the same issuer certain investment in equity security of non public company are accounted for using the equity method based on our ownership percentage and other factor that indicate we have significant influence over the investee see note collaboration and other arrangement for additional information our investment in equity security are recorded in prepaid and other current asset or other long term asset on our consolidated balance sheet we regularly review our security for indicator of impairment concentration of riskwe are subject to credit risk from our portfolio of cash equivalent and marketable security under our investment policy we limit amount invested in such security by credit rating maturity industry group investment type and issuer except for security issued by the government we are not exposed to any significant concentration of credit risk from these financial instrument the goal of our investment policy in order of priority are follows safety and preservation of principal and diversification of risk liquidity of investment sufficient to meet cash flow requirement and competitive after tax rate of return we are also subject to credit risk from our account receivable related to our product sale trade account receivable are recorded net of allowance for wholesaler chargebacks related to government and other program cash discount for prompt payment and credit loss estimate of our allowance for credit loss consider number of factor including existing contractual payment term individual customer circumstance historical payment pattern of our customer review of the local economic environment and it potential impact on expected future customer payment pattern and government funding and reimbursement practice the majority of our trade account receivable arises from product sale in the united state and europe addition to the allowance for credit loss write offs and recovery of customer receivables were not material for the year ended december and inventoriesinventories are recorded at the lower of cost or net realizable value with cost determined on first in first out basis we periodically review our inventory to identify obsolete slow moving excess or otherwise unsaleable item if obsolete slow moving excess or unsaleable item are observed and there are no alternate us for the inventory we record write down to net realizable value through charge to cost of good sold on our consolidated statement of income the determination of net realizable value requires judgment including consideration of many factor such estimate of future product demand product net selling price current and future market condition and potential product obsolescence among others when future commercialization is considered probable and the future economic benefit is expected to be realized based on management judgment we capitalize pre launch inventory cost prior to regulatory approval number of factor are considered including the current status in the regulatory approval process potential impediment to the approval process such safety or efficacy anticipated initiative that could impact the indication in which the compound will be used viability of commercialization and marketplace trend plant and equipmentproperty plant and equipment is stated at cost le accumulated depreciation and amortization depreciation and amortization are recognized using the straight line method repair and maintenance cost are expensed incurred estimated useful life in year are generally follows descriptionestimated useful life building and improvementsshorter of year or useful lifelaboratory and manufacturing computer equipment and improvementsshorter of useful life or lease termleaseswe determine if an arrangement contains lease at inception right of use asset and lease liability are recognized at the commencement date based on the present value of the lease payment over the lease term which is the non cancelable period stated in the contract adjusted for any option to extend or terminate when it is reasonably certain that we will exercise that option right of use asset are adjusted for prepaid lease payment lease incentive and initial direct cost incurred operating lease expense for the minimum lease payment is recognized on straight line basis over the lease term we account for lease and nonlease component in our lease agreement single lease component in determining lease asset and liability in addition we do not recognize the right of use asset and liability for lease with lease term of one year or le most of our operating lease do not provide an implicit interest rate we generally utilize collateralized incremental borrowing rate applied in portfolio approach when relevant based on the information available at the commencement date to determine the lease liability acquisitionswe account for business combination using the acquisition method of accounting which generally requires that asset acquired including ipr project and liability assumed be recorded at their fair value of the acquisition date on our consolidated balance sheet any excess of consideration over the fair value of net asset acquired is recorded goodwill the determination of estimated fair value requires to make significant estimate and assumption result we may record adjustment to the fair value of asset acquired and liability assumed within the measurement period which may be up to one year from the acquisition date with the corresponding offset to goodwill transaction cost associated with business combination are expensed they are incurred when we determine net asset acquired do not meet the definition of business combination under the acquisition method of accounting the transaction is accounted for an acquisition of asset and therefore no goodwill is recorded and contingent consideration such payment upon achievement of various developmental regulatory and commercial milestone generally is not recognized at the acquisition date in an asset acquisition upfront payment allocated to ipr project at the acquisition date and subsequent milestone payment are expensed incurred on our consolidated statement of income unless there is an alternative future use goodwill and intangible assetsgoodwill represents the excess of the consideration transferred over the estimated fair value of asset acquired and liability assumed in business combination intangible asset are measured at their respective fair value of the acquisition date and may be subject to adjustment within the measurement period which may be up to one year from the acquisition date intangible asset related to ipr project are considered to be indefinite lived until the completion or abandonment of the associated effort we do not amortize goodwill and intangible asset with indefinite useful life goodwill and indefinite lived intangible asset are tested for impairment annually or more frequently if event or change in circumstance indicate that it is more likely than not that the asset are impaired when development is successfully completed which generally occurs when regulatory approval is obtained the associated asset are deemed finite lived and amortized over their respective estimated useful life beginning at that point in time intangible asset with finite useful life are amortized over their estimated useful life primarily on straight line basis and are reviewed for impairment when fact or circumstance indicate that the carrying value of these asset may not be recoverable of long lived assetslong lived asset including property plant and equipment and finite lived intangible asset are reviewed for impairment whenever fact or circumstance either internally or externally may indicate that the carrying value of an asset may not be recoverable should there be an indication of impairment we test for recoverability by comparing the estimated undiscounted future cash flow expected to result from the use of the asset to the carrying amount of the asset or asset group if the asset or asset group is determined to be impaired any excess of the carrying value of the asset or asset group over it estimated fair value is recognized an impairment loss valuation of contingent consideration resulting from business combinationin connection with certain acquisition we may be required to pay future consideration that is contingent upon the achievement of specified development regulatory approval or sale based milestone event we record contingent consideration resulting from business combination at it fair value on the acquisition date each reporting period thereafter we revalue these obligation and record increase or decrease in their fair value in research and development expense on our consolidated statement of income until such time that the related product candidate receives marketing approval increase or decrease in fair value of the contingent consideration liability can result from update to assumption such the expected timing or probability of achieving the specified milestone change in projected revenue or change in discount rate significant judgment is employed in determining these assumption of the acquisition date and for each subsequent period update to assumption could have significant impact on our result of operation in any given period actual result may differ from estimate foreign currency translation transaction gain and loss and hedging contractsnon entity operation are recorded in the functional currency of each entity result of operation for non dollar functional currency entity are translated into dollar using average currency rate asset and liability are translated using currency rate at period end foreign currency translation adjustment are recorded component of aoci within stockholder equity foreign currency transaction gain and loss are recorded in other income expense net on our consolidated statement of income net foreign currency transaction gain and loss were not material for the year ended december and we hedge portion of our foreign currency exposure related to outstanding monetary asset and liability well forecasted product sale using foreign currency exchange forward contract in general the market risk related to these contract is offset by corresponding gain and loss on the hedged transaction the credit risk associated with these contract is driven by change in interest and currency exchange rate and result varies over time by working only with major bank and closely monitoring current market condition we seek to limit the risk that counterparties to these contract may be unable to perform we also seek to limit our risk of loss by entering into contract that permit net settlement at maturity therefore our overall risk of loss in the event of counterparty default is limited to the amount of any unrealized gain on outstanding contract those contract that have positive fair value at the date of default we do not enter into derivative contract for trading purpose fair value of financial instrumentswe apply fair value accounting for all financial and non financial asset and liability that are recognized or disclosed at fair value in the financial statement on recurring basis we define fair value the price that would be received from selling an asset or paid to transfer liability in an orderly transaction between market participant at the measurement date when determining the fair value measurement for asset and liability which are required to be recorded at fair value we consider the principal or most advantageous market in which we would transact and the market based risk measurement or assumption that market participant would use in pricing the asset or liability such risk inherent in valuation technique transfer restriction and credit risk derivative financial instrumentswe recognize all derivative instrument either asset or liability at fair value on our consolidated balance sheet unrealized change in the fair value of derivative designated part of hedge transaction are recorded in aoci the unrealized gain or loss in aoci are reclassified into product sale on our consolidated statement of income when the respective hedged transaction affect earnings change in the fair value of derivative that are not part of hedge transaction are recorded each period in other income expense net on our consolidated statement of income we ass both at inception and on an ongoing basis whether the derivative that are used in hedging transaction are effective in offsetting the change in cash flow or fair value of the hedged item if we determine that forecasted transaction is probable of not occurring we discontinue hedge accounting for the affected portion of the hedge instrument and any related unrealized gain or loss on the contract is recognized in other income expense net on our consolidated statement of income based compensationwe provide share based compensation in the form of various type of equity based award including restricted stock unit rsu performance share award or unit psu and stock option compensation expense is recognized on the consolidated statement of income based on the estimated fair value of the award on the grant date the estimated fair value of rsus is based on the closing price of our common stock for psus depending on the term of the award fair value on the date of grant is determined based on either the monte carlo valuation methodology or the closing stock price on the date of grant for stock option award estimated fair value is based on the black scholes option valuation model contingencieswe are party to various legal action we recognize accrual for such action to the extent that we conclude that loss is both probable and reasonably estimable we accrue the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that material loss is reasonably possible we disclose the possible loss or range of loss or that the amount of loss can not be estimated at this time income taxesour income tax provision is computed under the liability method deferred tax asset and liability are determined based on the difference between the financial statement and tax basis of asset and liability using enacted tax rate in effect for the year in which the difference are expected to reverse significant estimate are required in determining our provision for income tax some of these estimate are based on interpretation of applicable tax law or regulation we recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authority based on the technical merit of the position the tax benefit recognized in the consolidated financial statement for particular tax position is based on the largest benefit that is more likely than not to be realized the amount of unrecognized tax benefit utb is adjusted appropriate for change in fact and circumstance such significant amendment to existing tax law new regulation or interpretation by tax authority new information obtained during tax examination or resolution of an examination we recognize both accrued interest and penalty where appropriate related to utb in income tax expense benefit on our consolidated statement of income we have elected to account for the tax on global intangible low taxed income enacted part of the tax cut and job act component of tax expense in the period in which the tax is incurred other significant accounting policiesour other significant accounting policy are described in the remaining appropriate note to the consolidated financial statement revenuesdisaggregation of revenue revenue were follows year ended december ended december ended december in million europeother internationaltotalu europeother internationaltotalu europeother internationaltotalproduct sale hivatripla complera revenue share symtuza other hiv total hiv hepatitis virus hcv ledipasvir sofosbuvir sofosbuvir velpatasvir other hcv total hepatitis virus hbv hepatitis delta virus hdv other hbv hdv total hbv cell therapy total cell therapy other total other total product royalty contract and other total revenue _______________________________ represents our revenue from cobicistat emtricitabine ftc and tenofovir alafenamide taf in symtuza darunavir ftc taf fixed dose combination product commercialized by janssen science ireland unlimited company janssen includes emtriva and tybost amount consist of sale of harvoni and the authorized generic version of harvoni sold by our separate subsidiary asegua therapeutic llc amount consist of sale of epclusa and the authorized generic version of epclusa sold by our separate subsidiary asegua therapeutic llc includes vosevi and sovaldi includes hepcludex and hepsera includes cayston and jyseleca from major customersthe following table summarizes revenue from each of our customer who individually accounted for or more of our total revenue year ended december percentage of total revenue cardinal health inc mckesson revenue recognized from performance obligation satisfied in prior periodsrevenues recognized from performance obligation satisfied in prior year related to our revenue share with janssen described in note collaboration and other arrangement and royalty for license of our intellectual property were million million and million for the year ended december and respectively revenue from product sale net of gross to net deduction are recorded only to the extent significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross to net deduction is subsequently resolved estimate are assessed each period and updated to reflect current information change in estimate related to sale made in prior year resulted in million million and million increase in revenue for the year ended december and respectively this wa primarily related to change in estimate for accrued government and other rebate and allowance for sale return upon product expiration contract balance our contract asset which consist of unbilled amount primarily from arrangement where the licensing of intellectual property is the only or predominant performance obligation totaled million and million of december and respectively contract liability which generally result from receipt of advance payment before our performance under the contract were not material of december and respectively revenue expected to be recognized in the future from contract liability the related performance obligation are satisfied is not expected to be material in any one year fair value measurement we determine the fair value of financial and non financial asset and liability using the fair value hierarchy which establishes three level of input that may be used to measure fair value follows level input include quoted price in active market for identical asset or liability level input include observable input other than level input such quoted price for similar asset or liability quoted price for identical or similar asset or liability in market that are not active or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability and level input include unobservable input that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability our level asset and liability include those whose fair value measurement are determined using pricing model discounted cash flow methodology or similar valuation technique and significant management judgment or estimation our financial instrument consist primarily of cash and cash equivalent marketable debt security account receivable foreign currency exchange contract equity security account payable and short term and long term debt cash and cash equivalent marketable debt security certain equity security and foreign currency exchange contract are reported at their respective fair value on our consolidated balance sheet equity security without readily determinable fair value are recorded using the measurement alternative of cost le impairment if any adjusted for observable price change in orderly transaction for identical or similar investment of the same issuer short term and long term debt are reported at their amortized cost on our consolidated balance sheet the remaining financial instrument are reported on our consolidated balance sheet at amount that approximate current fair value there were no transfer between level level and level in the period presented following table summarizes the type of asset and liability measured at fair value on recurring basis by level within the fair value hierarchy december in million level available for sale debt security treasury security government agency security non government security certificate of deposit corporate debt security residential mortgage and asset backed security equity security money market equity investment in galapagos equity investment in arcus other publicly traded equity deferred compensation foreign currency derivative contract total liability liability for myr gmbh myr contingent consideration deferred compensation foreign currency derivative contract total _______________________________ see note collaboration and other arrangement for additional information equity securitiesthe following table summarizes the classification of our equity security measured at fair value on recurring basis on our consolidated balance sheet in million december and cash equivalent prepaid and other current other long term total change in the fair value of equity security resulted in net unrealized loss of million and billion and net unrealized gain of billion for the year ended december and respectively which were included in other income expense net on our consolidated statement of income other equity securitiesequity method investment and other equity investment without readily determinable fair value were million and million of december and respectively and were excluded from the above table these amount were included in other long term asset on our consolidated balance sheet related party transactionduring the second quarter of we donated certain equity security at fair value to the gilead foundation california nonprofit organization the foundation the foundation is related party certain officer of the company also serve director of the foundation the donation expense of million wa recorded within selling general and administrative expense on our consolidated statement of income for the year ended december inputswe estimate the fair value of level investment by taking into consideration valuation obtained from third party pricing service the pricing service utilize industry standard valuation model including both income based and market based approach for which all significant input are observable either directly or indirectly to estimate the fair value these input include reported trade of and broker dealer quote on the same or similar security issuer credit spread benchmark security prepayment default projection based on historical data and other observable input for our marketable security we review trading activity and pricing of the measurement date when sufficient quoted pricing for identical security is not available we use market pricing and other observable market input for similar security obtained from various third party data provider these input either represent quoted price for similar asset in active market or have been derived from observable market data substantially all of our foreign currency derivative contract have maturity within an month time horizon and all are with counterparties that have minimum credit rating of or equivalent by global rating moody investor service inc or fitch rating inc we estimate the fair value of these contract by taking into consideration the valuation obtained from third party valuation service that utilizes an income based industry standard valuation model for which all significant input are observable either directly or indirectly these input include foreign currency exchange rate london interbank offered rate libor and swap rate these input where applicable are observable at commonly quoted interval the total estimated fair value of our aggregate short term and long term debt determined using level input based on their quoted market value were approximately billion and billion of december and respectively and the carrying value were billion and billion of december and respectively level inputsin connection with our first quarter acquisition of myr we measured asset acquired and liability assumed at fair value on nonrecurring basis except for the liability for contingent consideration the estimated fair value of the liability for contingent consideration wa million and million of the acquisition date and december respectively the change in estimated fair value from the acquisition date wa primarily due to the effect of foreign exchange remeasurement the contingent consideration wa estimated using probability weighted scenario for food and drug administration fda approval of hepcludex see note acquisition for additional information in connection with our fourth quarter acquisition of immunomedics inc immunomedics we measured asset acquired and liability assumed at fair value on nonrecurring basis the liability assumed related to the sale of future royalty is subsequently amortized using the effective interest method over the remaining estimated life the fair value of the liability related to the sale of future royalty were billion and billion of december and respectively and the carrying value wa billion of december and see note acquisition and note debt and credit facility for additional information in in connection with collaboration and other equity arrangement we entered into with pionyr immunotherapeutics inc pionyr and tizona therapeutic inc tizona we also measured fair value of our exclusive option to acquire the remaining outstanding capital stock of pionyr and tizona on nonrecurring basis see note collaboration and other arrangement for additional information in we measured ipr intangible asset acquired in connection with the acquisition of kite pharma inc kite at fair value on nonrecurring basis and recognized pre tax impairment charge of million the fair value of the acquired ipr asset are estimated based on probability adjusted discounted cash flow calculation using level fair value measurement and input include estimated revenue cost probability of technical and regulatory success and discount rate amount capitalized ipr are subject to impairment testing until the completion or abandonment of the associated effort see note goodwill and intangible asset for additional information our policy is to recognize transfer into or out of level classification of the actual date of the event or change in circumstance that caused the transfer there were no transfer between level level and level in the period presented available for sale debt security the following table summarizes our available for sale debt security december in million amortizedcostgrossunrealizedgainsgrossunrealizedlossesestimatedfair value amortizedcostgrossunrealizedgainsgrossunrealizedlossesestimatedfair value treasury security government agency non government certificate of corporate debt residential mortgage and asset backed total the following table summarizes the classification of our available for sale debt security in our consolidated balance sheet in million december and cash equivalent short term marketable debt long term marketable debt total the following table summarizes our available for sale debt security by contractual maturity december in million amortized costfair valuewithin one year after one year through five after five total we held total of and position which were in unrealized loss position of december and respectively aggregated gross unrealized loss on available for sale debt security were not material for the year ended december and no impairment wa recognized for the year ended december and derivative financial instrumentsour operation in foreign country expose to market risk associated with foreign currency exchange rate fluctuation between the dollar and various foreign currency primarily the euro to manage this risk we may hedge portion of our foreign currency exposure related to outstanding monetary asset and liability well forecasted product sale using foreign currency exchange forward or option contract in general the market risk related to these contract is offset by corresponding gain and loss on the hedged transaction the credit risk associated with these contract is driven by change in interest and currency exchange rate and result varies over time by working only with major bank and closely monitoring current market condition we seek to limit the risk that counterparties to these contract may be unable to perform we also seek to limit our risk of loss by entering into contract that permit net settlement at maturity therefore our overall risk of loss in the event of counterparty default is limited to the amount of any unrealized gain on outstanding contract those contract that have positive fair value at the date of default we do not enter into derivative contract for trading purpose we hedge our exposure to foreign currency exchange rate fluctuation for certain monetary asset and liability that are denominated in non functional currency the derivative instrument we use to hedge this exposure are not designated hedge and result change in their fair value are recorded in other income expense net on our consolidated statement of income hedge our exposure to foreign currency exchange rate fluctuation for forecasted product sale that are denominated in non functional currency the derivative instrument we use to hedge this exposure are designated cash flow hedge and have maturity of month or le upon executing hedging contract and each reporting period thereafter we ass hedge effectiveness using regression analysis the unrealized gain or loss in aoci are reclassified into product sale on our consolidated statement of income when the respective hedged transaction affect earnings the majority of gain and loss related to the hedged forecasted transaction reported in aoci of december are expected to be reclassified to product sale within month the cash flow effect of our derivative contract for the year ended december and were included within net cash provided by operating activity on our consolidated statement of cash flow we had notional amount on foreign currency exchange contract outstanding of billion and billion of december and respectively while all our derivative contract allow the right to offset asset and liability we have presented amount on gross basis the following table summarizes the classification and fair value of derivative instrument in our consolidated balance sheet december derivative asset derivative liability in million classificationfair value classificationfairvaluederivatives designated hedge foreign currency exchange contractsprepaid and other current asset accrued and other current liability foreign currency exchange contractsother long term other long term total derivative designated derivative not designated hedge foreign currency exchange contractsprepaid and other current asset accrued and other current liability total derivative not designated hedge total derivative december assetsderivative liability in million classificationfair value classificationfairvaluederivatives designated hedge foreign currency exchange contractsprepaid and other current asset accrued and other current liability foreign currency exchange contractsother long term asset other long term total derivative designated hedge derivative not designated hedge foreign currency exchange contractsprepaid and other current accrued and other current total derivative not designated total derivative following table summarizes the effect of our foreign currency exchange contract on our consolidated financial statement year ended december in million designated hedge gain loss recognized in aoci gain loss reclassified from aoci into product sale derivative not designated hedge gain loss recognized in other income expense net from time to time we may discontinue cash flow hedge and result record related amount in other income expense net on our consolidated statement of income there were no discontinuance of cash flow hedge for the year presented of december and we only held foreign currency exchange contract the following table summarizes the potential effect of offsetting our foreign currency exchange contract on our consolidated balance sheet gross amount not offset on the consolidated balance sheet in million gross amount of recognized asset liabilitiesgross amount offset on the consolidated balance sheetsamounts of asset liability presented on the consolidated balance sheetsderivative financial instrumentscash collateral received pledgednet amount legal offset of december asset derivative liability of december asset derivative liability acquisition myrin the first quarter of we completed the acquisition of myr german biotechnology company myr focus on the development and commercialization of therapeutic for the treatment of hdv the acquisition provided gilead with hepcludex which wa conditionally approved by the european medicine agency ema in july for the treatment of chronic hdv infection in adult with compensated liver disease upon closing myr became wholly owned subsidiary of gilead the financial result of myr were included in our consolidated financial statement from the date of the acquisition acquisition related expense were not material for the year ended december the aggregate consideration for this acquisition of billion or billion primarily consisted of billion or billion paid upon closing and contingent consideration of up to million subject to customary adjustment representing potential future milestone payment upon fda approval of hepcludex the fair value of this contingent liability estimated using probability weighted scenario for fda approval wa million of the acquisition date and wa initially recorded in other long term obligation on our consolidated balance sheet in the second quarter of the balance wa reclassified to accrued and other current liability on our consolidated balance sheet the estimated fair value of this contingent liability wa million of december the change in estimated fair value from the acquisition date wa primarily due to the effect of foreign exchange remeasurement the acquisition of myr wa accounted for business combination using the acquisition method of accounting this method requires among other thing that asset acquired and liability assumed be generally recognized at fair value of the acquisition date the fair value estimate for the asset acquired and liability assumed were based upon valuation using information known and knowable of the date of this filing change to these assumption and estimate could cause an impact to the valuation of asset acquired including intangible asset goodwill and the related tax impact of the acquisition well legal and other contingency the amount recognized will be finalized the information necessary to complete the analysis is obtained but no later than one year after the acquisition date following table summarizes estimated fair value of asset acquired and liability assumed of the acquisition date in million amountintangible asset finite lived intangible asset acquired ipr deferred income tax net other asset and liability net total identifiable net total consideration intangible assetsthe finite lived intangible asset of million represents the estimated fair value of hepcludex for hdv in europe of the acquisition date the fair value wa determined by applying the income approach using unobservable input to estimate probability weighted net cash flow attributable to hepcludex for hdv in europe and discount rate of the discount rate used represents the estimated rate that market participant would use to value this intangible asset this intangible asset is being amortized over an estimated useful life of year acquired ipr consists of hepcludex for hdv in all other region without regulatory approval including the united state the estimated aggregate fair value of billion of the acquisition date wa determined by applying the income approach using unobservable input to estimate probability weighted net cash flow attributable to this asset and discount rate of the discount rate used represents the estimated rate that market participant would use to value this intangible asset some of the more significant assumption inherent in the development of intangible asset fair value include estimate of projected future cash flow including revenue and operating profit probability of success the discount rate selected the life of the potential commercialized product and the risk related to the viability of and potential alternative treatment in any future target market among other factor the input used for valuing these identifiable intangible are unobservable and considered level under the fair value measurement and disclosure guidance see note fair value measurement for additional information deferred income taxesthe net deferred tax liability wa based upon the difference between the estimated financial statement basis and tax basis of net asset acquired and an estimate for the final pre acquisition net operating loss of myr goodwill the excess of the consideration transferred over the fair value of asset acquired and liability assumed of million wa recorded goodwill which primarily reflects the future economic benefit arising from other asset acquired that could not be individually identified and separately recognized goodwill recognized for myr is not expected to be deductible for income tax purpose there were no material measurement period adjustment recorded to the fair value of asset acquired and liability assumed during the year ended december immunomedicsin the fourth quarter of we completed the acquisition of immunomedics company focused on the development of antibody drug conjugate technology for cash consideration of billion upon closing immunomedics became wholly owned subsidiary of gilead the acquisition wa financed with the majority of the proceeds from the september senior unsecured note offering an additional billion borrowing under new senior unsecured term loan facility and cash on hand in we repaid the borrowing under the senior unsecured term loan facility see note debt and credit facility for additional information we recorded share based compensation expense of million related to the cash settlement of the accelerated share based compensation expense attributable to the post combination period which wa primarily recorded in selling general and administrative expense and research and development expense on our consolidated statement of income for the year ended december we also recorded other acquisition related expense of million primarily representing closing cost and related fee in selling general and administrative expense on our consolidated statement of income for the year ended december acquisition of immunomedics wa accounted for business combination using the acquisition method of accounting this method requires among other thing that asset acquired and liability assumed be generally recognized at fair value of the acquisition date there were no material measurement period adjustment recorded to the fair value of asset acquired and liability assumed during the year ended december the fair value estimate for the asset acquired and liability assumed have been completed the following table summarizes fair value of asset acquired and liability assumed of the acquisition date in million amountcash and cash equivalent intangible asset finite lived intangible acquired ipr outlicense deferred tax liability liability related to future royalty other asset and liability total identifiable net total consideration transferred inventoriesthe fair value step up adjustment of million included in inventory of million of the acquisition date wa primarily determined by the estimated selling price of finished inventory le the cost to complete the manufacturing process and selling effort the step up adjustment is recorded in cost of good sold on our consolidated statement of income the inventory is sold to customer and in research and development expense on our consolidated statement of income for inventory used for clinical purpose intangible assetsthe finite lived intangible asset of billion represents the estimated fair value of trodelvy for metastatic triple negative breast cancer tnbc of the acquisition date the fair value wa determined by applying the income approach using unobservable input to estimate probability weighted net cash flow attributable to trodelvy for metastatic tnbc and discount rate of the discount rate used represents the estimated rate that market participant would use to value this intangible asset this intangible asset is being amortized over an estimated useful life of year acquired ipr asset consist of trodelvy for hormone receptor positive human epidermal growth factor receptor negative metastatic breast cancer trodelvy for non small cell lung cancer and trodelvy for urothelial cancer uc the estimated aggregate fair value of billion of the acquisition date wa determined by applying the income approach using unobservable input to estimate probability weighted net cash flow attributable to these asset and discount rate of the discount rate used represents the estimated rate that market participant would use to value these intangible asset trodelvy for uc wa granted accelerated approval by fda in april and billion wa reclassified to finite lived intangible from ipr see note goodwill and intangible asset for additional information some of the more significant assumption inherent in the development of intangible asset fair value include the amount and timing of projected future cash flow including revenue cost of sale research and development cost and sale and marketing expense probability of success the discount rate selected to measure the inherent risk of future cash flow the assessment of the asset life cycle and the competitive trend impacting the asset among other factor we also recorded an intangible asset related to license and supply agreement with third party which wa entered into by immunomedics prior to the acquisition under the agreement the third party wa granted an exclusive license to develop and commercialize trodelvy in certain territory in asia and make certain sale milestone and royalty payment to the acquisition date fair value of million wa determined by estimating the probability weighted net cash flow attributable to the outlicense and discount rate of the discount rate represents the estimated rate that market participant would use to value this intangible asset this intangible asset is being amortized over an estimated useful life of year on straight line basis the input used for valuing these identifiable intangible are unobservable and considered level under the fair value measurement and disclosure guidance income taxesthe net deferred tax liability wa based upon the difference between the estimated financial statement basis and tax basis of net asset acquired and an estimate for the final pre acquisition net operating loss of immunomedics liability related to future royaltieswe assumed liability related to funding arrangement which wa originally entered into by immunomedics and rpi finance trust rpi prior to our acquisition of immunomedics under the funding agreement rpi ha the right to receive certain royalty amount subject to certain reduction based on the net sale of trodelvy for each calendar quarter during the term of the agreement through approximately the acquisition date fair value of the liability wa estimated billion which wa primarily determined based on current estimate of future royalty payment to rpi over the life of the arrangement using the real option method and an effective annual interest rate of the liability is amortized using the effective interest rate method resulting in recognition of interest expense over year the estimated timing and amount of future expected royalty payment over the estimated term will be re assessed each reporting period the impact from change in estimate will be recognized in the liability and the related interest expense prospectively the input used for valuation of this liability are unobservable and are considered level under the fair value measurement and disclosure guidance see note fair value measurement for additional information the liability related to future royalty wa categorized debt and primarily included in long term debt net on our consolidated balance sheet see note debt and credit facility for additional information goodwill the excess of the consideration transferred over the fair value of asset acquired and liability assumed of billion wa recorded goodwill which primarily reflects the future economic benefit arising from other asset acquired that could not be individually identified and separately recognized goodwill recognized for immunomedics is not expected to be deductible for income tax purpose forty seven inc forty seven in the second quarter of we completed the acquisition of forty seven clinical stage immuno oncology company focused on developing therapy targeting cancer immune evasion pathway and specific cell targeting approach for total consideration of billion net of acquired cash upon closing forty seven became wholly owned subsidiary of gilead we accounted for the transaction an asset acquisition since the lead asset magrolimab represented substantially all the fair value of the gross asset acquired during the year ended december we recorded billion charge representing an acquired ipr asset with no alternative future use in acquired in process research and development expense and stock based compensation expense of million primarily in research and development expense on our consolidated statement of income inventoriesthe following table summarizes our inventory december in million material work in finished total reported inventory other long term total amount reported other long term asset primarily consisted of raw material of december and total inventory of december and include million and million respectively of fair value adjustment resulting from the immunomedics acquisition inventory write down charge were million million and million for the year ended december and respectively during the year ended december million of the million inventory write down charge wa related to slow moving and excess raw material and work in process inventory primarily due to lower long term demand for our hcv product property plant and equipmentthe following table summarizes our property plant and equipment net december in million and land improvement building and improvement including leasehold improvement laboratory and manufacturing office computer equipment and construction in le accumulated depreciation and total we had unamortized capitalized software cost included in office computer equipment and other of million and million of december and respectively capitalized interest on construction in progress is included in property plant and equipment net on our consolidated balance sheet interest capitalized in and wa not material the net book value of our property plant and equipment in the united state wa billion and billion of december and respectively the corresponding amount in international location wa million and million of december and respectively all individual international location accounted for le than of the total balance goodwill and intangible asset goodwillthe following table summarizes the change in the carrying amount of goodwill december in million balance goodwill resulting from measurement period adjustment ending balance we perform an annual goodwill impairment assessment in the fourth quarter or earlier if impairment indicator exist of december there were no accumulated goodwill impairment loss intangible assetsthe following table summarizes our intangible asset net december in million gross carryingamountaccumulatedamortizationforeign currency translation adjustmentnet carrying amountgross carryingamountaccumulatedamortizationforeign currency translation adjustmentnet carrying amountfinite lived assetsintangible asset sofosbuvir intangible asset axicabtagene ciloleucel intangible asset trodelvy intangible asset other total finite lived indefinite lived asset ipr total intangible asset ________________________________ gross carrying amount of december includes million reclassified in the first quarter of from indefinite lived asset ipr following the march fda approval of yescarta for the treatment of adult patient with relapsed or refractory follicular lymphoma gross carrying amount of december includes trodelvy for metastatic tnbc and trodelvy for use in adult patient with locally advanced or metastatic uc the amount related to uc of billion wa reclassified to finite lived asset from indefinite lived asset ipr upon the accelerated approval by fda in april in october fda granted approval of tecartus for the treatment of adult patient with relapsed or refractory cell precursor acute lymphoblastic leukemia accordingly the related amount of million wa reclassified to finite lived asset in the fourth quarter of gross carrying amount of december includes ipr from our acquisition of myr and remaining ipr from our acquisition of immunomedics gross carrying amount of december includes ipr from our acquisition of immunomedics and remaining ipr from our acquisition of kite aggregate amortization expense related to finite lived intangible asset wa billion billion and billion for the year ended december and respectively and is primarily included in cost of good sold on our consolidated statement of income amount capitalized ipr are subject to impairment testing until the completion or abandonment of the associated effort during we performed qualitative assessment of our ipr intangible asset obtained in connection with our first quarter acquisition of myr and did not identify any indicator of impairment during and we performed quantitative impairment testing of our ipr intangible asset other than the myr asset described above using probability weighted income approach that discount expected future cash flow to present value using discount rate of and respectively the discount rate are based on the estimated weighted average cost of capital for company with profile similar to our profile and represents the rate that market participant would use to value the intangible asset the discounted cash flow model used in valuing these intangible asset also require the use of level fair value measurement and input including estimated revenue cost and probability of technical and regulatory success no ipr impairment charge were recorded in and we lowered our estimated revenue related to our ipr intangible asset axicabtagene ciloleucel for the treatment of indolent cell non hodgkin lymphoma due to change in the estimated market opportunity new therapy or combination of existing therapy were approved the lower estimated revenue reduced the fair value of the ipr intangible asset below carrying value resulting in the recognition of an impairment charge of million which wa recorded within acquired in process research and development expense on our consolidated statement of income the following table summarizes the estimated future amortization expense associated with our finite lived intangible asset of december in million total other financial informationaccounts receivable netthe following table summarizes our account receivable net december in million receivable le le cash discount and le allowance for credit account receivable net accrued and other current liabilitiesthe following table summarizes the component of accrued and other current liability december in million and employee benefit income tax allowance for sale accrual for settlement related to bictegravir litigation other accrued accrued and other current liability _______________________________ see note commitment and contingency for additional information collaboration and other arrangement we enter into licensing and strategic collaboration and other similar arrangement with third party for the development and commercialization of certain product and product candidate these arrangement may involve two or more party who are active participant in the operating activity of the collaboration and are exposed to significant risk and reward depending on the commercial success of the activity these arrangement may include non refundable upfront payment expense reimbursement or payment by for option to acquire certain right contingent obligation by for potential development and regulatory milestone payment and or sale based milestone payment royalty payment revenue or profit sharing arrangement and cost sharing arrangement we also have equity investment in third party focused on the development and commercialization of product and product candidate co inc merck on march we entered into license and collaboration agreement with merck sharp dohme corp subsidiary of merck to jointly develop and commercialize long acting investigational treatment in hiv that combine gilead investigational capsid inhibitor lenacapavir and merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir the collaboration will initially focus on long acting oral and injectable formulation under the term of the agreement gilead and merck will share global development and commercialization cost at and respectively across the oral and injectable formulation program for long acting oral product if approved gilead would lead commercialization in the united state and merck would lead commercialization in the european union eu and rest of the world for long acting injectable product if approved merck would lead commercialization in the united state and gilead would lead commercialization in the eu and rest of the world under the term of the agreement gilead and merck would jointly promote the combination product in the united state and certain other major market if successful we would share global product revenue with merck equally until product revenue surpass certain pre determined per formulation revenue tier upon passing billion in net product sale for the oral combination in given calendar year our share of revenue would increase to for any revenue above the threshold for such calendar year upon passing billion in net product sale for the injectable combination in given calendar year our share of revenue will increase to for any revenue above the threshold for such calendar year reimbursement of research and development cost to or from merck are recorded within research and development expense on our consolidated statement of income expense recognized under the agreement were not material for the year ended december no revenue have been recognized under the agreement for the year ended december we will also have the option to license certain of merck investigational oral integrase inhibitor to develop in combination with lenacapavir reciprocally merck will have the option to license certain of gilead investigational oral integrase inhibitor to develop in combination with islatravir each company may exercise it option for such investigational oral integrase inhibitor of the other company within the first five year after execution of the agreement following completion of the first phase clinical trial of that integrase inhibitor upon exercise of an option the company will split development cost and revenue unless the non exercising company decides to opt out in which case the non exercising company will be paid royalty in december merck announced the decision of the party to stop all dosing of participant in the phase clinical study evaluating an oral weekly combination treatment regimen of lenacapavir and islatravir following the decision of fda to place clinical hold on the investigational new drug application for certain formulation of islatravir arcuson may we entered into transaction with arcus publicly traded oncology focused biopharmaceutical company which included entry into an option license and collaboration agreement the collaboration agreement and common stock purchase agreement and an investor right agreement together and subsequently amended the stock purchase agreement in accordance with the term of the collaboration agreement and stock purchase agreement which closed on july we made an upfront payment of million and acquired approximately million share of arcus common stock for approximately million of the total million initial cash payment including transactional cost made under the agreement we recorded million an equity investment which wa calculated based on arcus closing stock price on the closing date of the transaction the remaining million wa attributed to the acquired license and option right of million representing ipr asset with no alternative future use ii million of an issuance premium for the equity purchase and iii million of direct transactional cost these amount were expensed acquired in process research and development expense during the year ended december on our consolidated statement of income under the stock purchase agreement we have the right to purchase additional share of arcus from arcus over the five year period beginning on the closing of the stock purchase agreement up to maximum of of the outstanding voting stock we are subject to three year standstill restricting our ability to acquire voting stock of arcus exceeding more than of the then issued and outstanding voting stock of arcus subject to certain exception additionally we agreed not to dispose of any equity security of arcus prior to the second anniversary of the closing of the stock purchase agreement without the prior consent of arcus subject to certain exception on may in separate secondary equity offering we acquired million share of common stock of arcus for approximately million in the first quarter of we also acquired approximately million additional share of arcus common stock for million result we currently own total of million share of arcus which represented approximately of the issued and outstanding voting stock of arcus immediately following the closing of the first quarter transaction to the collaboration agreement gilead had the right to opt in to all current and future clinical stage product candidate for up to ten year following the closing of the transaction in november we exercised our option to three of arcus clinical stage program and amended the collaboration agreement the option exercise and amendment transaction closed in december triggering collaboration opt in payment of million and waiving the million option continuation payment which would have been due to arcus in the third quarter of the net option charge of million wa recorded within research and development expense on our consolidated statement of income for the year ended december the collaboration opt in payment of million were recorded in accrued and other current liability on our consolidated balance sheet of december and paid to arcus in january our payment to arcus will be included within net cash provided by investing activity on our consolidated statement of cash flow in the first quarter of under the amended collaboration agreement the company will co develop and share the global cost related to these clinical program if the optioned molecule achieve regulatory approval the company will co commercialize and equally share profit in the gilead will hold exclusive commercialization right outside the subject to any right of arcus existing collaboration partner and will pay to arcus tiered royalty percentage of net sale ranging from the mid teen and low twenty under the collaboration agreement we may also pay an additional million at our option on each of the fourth sixth and eighth anniversary of the agreement unless terminated early to maintain the right to opt in to future arcus program for the duration of the contact term we elected and applied the fair value option to account for our equity investment in arcus whereby the investment is marked to market each reporting period based on the market price of arcus share we believe the fair value option best reflects the underlying economics of the investment during the year ended december and we recorded pre tax unrealized gain of million and million respectively related to our investment in arcus in other income expense net on our consolidated statement of income we initially recorded our equity investment in arcus in other long term asset on our consolidated balance sheet the investment were subject to contractual lock up provision for period of two year from the closing date of the stock purchase agreement subject to certain condition in the third quarter of we reclassified our equity investment in arcus to prepaid and other current asset on our consolidated balance sheet the contractual lock up provision are expected to expire in july our equity investment in arcus wa million and million of december and respectively pionyron june we entered into transaction with pionyr privately held company pursuing novel biology in the field of immuno oncology which included entry into two separate merger agreement one contemplating the initial acquisition of equity interest in pionyr and the other providing the exclusive option subject to certain term and condition to acquire the remaining outstanding capital stock of pionyr together the pionyr merger and option agreement and research and development service agreement on july we closed the transaction and made cash payment of million we account for our investment in pionyr using the equity method of accounting because our equity interest provides with the ability to exercise significant influence over pionyr our investment in pionyr consisting of the transaction price noted above and transaction cost exceeded our pro rata portion of pionyr net asset at transaction closing we determined that the resulting basis difference primarily relates to pionyr ipr which ha no alternative future use and that pionyr is not business defined in asc business combination result we immediately recorded charge for this basis difference of million in acquired in process research and development expense on our consolidated statement of income during the year ended december the carrying value of our equity method investment in pionyr wa zero of december and the estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of pionyr is approximately million based on probability weighted option pricing model using unobservable input which are considered level under the fair value measurement and disclosure guidance the estimated amount is recorded in other long term asset on our consolidated balance sheet we may choose to exercise our exclusive option to purchase the remaining equity interest from pionyr current shareholder for million option exercise fee and up to billion in potential future milestone payment upon achievement of certain development and regulatory milestone such option to purchase will expire following the earliest occurrence of specified event including the delivery of data following completion of certain phase trial by pionyr under the research and development service agreement we made an initial cash funding of million and recorded charge in acquired in process research and development expense on our consolidated statement of income during the year ended december in addition we committed to provide additional payment of up to million to pionyr upon achievement of certain development milestone we accrued million in milestone payment related to the initiation of two phase study with charge to research and development expense on our consolidated statement of income during the year ended december and the payment wa made in the first quarter of july we entered into transaction with tizona privately held company developing cancer immunotherapy which included entry into two separate merger agreement one contemplating the initial acquisition of equity interest in tizona and the other providing the exclusive option subject to certain term and condition to acquire the remaining outstanding capital stock of tizona together the tizona merger and option agreement and development agreement on august we closed the transaction with tizona and made cash payment of million to tizona shareholder in accordance with the term of the tizona merger and option agreement we account for our investment in tizona using the equity method of accounting because our equity interest provides with the ability to exercise significant influence over tizona our investment in tizona consisting of the transaction price noted above and transaction cost exceeded our pro rata portion of tizona net asset at transaction closing we determined that the resulting basis difference primarily relates to tizona ipr with no alternative future use and that tizona is not business defined in asc business combination result during the year ended december we immediately recorded charge for this basis difference of million in acquired in process research and development expense on our consolidated statement of income the carrying value of our equity method investment in tizona wa zero of december and the estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of tizona is approximately million based on probability weighted option pricing model using unobservable input which are considered level under the fair value measurement and disclosure guidance the estimated amount is recorded in other long term asset on our consolidated balance sheet we may choose to exercise our exclusive option to purchase the remaining equity interest from tizona current shareholder for million option exercise fee and up to billion in potential future milestone payment upon achievement of certain development and regulatory milestone such option to purchase will expire following the earliest occurrence of specified event including the delivery of data following completion of certain phase trial by tizona under the development agreement we committed to provide funding to tizona of million which wa recorded in acquired in process research and development expense on our consolidated statement of income during the year ended december tango therapeutic inc tango on august we entered into transaction with tango privately held company pursuing innovative targeted immune evasion therapy for patient with cancer through it proprietary crispr enabled functional genomics target discovery platform which included entry into an amended and restated research collaboration and license agreement and stock purchase agreement together the tango collaboration and stock purchase agreement upon entering into this transaction we made an upfront payment of million and million equity investment in tango during the year ended december we recorded the million upfront expense in acquired in process research and development expense on our consolidated statement of income in the third quarter of we made an additional million equity investment tango became publicly traded company in the third quarter of and accordingly our equity investment is recorded in prepaid and other current asset on our consolidated balance sheet at fair market value of december under the tango collaboration and stock purchase agreement gilead ha the right to option up to program over the seven year collaboration for up to million per program in opt in extension and milestone payment for the product that tango opts to co develop and co promote the party will equally split profit and loss well development cost in the for product that tango doe not opt to co develop and co promote we will pay tango up to low double digit tiered royalty on net sale we will provide tango milestone payment and royalty on sale outside of the jounce therapeutic inc jounce on september we entered into transaction with jounce publicly traded company developing novel cancer immunotherapy which included entry into license registration right and stock purchase agreement together jounce license and stock purchase agreement in october we closed this transaction and made total payment of million we recorded million upfront expense in acquired in process research and development expense on our consolidated statement of income and million an equity investment in other long term asset on our consolidated balance sheet representing approximately of the issued and outstanding voting stock of jounce immediately following the transaction which wa calculated based on jounce closing stock price on the closing date of the transaction of december jounce wa eligible to receive from up to million in future potential clinical regulatory and commercial milestone payment upon achievement of certain milestone and royalty ranging from high single digit to mid teen based upon worldwide sale subject to certain adjustment collaborationin we closed license and collaboration agreement with galapagos clinical stage biotechnology company based in belgium for the development and commercialization of filgotinib selective inhibitor being evaluated for inflammatory disease indication the filgotinib agreement upon closing we made an upfront license fee payment and an equity investment in galapagos by subscribing for million new ordinary share of galapagos at price of per share we amended the term of the agreement in and under the term of the filgotinib agreement amended in the agreement we obtained an exclusive worldwide royalty bearing sublicensable license for filgotinib and product containing filgotinib in december following type meeting with fda to discus the point raised in the complete response letter related to the new drug application for filgotinib in the treatment of rheumatoid arthritis gilead and galapagos agreed to amend the agreement to allow galapagos to assume development manufacturing commercialization and certain other right for filgotinib in europe which the party reflected in an amendment to the agreement in december beginning on january galapagos bore the development cost for certain study in lieu of the equal cost split contemplated by the agreement the party transferred filgotinib marketing authorization in the eu and great britain to galapagos in december of january all commercial economics on filgotinib in europe transferred to galapagos subject to payment of tiered royalty of to of net sale in europe to gilead starting in in connection with the amendment to the agreement gilead agreed to irrevocably pay galapagos million or approximately million which is subject to certain adjustment for higher than budgeted development cost of this total amount gilead paid million or approximately million in january and paid an additional million or approximately million in april and will pay million or approximately million in we accrued the full amount of this liability with charge to research and development expense on our consolidated statement of income for the year ended december in addition galapagos will no longer be eligible to receive any future milestone payment relating to filgotinib in europe global collaborationin august we closed an option license and collaboration agreement the galapagos collaboration agreement and subscription agreement the galapagos subscription agreement each with galapagos pursuant to which the party entered into global collaboration that cover galapagos current and future product portfolio other than filgotinib upon closing we paid billion for the license and option right and for million new ordinary share of galapagos at subscription price of per share with fair value of billion which included an issuance discount of million calculated based on galapagos closing stock price on the date of closing of the galapagos subscription agreement the remaining billion of the payment wa recorded within acquired in process research and development expense on our consolidated statement of income for the year ended december pursuant to the galapagos subscription agreement we were issued warrant that confer the right to subscribe from time to time for number of new share to be issued by galapagos sufficient to bring the number of share owned by to of the issued and outstanding share at the time of our exercise in we exercised warrant to subscribe for million ordinary share of galapagos at per share and purchased share on the open market with an aggregate fair value of million which brought the number of share owned by to million or approximately of the share then issued and outstanding we are subject to year standstill restricting our ability to acquire voting security of galapagos exceeding more than of the then issued and outstanding voting security of galapagos we agreed not to without the prior consent of galapagos dispose of any equity security of galapagos prior to the second anniversary of the closing of the galapagos subscription agreement or dispose of any equity security of galapagos thereafter until the fifth anniversary of the closing of the galapagos subscription agreement if after such disposal we would own le than of the then issued and outstanding voting security of galapagos subject to certain exception and termination event in april we amended the galapagos subscription agreement to extend the initial lock up provision for certain galapagos share from august to august we have two designees appointed to galapagos board of director the initial contractual lock up provision for certain galapagos share wa due to expire in august such million wa included within prepaid and other current asset on our consolidated balance sheet and the remainder of billion wa included within other long term asset on our consolidated balance sheet of december subsequent to the extension of the contractual lock up period all of our equity investment in galapagos wa classified to other long term asset on our consolidated balance sheet and wa million of december have elected the fair value option to account for our equity investment in galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of galapagos share we believe the fair value option best reflects the underlying economics of the investment during the year ended december and we recorded pre tax unrealized loss of million and billion and pre tax unrealized gain of billion respectively related to our investment in galapagos in other income expense net on our consolidated statement of income due to change in galapagos stock price under the galapagos collaboration agreement we had an exclusive license for the development and commercialization of glpg late stage candidate for idiopathic pulmonary fibrosis in our territory and had an option to participate in the development and commercialization of galapagos other current and future clinical program that have entered clinical development during the first ten year of the collaboration subject to extension in certain circumstance gilead and galapagos terminated the phase clinical study with glpg in february with respect to all other program in galapagos current and future pipeline if we exercise our option to program we will pay million option exercise fee per program in addition galapagos will receive tiered royalty ranging from to on net sale in our territory of each galapagos product optioned by if we exercise our option for program the party will share equally in development cost and mutually agreed commercialization cost incurred subsequent to our exercise of the option we may terminate the collaboration in it entirety or on program by program and country by country basis with advance notice well following other customary termination event janssencomplera eviplera and odefseyin we entered into license and collaboration agreement with janssen formerly tibotec pharmaceutical to develop and commercialize fixed dose combination of our truvada and janssen non nucleoside reverse transcriptase inhibitor rilpivirine this combination wa approved in the and eu in and is sold under the brand name complera in the and eviplera in the eu the agreement wa amended in to expand the collaboration to include another product containing janssen rilpivirine and our emtricitabine and tenofovir alafenamide odefsey under the amended agreement janssen granted an exclusive license to complera eviplera and odefsey worldwide but retained right to distribute both combination product in certain country outside of the neither party is restricted from combining it drug with any other drug product except those which are similar to the component of complera eviplera and odefsey we are responsible for manufacturing complera eviplera and odefsey and have the lead role in registration distribution and commercialization of both product except in the country where janssen distributes janssen ha exercised right to co detail the combination product in some of the country where we are the selling party under the financial provision of the amendment the selling party set the price of the combined product and the party share revenue based on the ratio of the net selling price of the party component subject to certain restriction and adjustment we retain specified percentage of janssen share of revenue including up to in major market sale of these product are included in product sale and janssen share of revenue is included in cost of good sold on our consolidated statement of income cost of good sold relating to janssen share wa million million and million for the year ended december and respectively termination of the agreement may be on product or country basis and will depend on the circumstance including withdrawal of product from the market material breach by either party or expiry of the revenue share payment term we may terminate the agreement without cause with respect to the country where we sell the product in which case janssen ha the right to become the selling party for such country if the product ha launched but ha been on the market for fewer than year symtuzain we amended license and collaboration agreement with janssen to develop and commercialize fixed dose combination of janssen darunavir and our cobicistat emtricitabine and tenofovir alafenamide gilead compound this combination wa approved in the and eu in july and september respectively and is sold under the brand name symtuza under the term of the amendment we granted janssen an exclusive license to symtuza worldwide janssen is responsible for manufacturing registration distribution and commercialization of symtuza worldwide we are responsible for the intellectual property related to the gilead compound and are the exclusive supplier of the gilead compound neither party is restricted from combining it drug with any other drug product except those which are similar to the component of symtuza set the price of symtuza and the party share revenue based on the ratio of the net selling price of the party component subject to certain restriction and adjustment the intellectual property license and supply obligation related to the gilead compound are accounted for single performance obligation the license wa deemed to be the predominant item to which the revenue share relates we recognize our share of the symtuza revenue in the period when the corresponding sale of symtuza by janssen occur we record our share of the symtuza revenue product sale on our consolidated statement of income primarily because we supply the gilead compound to janssen for symtuza termination of the agreement may be on product or country basis and will depend on the circumstance including withdrawal of product from the market material breach by either party or expiry of the revenue share payment term janssen may terminate the agreement without cause on country by country basis in which case gilead ha the right to become the selling party for such country if the product ha launched but ha been on the market for fewer than year janssen may also terminate the entire agreement without cause japan tobacco inc japan tobacco in japan tobacco granted exclusive right to develop and commercialize elvitegravir novel hiv integrase inhibitor in all country of the world excluding japan where japan tobacco retained such right effective december we entered into an agreement with japan tobacco to acquire the right to market and distribute certain product in our hiv portfolio in japan and to expand our right to develop and commercialize elvitegravir to include japan we are responsible for the marketing of the product of january we are responsible for seeking regulatory approval in our territory and are required to use diligent effort to commercialize elvitegravir for the treatment of hiv infection we bear all cost and expense associated with such commercialization effort and pay royalty to japan tobacco based on our product sale our sale of these product are included in product sale on our consolidated statement of income royalty due to japan tobacco are included in cost of good sold on our consolidated statement of income royalty expense recognized were million million and million for the year ended december and respectively under the term of the agreement we paid japan tobacco million in cash and recognized an intangible asset of million reflecting the estimated fair value of the marketing related right acquired from japan tobacco the intangible asset is being amortized over nine year representing the period over which the majority of the benefit are expected to be derived from the applicable product in our hiv portfolio the amortization expense is classified selling expense and recorded selling general and administrative expense on our consolidated statement of income termination of the agreement may be on product or country basis and will depend on the circumstance including material breach by either party or expiry of royalty payment term we may also terminate the entire agreement without cause gadeta gadeta in july we entered into collaboration arrangement with gadeta and made purchase of equity in gadeta from gadeta shareholder we determined that gadeta wa vie and we were it primary beneficiary because we had the power to direct the activity of gadeta that most significantly impact it economic performance upon the initial consolidation of gadeta we recorded million to noncontrolling interest primarily reflecting acquired intangible asset related to ipr on our consolidated balance sheet during the year ended december we effectively terminated the agreement with gadeta upon the effective termination we ceased to have controlling interest and deconsolidated this vie by removing the related net asset and noncontrolling interest of million from our consolidated balance sheet the net loss from the deconsolidation wa not material other collaboration arrangement that are not individually significant during and we entered into several collaboration equity investment and licensing arrangement well other similar arrangement that we do not consider to be individually material we recorded upfront collaboration expense related to these arrangement of million million and million for the year ended december and respectively within acquired in process research and development expense on our consolidated statement of income cash payment for our equity investment other than those noted above during the year ended december and were million million and million respectively which were primarily recorded within prepaid and other current asset and other long term asset on our consolidated balance sheet the financial term of these arrangement we may be required to make payment upon achievement of various developmental regulatory and commercial milestone which could be significant future milestone payment if any will be reflected in our consolidated statement of income when the corresponding event become probable in connection with the regulatory approval milestone payment made will be capitalized intangible asset and will be amortized to cost of good sold through the term of these collaboration arrangement in addition we may be required to pay significant royalty on future sale if product related to these arrangement are commercialized the payment of these amount however is contingent upon the occurrence of various future event which have high degree of uncertainty debt and credit facilitiesthe following table summarizes the carrying amount of our borrowing under various financing arrangement in million december type of borrowingissue datedue dateinterest unsecuredmarch senior unsecuredseptember month libor senior unsecureddecember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember month libor senior unsecuredseptember term loanoctober senior unsecuredmarch senior unsecurednovember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember senior unsecureddecember senior unsecuredmarch senior unsecurednovember senior unsecuredseptember senior unsecuredseptember senior unsecuredseptember total senior unsecured note and term loan liability related to future total debt le current portion of long term debt and other obligation total long term debt net senior unsecured note and term loan facilityin we repaid billion of debt consisting of billion senior unsecured note and billion of our senior unsecured term loan facility we repaid billion of senior unsecured note due april in the first quarter of and billion of senior unsecured note due december in the third quarter of additionally we repaid million of senior unsecured floating rate note due upon maturity in september in october we exercised our option to call million of senior unsecured floating rate note and million of senior unsecured note both having final maturity date of september these two early repayment totaling billion principal amount were made in the fourth quarter of in december we exercised our option to call million of senior unsecured note having final maturity of march the note were repaid in february no new debt wa issued in our senior unsecured fixed rate note may be redeemed at our option at redemption price equal to the greater of of the principal amount of the note to be redeemed and ii the sum determined by an independent investment banker of the present value of the remaining scheduled payment of principal and interest on the note to be redeemed exclusive of interest accrued to the date of redemption discounted to the redemption date on semiannual basis at the treasury rate plus make whole premium defined in the indenture the senior unsecured fixed rate note also have call feature exercisable at our option to redeem the note at par in whole or in part on date ranging from one month to two year prior to maturity in each case accrued and unpaid interest is also required to be redeemed to the date of redemption the billion of senior unsecured note due september also have call feature exercisable at our option to redeem the note at par in whole or in part after september in the event of the occurrence of change in control and downgrade in the rating of our senior unsecured note below investment grade by moody investor service inc and global rating the holder may require to purchase all or portion of their note at price equal to of the aggregate principal amount of the note repurchased plus accrued and unpaid interest to the date of repurchase we are required to comply with certain covenant under our note indenture governing our senior unsecured note of december and we were not in violation of any covenant in september we entered into commitment letter with group of institutional lender to provide for three year senior unsecured term loan facility in an aggregate principal amount of billion in october in connection with our acquisition of immunomedics we entered into term loan credit agreement the term loan facility and borrowed an aggregate principal amount of billion in we repaid billion principal amount outstanding under the term loan facility which wa due upon maturity in october liability related to future royaltiesin connection with our acquisition of immunomedics we assumed liability related to funding arrangement which wa originally entered into by immunomedics and rpi prior to our acquisition of immunomedics the liability related to future royalty wa primarily included in long term debt net on our consolidated balance sheet see note acquisition for additional information revolving credit facilitiesin june we terminated our billion five year revolving credit facility maturing in may the revolving credit facility and entered into new billion five year revolving credit facility maturing in june the revolving credit facility the revolving credit facility can be used for working capital requirement and for general corporate purpose including without limitation acquisition of december and there were no amount outstanding under the revolving credit facility the revolving credit facility contains customary representation warranty affirmative and negative covenant and event of default of december we were in compliance with all covenant loan under the revolving credit facility bear interest at either the eurodollar rate plus the applicable percentage or ii the base rate plus the applicable percentage each defined in the revolving credit facility agreement we may terminate or reduce the commitment and may prepay any loan under the credit facility in whole or in part at any time without premium or penalty contractual maturity of financing obligationsthe following table summarizes the aggregate future principal maturity of our senior unsecured note of december in million total interest expenseinterest expense on our debt and credit facility related to the contractual coupon rate and amortization of the debt discount and issuance cost wa billion in and leasesour operating lease consist primarily of property and equipment for our administrative manufacturing and activity some of our lease include option to extend the term for up to year and some include option to terminate the lease within one year after the lease commencement date of december and we did not have material finance lease operating lease expense including variable cost and short term lease wa million million and million in and respectively the following table summarizes balance sheet and other information related to our operating lease december in million except weighted average amount of use asset netother long term asset lease liability currentaccrued and other current liability lease liability noncurrentother long term obligation weighted average remaining lease yearsweighted average discount the following table summarizes other supplemental information related to our operating lease year ended december in million paid for amount included in the measurement of lease liability right of use asset obtained in exchange for lease liability the following table summarizes maturity analysis of our operating lease liability showing the aggregate lease payment of december in million total undiscounted lease le imputed total discounted lease payment commitment and contingency legal proceedingswe are party to various legal action the most significant of these are described below we recognize accrual for such action to the extent that we conclude that loss is both probable and reasonably estimable we accrue for the best estimate of loss within range however if no estimate in the range is better than any other then we accrue the minimum amount in the range if we determine that material loss is reasonably possible and the loss or range of loss can be estimated we disclose the possible loss unless otherwise noted the outcome of these matter either is not expected to be material or is not possible to determine such that we can not reasonably estimate the maximum potential exposure or the range of possible loss in the third quarter of we reversed million previously recorded litigation accrual following favorable court decision for the litigation related to axicabtagene ciloleucel described below in the fourth quarter of we recorded an accrual of billion in accrued and other current liability on our consolidated balance sheet for the settlement related to bictegravir litigation described below related to sofosbuvirin we acquired pharmasset inc through the acquisition we acquired sofosbuvir nucleotide analog that act to inhibit the replication of hcv in we received approval from fda for sofosbuvir now known commercially sovaldi sofosbuvir is also included in all of our marketed hcv product we have received number of litigation claim regarding sofosbuvir while we have carefully considered these claim both prior to and following the acquisition and believe they are without merit we can not predict the ultimate outcome of such claim or range of loss we are aware of patent and patent application owned by third party that have been or may in the future be alleged by such party to cover the use of our hcv product if third party obtain valid and enforceable patent and successfully prove infringement of those patent by our hcv product we could be required to pay significant monetary damage we can not predict the ultimate outcome of intellectual property claim related to our hcv product we have spent and will continue to spend significant resource defending against these claim litigation with the university of minnesotathe university of minnesota the university ha obtained patent no the patent which purport to broadly cover nucleoside with antiviral and anticancer activity in the university filed lawsuit against in the district court for the district of minnesota alleging that the commercialization of sofosbuvir containing product infringes the patent we believe the patent is invalid and will not be infringed by the continued commercialization of sofosbuvir in the court granted our motion to transfer the case to california we have also filed petition for inter partes review with the patent and trademark office patent trial and appeal board ptab alleging that all asserted claim are invalid for anticipation and obviousness the ptab instituted one of these petition and merit hearing wa held in february in the district court for the northern district of california stayed the litigation until after the ptab concludes the inter partes review that it ha initiated in may the ptab issued written decision finding the asserted claim of the university patent invalid in july the university appealed this decision the litigation in the district court will remain stayed through the appeal proceeding litigation with nucana plc nucana nucana ha obtained european patent no the ep patent that allegedly cover sofosbuvir in opposition proceeding before the european patent office epo held in february the epo opposition division upheld the validity of the ep patent in amended form we believe that the amended ep patent claim are invalid subsequently we initiated proceeding to invalidate the uk counterpart of the ep patent in the high court of england wale in march nucana filed counterclaim against in the high court of england wale alleging patent infringement of the uk counterpart and seeking damage and other relief in april nucana also filed lawsuit against in germany at the landgericht dsseldorf alleging patent infringement of the german counterpart of the ep patent and seeking damage and injunctive relief the hearing date for the german nucana case ha been scheduled for may the hearing date for the uk nucana case ha been scheduled for january litigation related to axicabtagene ciloleucelin october juno therapeutic inc and sloan kettering cancer center collectively juno filed lawsuit against in the district court for the central district of california alleging that the commercialization of axicabtagene ciloleucel sold commercially yescarta infringes on patent no the patent jury trial wa held on the patent and in december the jury found that the asserted claim of the patent were valid and that we willfully infringed the asserted claim of the patent the jury also awarded juno damage in amount of million in an upfront payment and running royalty from october through the date of the jury verdict the party filed post trial motion in the first quarter of and the trial judge entered judgment in april the trial judge affirmed the jury verdict enhanced the past damage by and maintained the royalty on future yescarta sale at in april we filed an appeal seeking to reverse the judgment or obtain new trial due to error made by the trial judge and in july the appeal court heard oral argument in august the court of appeal for the federal circuit the cafc reversed the jury verdict finding the asserted claim of juno patent invalid in october juno filed petition for rehearing with the cafc in january the cafc denied juno petition for rehearing we believe that the likelihood of material adverse outcome in this matter is remote litigation related to bictegravirin viiv healthcare company vhc filed lawsuit against in the district court of delaware alleging that the commercialization of bictegravir sold commercially in combination with tenofovir alafenamide and emtricitabine biktarvy infringes vhc patent no the patent covering vhc dolutegravir bictegravir is structurally different from dolutegravir and we believe that bictegravir doe not infringe the claim of the patent in it lawsuit vhc wa seeking billion of dollar for alleged damage comprised of vhc lost profit and royalty on sale of bictegravir from launch through the trial in addition should court find that we are liable for infringement we also expected vhc to seek royalty on sale after the trial vhc also filed lawsuit against in the federal court of canada alleging that our activity relating to our bictegravir compound infringes vhc canadian patent no the patent which wa issued to shionogi co ltd and vhc the patent is the compound patent covering vhc dolutegravir we believe that bictegravir doe not infringe the claim of the patent in november and december vhc filed lawsuit in france germany ireland and the uk asserting the relevant national designation of european patent no in australia asserting australian patent no in japan asserting japanese patent no and in korea asserting korean patent no and these patent all relate to molecule that vhc claim would act integrase inhibitor we believe that bictegravir doe not infringe any valid claim of vhc patent and have prevailed in court proceeding to date in canada and germany on february gilead reached an agreement the settlement with vhc viiv healthcare uk no limited viiv healthcare uk limited shionogi co ltd and glaxosmithkline mercury limited collectively viiv for global resolution of all pending or potential claim related to gilead sale of biktarvy including the litigation pending in the district court of delaware and other jurisdiction outside the united state described above in february the lawsuit pending in the united state wa dismissed well the lawsuit in canada france ireland the uk australia japan and korea pursuant to the term of the settlement viiv grant gilead broad worldwide license and covenant not to sue relating to any past present or future development or commercialization of bictegravir in connection with the settlement gilead made one time payment to viiv of billion in the first quarter of and will provide viiv an ongoing royalty at rate of on future sale of biktarvy and the bictegravir component of bictegravir containing product in the united state until october in connection with the settlement gilead recorded pre tax charge of billion to cost of good sold on our consolidated statement of income in the fourth quarter of litigation relating to pre exposure prophylaxisin august we filed petition requesting inter partes review of patent no and collectively hhs patent by ptab the hhs patent are assigned to the department of health and human service hhs and purport to claim process of protecting primate host from infection by an immunodeficiency retrovirus by administering combination of emtricitabine or tenofovir disoproxil fumarate tdf prior to exposure of the host to the immunodeficiency retrovirus process commonly known pre exposure prophylaxis prep in november the department of justice filed lawsuit against in the district court of delaware alleging that the sale of truvada and descovy for use prep infringes the hhs patent in february ptab declined to institute our petition for inter partes review of the hhs patent in april we filed breach of contract lawsuit against the federal government in the court of federal claim alleging violation of four material transfer agreement mtas related to the research underlying the hhs patent and clinical trial agreement cta by the center for disease control and prevention related to prep research although we can not predict with certainty the ultimate outcome of these litigation matter we believe that the federal government breached the mtas and cta that truvada and descovy do not infringe the hhs patent and that the hhs patent are invalid over prior art description of truvada use for prep and post exposure prophylaxis well because physician and patient were using the claimed method year before hhs filed the application for the patent trial date for the lawsuit in the court of federal claim ha been set for june and trial date for the lawsuit in the district court of delaware ha been set for may litigation with generic manufacturersas part of the approval process for some of our product fda granted new chemical entity nce exclusivity period during which other manufacturer application for approval of generic version of our product will not be approved generic manufacturer may challenge the patent protecting product that have been granted nce exclusivity one year prior to the end of the nce exclusivity period generic manufacturer have sought and may continue to seek fda approval for similar or identical drug through an abbreviated new drug application anda the application form typically used by manufacturer seeking approval of generic drug the sale of generic version of our product prior to their patent expiration would have significant negative effect on our revenue and result of operation to seek approval for generic version of product having nce status generic company may submit it anda to fda four year after the branded product approval starting in december we received letter from lupin ltd apotex inc shilpa medicare ltd shilpa sunshine lake pharma co ltd sunshine lake laurus lab natco pharma ltd macleod pharma ltd hetero lab ltd and cipla ltd collectively generic manufacturer indicating that they have submitted andas to fda requesting permission to market and manufacture generic version of certain of our taf containing product between them these generic manufacturer seek to market generic version of odefsey descovy and vemlidy the generic manufacturer have challenged the validity of two to four patent listed on the orange book and associated with taf we filed lawsuit against the generic manufacturer and we intend to enforce and defend our intellectual property in november we reached an agreement with shilpa to resolve the lawsuit against shilpa in addition in january we reached an agreement with sunshine lake to resolve the lawsuit against sunshine lake the settlement agreement have been filed with the federal trade commission and the department of justice required by law october we received letter from lupin ltd lupin indicating that it ha submitted an anda to fda requesting permission to market and manufacture generic version of symtuza product commercialized by janssen and for which gilead share in revenue in november we along with janssen product and janssen filed patent infringement lawsuit against lupin co plaintiff in the district court of delaware we separately filed an additional lawsuit against lupin asserting infringement of two additional patent in the same court european patent claimsin several party filed opposition in the epo requesting revocation of one of our granted european patent covering sofosbuvir that expires in in the epo upheld the validity of certain claim of our sofosbuvir patent we have appealed this decision seeking to restore all of the original claim and several of the original opposing party have also appealed requesting full revocation an appeal hearing originally scheduled for july ha been canceled and new date ha not yet been set by the epo in several party filed opposition in the epo requesting revocation of our granted european patent relating to sofosbuvir that expires in the epo conducted an oral hearing for this opposition in and upheld the claim two of the original opposing party have appealed requesting full revocation in several party filed opposition in the epo requesting revocation of our granted european patent covering taf that expires in in the epo upheld the validity of the claim of our taf patent three party have appealed this decision the appeal hearing wa held in march and the validity of all claim were upheld in several party filed opposition in the epo requesting revocation of our granted european patent relating to taf hemifumarate that expires in in the epo upheld the validity of the claim of our taf hemifumarate patent three party have appealed this decision in three party filed opposition in the epo requesting revocation of our granted european patent covering cobicistat that expires in in the epo upheld the validity of the claim of our cobicistat patent two party have appealed this decision the appeal process may take several year for all epo opposition proceeding while we are confident in the strength of our patent we can not predict the ultimate outcome of these opposition if we are unsuccessful in defending these opposition some or all of our patent claim may be narrowed or revoked and the patent protection for sofosbuvir taf taf hemifumarate and cobicistat in the eu could be substantially shortened or eliminated entirely if our patent are revoked and no other european patent are granted covering these compound our exclusivity may be based entirely on regulatory exclusivity granted by ema if we lose patent protection for any of these compound our revenue and result of operation could be negatively impacted for the year including and succeeding the year in which such exclusivity is lost antitrust and consumer protectionwe along with bristol myers squibb company bm and johnson johnson inc have been named defendant in class action lawsuit filed in and related to various drug used to treat hiv including drug used in combination antiretroviral therapy plaintiff allege that we and the other defendant engaged in various conduct to restrain competition in violation of federal and state antitrust law and state consumer protection law the lawsuit which have been consolidated are pending in the district court for the northern district of california the lawsuit seek to bring claim on behalf of two nationwide class one of direct purchaser consisting largely of wholesaler and another of indirect or end payor purchaser including health insurer and individual patient plaintiff seek damage permanent injunctive relief and other relief in the fall of several plaintiff filed separate lawsuit effectively opting out of the class action case asserting claim that are substantively the same the putative class these case have been coordinated with the class action trial is set for march in september we along with generic manufacturer cipla ltd and cipla usa inc together cipla were named defendant in class action lawsuit filed in the district court for the northern district of california by jacksonville police officer and fire fighter health insurance trust jacksonville trust on behalf of end payor purchaser jacksonville trust claim that the settlement agreement between and cipla which settled patent dispute relating to patent covering our emtriva truvada and atripla product and permitted generic entry prior to patent expiry violates certain federal and state antitrust and consumer protection law the plaintiff seek damage permanent injunctive relief and other relief in february we along with bm and teva pharmaceutical industry ltd were named defendant in lawsuit filed in the first judicial district court for the state of new mexico county of santa fe by the new mexico attorney general the new mexico attorney general alleges that we and the other defendant restrained competition in violation of new mexico antitrust and consumer protection law the new mexico attorney general seek damage and other relief while we believe these case are without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage or could be subject to permanent injunctive relief awarded in favor of plaintiff liabilitywe have been named defendant in one class action lawsuit and various product liability lawsuit related to viread truvada atripla complera and stribild plaintiff allege that viread truvada atripla complera and or stribild caused them to experience kidney bone and or tooth injury the lawsuit which are pending in state or federal court in california delaware maryland missouri and new jersey involve more than plaintiff plaintiff in these case seek damage and other relief on various ground for alleged personal injury and economic loss we intend to vigorously defend ourselves in these action while we believe these case are without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage government investigationin we received subpoena from the attorney office for the southern district of new york requesting document related to our promotional speaker program for hiv we are cooperating with this inquiry qui tam litigationa former sale employee filed qui tam lawsuit against gilead in march in district court for the eastern district of pennsylvania following the government decision not to intervene in the suit the case wa unsealed in december the lawsuit alleges that certain of gilead hcv sale and marketing activity violated the federal false claim act and various state false claim act the relator seek all available relief under these statute two former employee filed qui tam lawsuit against gilead in april in california state court following the california attorney general office decision not to intervene relators served gilead with their complaint in august the complaint alleges violation of the california false claim act cfca and employment law claim relators seek all available relief under the cfca in december gilead and relators executed settlement agreement to resolve the lawsuit and in february the court issued an order dismissing the lawsuit with prejudice the settlement doe not have material impact to our consolidated financial statement health choice advocate llc health choice filed qui tam lawsuit against gilead in april in new jersey state court following the new jersey attorney general office decision not to intervene in the suit health choice served with their original complaint in august the lawsuit alleges that gilead violated the new jersey false claim act through our clinical educator program for sovaldi and harvoni and our hcv and hiv patient access program the lawsuit seek all available relief under the new jersey false claim act in april the trial court granted our motion to dismiss with prejudice health choice ha appealed the trial court dismissal health choice filed another qui tam lawsuit against gilead in may making similar allegation in texas state court following the texas attorney general office decision not to intervene in the suit health choice served with their original complaint in october the lawsuit alleges that gilead violated the texas medicare fraud prevention act tmfpa through our clinical educator program for sovaldi and harvoni and our hcv and hiv patient access program the lawsuit seek all available relief under the tmfpa in september the texas court of appeal for the sixth court appeal district granted our request to stay the texas litigation the case is stayed pending final judgment in the eastern district of pennsylvania lawsuit filed in march discussed above we intend to vigorously defend ourselves in these action while we believe these case are without merit we can not predict the ultimate outcome if any of these plaintiff are successful in their claim we could be required to pay significant monetary damage security litigationimmunomedics and several of it former officer and director have been named defendant in putative class action filed in and which were consolidated in september plaintiff filed consolidated complaint in november and an amended complaint in july plaintiff allege that immunomedics and the individual defendant violated the federal security law in connection with immunomedics biologics license application for trodelvy and seek certification of class of shareholder damage and other relief the consolidated lawsuit is pending in the district court for the district of new jersey while we believe this case is without merit we can not predict the ultimate outcome if plaintiff are successful in their claim we could be required to pay significant monetary damage other matterswe are party to various legal action that arose in the ordinary course of our business we do not believe that these other legal action will have material adverse impact on our consolidated business financial position or result of operation commitment in the normal course of business we enter into firm purchase commitment related to inventory of december these commitment for the next five year were approximately billion in million in million in million in and million in stockholder equity stock repurchase programsin the first quarter of our board of director authorized billion stock repurchase program program under which repurchase may be made in the open market or in privately negotiated transaction we started repurchase under the program in april in the first quarter of our board of director authorized new billion stock repurchase program program which will commence upon the completion of the program purchase under the program may be made in the open market or in privately negotiated transaction of december the remaining authorized repurchase amount under both program wa billion the following table summarizes our stock repurchase under the program year ended december in million except per share amount repurchased and amount average price per share in addition to repurchase from the program and program we repurchased share of common stock withheld by from employee restricted stock award to satisfy our applicable tax withholding obligation these share are excluded from the table above we use the par value method of accounting for our stock repurchase under the par value method common stock is first charged with the par value of the share involved the excess of the cost of share acquired over the par value is allocated to additional paid in capital based on an estimated average sale price per issued share with the excess amount charged to retained earnings dividendsthe following table summarizes cash dividend declared on our common stock in million except per share amount dividend per shareamountdividend per shareamountfirst quarter second third fourth total our restricted stock and performance share award or unit have dividend equivalent right entitling holder to dividend equivalent to be paid upon vesting for each share of the underlying unit on february we announced that our board of director declared quarterly cash dividend of per share of our common stock with payment date of march to all stockholder of record of the close of business on march future dividend are subject to declaration by our board of director preferred stockwe have million share of authorized preferred stock issuable in series our board is authorized to determine the designation power preference and right of any such series there wa no preferred stock outstanding of december and other comprehensive income the following table summarizes the change in aoci by component net of tax in million foreign currency translation net of taxunrealized gain and loss on available for sale debt security net of taxunrealized gain and loss on cash flow hedge net of taxtotalbalance of december net unrealized gain reclassification to net income net current period other comprehensive income loss balance of december net unrealized gain loss reclassification to net income net current period other comprehensive income loss balance of december net unrealized gain loss reclassification to net income net current period other comprehensive income loss balance of december the amount reclassified to net income for gain and loss on cash flow hedge are recorded part of product sale on our consolidated statement of income see note derivative financial instrument for additional information the amount reclassified to net income for gain and loss on available for sale debt security are recorded part of other income expense net on our consolidated statement of income the income tax impact allocated to each component of other comprehensive income wa not material for the period presented employee benefit equity incentive plan in may our stockholder approved and we adopted the gilead science inc equity incentive plan amended the plan the plan authorized the issuance of total of million share of common stock part of the forty seven acquisition we assumed the forty seven inc equity incentive plan which we subsequently amended and restated the gilead science inc equity incentive plan amended and restated the plan the aggregate amount of share that may be issued under the plan on or after the assumption date will not exceed million share part of the immunomedics acquisition we assumed the immunomedics amended and restated long term incentive plan the immunomedics plan and referred together with the plan and plan the plan which we subsequently merged into the plan the aggregate amount of share that may be issued under the immunomedics plan on or after the assumption date will not exceed million share see note acquisition for additional information on the settlement of stock award the plan are broad based incentive plan that provide for the grant of equity based award including stock option restricted stock unit restricted stock award and performance share award to employee director and consultant of december total of million share remain available for future grant under the plan stock option the plan provide for option grant designated either non qualified or incentive stock option all stock option granted after january have been non qualified stock option employee stock option generally vest over three or four year all option are exercisable over period not to exceed the contractual term of ten year from the date the stock option are issued and are granted at price not le than the fair market value of our common stock on the grant date stock option exercise are settled with common stock from the plan previously authorized and available pool of share following table summarizes activity and related information under our stock option plan all option grant presented in the table had exercise price not le than the fair value of the underlying common stock on the grant date share in million weighted averageexercise price in dollar weighted average remaining contractual term year aggregate intrinsic value in million outstanding of december forfeited expired exercised outstanding of december exercisable of december expected to vest net of estimated forfeiture of december aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted average exercise price multiplied by the number of option outstanding or exercisable total intrinsic value of option exercised wa million million and million for and respectively the weighted average grant date fair value of the stock option granted wa per share per share and per share for and respectively of december there wa million of unrecognized compensation cost related to stock option which is expected to be recognized over an estimated weighted average period of year restricted stock and performance share awardswe grant time based rsus to certain employee part of our annual employee equity compensation review program well to new hire employee and to non employee member of our board rsus are share based award that entitle the holder to receive freely tradable share of our common stock upon vesting rsus generally vest over three or four year from the date of grant the fair value of an rsu is equal to the closing price of our common stock on the grant date we grant psus which vest upon the achievement of specified market or performance goal which could include achieving total shareholder return compared to pre determined peer group or achieving revenue target the actual number of common share ultimately issued is calculated by multiplying the number of psus by payout percentage ranging from to and these award generally vest only when committee or subcommittee of our board ha determined that the specified market and performance goal have been achieved the fair value of each psu is estimated at the date of grant or when performance objective are defined for the grant depending on the term of the award fair value on the date of grant is determined based on either the monte carlo valuation methodology or the closing stock price on the date of grant in addition we have also granted other psus to certain of our employee under the plan the vesting of these award is subject to the achievement of specified individual performance goal typically within one to two year period the fair value of such an award is equal to the closing price of our common stock on the grant date the following table summarizes our rsu and psu activity and related information rsuspsus in million except per share amount sharesweighted averagegrant date fair value per shareshares weighted averagegrant date fair value per share outstanding of december vested forfeited outstanding of december ________________________________ weighted average grant date fair value per share excludes share related to grant that currently have no grant date the performance objective have not yet been defined weighted average grant date fair value of rsus granted wa per share per share and per share for and respectively the weighted average grant date fair value of psus granted wa per share per share and per share for and respectively the total grant date fair value of our vested rsus and psus wa million million and million for and respectively and total fair value of the respective vesting date wa million million and million for and respectively of december there wa million of unrecognized compensation cost related to unvested rsus and psus which is expected to be recognized over weighted average period of year employee stock purchase planunder our employee stock purchase plan and the international employee stock purchase plan together amended the espp employee can purchase share of our common stock based on percentage of their compensation subject to certain limit the purchase price per share is equal to the lower of of the fair market value of our common stock on the offering date or the purchase date the espp offer six month look back feature well an automatic reset feature that provides for an offering period to be reset to new lower priced offering if the offering price of the new offering period is le than that of the current offering period espp purchase are settled with common stock from the espp previously authorized and available pool of share during million share were issued under the espp for million total of million share of common stock have been authorized for issuance under the espp and there were million share available for issuance under the espp of december stock based compensationthe following table summarizes total stock based compensation expense included on our consolidated statement of income year ended december in million of good sold research and development selling general and administrative stock based compensation expense included in total cost and expense income tax effect stock based compensation expense net of tax ________________________________ pre tax stock based compensation expense for the year ended december of billion included million non cash stock based expense and million and million of accelerated post acquisition stock based expense related to the acquisition of immunomedics and forty seven respectively see note acquisition for additional information income tax effect for the year ended december included million income tax expense following the court of appeal decision in altera corp commissioner which requires related party in an intercompany cost sharing arrangement to share expense related to stock based compensation stock based compensation is recognized expense over the requisite service period on our consolidated statement of income using the straight line expense attribution approach reduced for estimated forfeiture we estimate forfeiture based on our historical experience the requisite service period could be shorter than the vesting period if an employee is retirement eligible valuation assumptionsfair value of option granted under our plan and purchase under our espp were estimated at grant or purchase date using black scholes option valuation model the black scholes option valuation model wa developed for use in estimating the fair value of traded option which have no vesting restriction and are fully transferable in addition option valuation model require the input of highly subjective assumption including expected stock price volatility and expected award life used the following assumption to calculate the estimated fair value of the award year ended december volatility stock expected term in year stock free interest rate stock expected dividend the fair value of stock option granted wa calculated using the single option approach we use blend of historical volatility along with implied volatility for traded option on our common stock to determine our expected volatility the expected term of stock based award represents the weighted average period the award are expected to remain outstanding we estimate the weighted average expected term based on historical cancellation and historical exercise data related to our stock option well the contractual term and vesting term of the award the risk free interest rate is based upon observed interest rate appropriate for the term of the stock based award the dividend yield is based on our history and expectation of dividend payouts deferred compensationwe maintain retirement saving plan under which eligible employee may defer compensation for income tax purpose under section of the internal revenue code the gilead science plan in certain foreign subsidiary we maintain defined benefit plan required by local regulatory requirement our total matching contribution expense under the gilead science plan and other defined benefit plan wa million million and million during and respectively we maintain deferred compensation plan under which our director and key employee may defer compensation amount deferred by participant are deposited into rabbi trust the total asset and liability associated with the deferred compensation plan were million and million of december and respectively net income per share attributable to gilead common stockholdersbasic net income per share attributable to gilead common stockholder is calculated based on the weighted average number of share of our common stock outstanding during the period diluted net income per share attributable to gilead common stockholder is calculated based on the weighted average number of share of our common stock and other dilutive security outstanding during the period the potentially dilutive share of our common stock resulting from the assumed exercise of outstanding stock option and equivalent were determined under the treasury stock method potential share of common stock excluded from the computation of diluted net income per share attributable to gilead common shareholder because their effect would have been antidilutive were million million and million during and respectively the following table show the calculation of basic and diluted net income per share attributable to gilead common stockholder year ended december in million except per share amount income attributable to gilead share used in per share calculation dilutive effect of stock option and share used in per share calculation diluted net income per share attributable to gilead common stockholder basic net income per share attributable to gilead common stockholder diluted income tax income before income tax consists of the following year ended december in million foreign income before income tax the income tax expense benefit consists of the following year ended december in million current state current deferred foreign current income tax expense benefit the income tax benefit included billion deferred tax benefit related to intangible asset transfer from foreign subsidiary to ireland and the united state in the fourth quarter of we completed an intra entity asset transfer of certain intangible asset from foreign subsidiary to ireland the transaction resulted in step up of the irish tax deductible basis in the transferred asset and accordingly created temporary difference where the tax basis exceeded the financial statement basis of such intangible asset result we recognized deferred tax asset of billion on our consolidated financial statement we expect to be able to realize the deferred tax asset resulting from this intra entity asset transfer the impact of the intangible asset transfer from foreign subsidiary to the united state wa not material the reconciliation between the federal statutory tax rate applied to income before income tax and our effective tax rate is summarized follows year ended december statutory state tax net of federal foreign earnings at different rate research and other credit tax on foreign foreign derived intangible income deduction deferred tax intra entity transfer of intangible asset settlement of tax examination acquired ipr and related charge change in valuation non taxable unrealized gain loss on effective tax income tax reflect the net tax effect of temporary difference between the carrying amount of asset and liability for financial reporting purpose and the amount used for income tax purpose significant component of our deferred tax asset and liability are follows december in million tax asset net operating loss carryforwards stock based reserve and accrual not currently excess of tax basis over book basis of intangible upfront and milestone research and other credit equity liability related to future other total deferred tax asset before valuation valuation allowance total deferred tax deferred tax liability property plant and equipment excess of book basis over tax basis of intangible asset other total deferred tax liability net deferred tax asset liability the valuation allowance wa million and million of december and respectively the increase of our valuation allowance in wa primarily related to california research and development tax credit the valuation allowance wa million and million of december and respectively the increase of our valuation allowance in wa primarily related to acquired attribute related to forty seven and immunomedics acquisition and capital loss related to our equity method investment of december we had federal net operating loss and tax credit carryforwards of approximately million and million respectively which will start to expire in if not utilized in addition we had state net operating loss and tax credit carryforwards of approximately billion and million respectively the state net operating loss and state tax credit carryforwards will start to expire in if not utilized utilization of net operating loss and tax credit may be subject to an annual limitation due to ownership change limitation provided in the internal revenue code of amended and similar state provision this annual limitation may result in the expiration of the net operating loss and credit before utilization we file federal state and foreign income tax return in the united state and in many foreign jurisdiction for federal income tax purpose the statute of limitation is open for and onwards and and onwards for california income tax purpose for certain acquired entity the statute of limitation is open for all year from inception due to our utilization of their net operating loss and credit carried over from prior year our income tax return are subject to audit by federal state and foreign tax authority we are currently under examination by the internal revenue service and irish tax authority for our to tax year there are differing interpretation of tax law and regulation and result significant dispute may arise with these tax authority involving issue of the timing and amount of deduction and allocation of income among various tax jurisdiction we periodically evaluate our exposure associated with our tax filing position the total unrecognized tax benefit million and billion of december and respectively if recognized would reduce our effective tax rate in the period of recognition interest and penalty related to unrecognized tax benefit included income tax expense of million income tax benefit of million and income tax expense of million on our consolidated statement of income for the year ended december and respectively accrued interest and penalty related to unrecognized tax benefit were million and million of december and respectively of december we believe that it is reasonably possible that our unrecognized tax benefit will decrease by approximately million in the next month due to potential settlement with various taxing authority the following is rollforward of our total gross unrecognized tax benefit year ended december in million beginning of period tax position related to current year reduction tax position related to prior year reduction settlement lapse of statute of limitation balance end of period in connection with the tax cut and job act we recorded federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight year period of december and we have accrued billion and billion respectively for transition tax of the amount accrued of december approximately million is expected to be paid within one year change in and disagreement with accountant on accounting and financial disclosure not applicable of independent registered public accounting firmto the stockholder and the board of director of gilead science inc opinion on internal control over financial reporting we have audited gilead science inc internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion gilead science inc the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of income comprehensive income stockholder equity and cash flow for each of the three year in the period ended december and the related note and our report dated february expressed an unqualified opinion thereon basis for opinion the company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reporting company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llpsan jose californiafebruary control and procedure evaluation of disclosure control and procedure an evaluation of december wa carried out under the supervision and with the participation of our management including our chief executive officer and chief financial officer of the effectiveness of our disclosure control and procedure which are defined in rule and under the security exchange act of amended the exchange act control and other procedure of company that are designed to ensure that the information required to be disclosed by company in the report that it file or submits under the exchange act is recorded processed summarized and reported within the time period specified in the security and exchange commission rule and form and that such information is accumulated and communicated to the company management including it chief executive officer and chief financial officer appropriate to allow timely decision regarding required disclosure based upon that evaluation our chief executive officer and chief financial officer concluded that our disclosure control and procedure were effective of december management report on internal control over financial reporting our management is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule and of the exchange act our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statement for external purpose in accordance with generally accepted accounting principle all internal control system no matter how well designed have inherent limitation and can provide only reasonable assurance that the objective of the internal control system are met under the supervision and with the participation of our management including our chief executive officer and chief financial officer we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criterion established by the committee of sponsoring organization of the treadway commission coso in it internal control integrated framework based on our evaluation we concluded that our internal control over financial reporting wa effective of december our independent registered public accounting firm ernst young llp ha audited our consolidated financial statement included in item of this annual report on form and have issued report on our internal control over financial reporting of december it report on the audit of internal control over financial reporting appears above change in internal control over financial reporting our management including our chief executive officer and chief financial officer ha evaluated any change in our internal control over financial reporting that occurred during the quarter ended december and ha concluded that there wa no change during such quarter that ha materially affected or is reasonably likely to materially affect our internal control over financial reporting item other informationnot applicable item disclosure regarding foreign jurisdiction that prevent inspectionsnot applicable part iii item director executive officer and corporate governance the information required by this item concerning our director and executive officer is incorporated by reference to the section of our definitive proxy statement to be filed with the security and exchange commission pursuant to regulation in connection with our annual meeting of stockholder the proxy statement under the heading the gilead board of director nominee board structure executive officer and if applicable delinquent section report our written code of ethic applies to all of our director and employee including our executive officer including without limitation our principal executive officer principal financial officer principal accounting officer or controller or person performing similar function the code of ethic is available on our website at www gilead com in the investor section under corporate governance we intend to disclose future amendment to certain provision of the code of ethic and waiver of the code of ethic granted to executive officer and director on the website within four business day following the date of the amendment or waiver executive compensation the information required by this item is incorporated by reference to the section of the proxy statement under the heading executive compensation committee of our board of director compensation and talent committee report and compensation of non employee board member item security ownership of certain beneficial owner and management and related stockholder mattersthe information required by this item is incorporated by reference to item of our annual report on form under the heading equity compensation plan information and the section of the proxy statement under the heading security ownership of certain beneficial owner and management item certain relationship and related transaction and director independence the information required by this item is incorporated by reference to the section of the proxy statement under the heading the gilead board of director and board process item principal accountant fee and service the information required by this item is incorporated by reference to the section of the proxy statement under the heading principal accountant fee and service part iv item exhibit and financial statement schedule the following document are filed part of this annual report on form index list to consolidated financial statement report of independent registered public accounting firm pcaob id consolidated financial statement consolidated balance statement of statement of comprehensive income loss statement of stockholder statement of cash to consolidated financial all other schedule are omitted because they are not required or the required information is included in the financial statement or note thereto exhibit the following exhibit are filed herewith or incorporated by reference exhibitfootnoteexhibit numberdescription of document and plan of merger dated september among immunomedics inc gilead science inc and maui merger sub inc and plan of merger by and among forty seven inc registrant and toro merger sub inc dated march certificate of incorporation of registrant and restated bylaw of registrant related to senior note dated of march between registrant and well fargo national association trustee supplemental indenture related to senior note dated of march between registrant and well fargo national association trustee including form of senior note supplemental indenture related to senior note dated of december between registrant and well fargo national association trustee including form of note supplemental indenture related to senior note dated of march between registrant and well fargo national association trustee including form of note and form of note supplemental indenture related to senior note dated of november between registrant and well fargo national association trustee including form of note and form of note supplemental indenture dated of september between registrant and well fargo bank national association trustee including form of note form of note and form of note supplemental indenture dated of september between registrant and well fargo bank national association trustee including form of note form of note form of note and form of note supplemental indenture dated of september between the registrant and well fargo bank national association trustee including form of note of registrant security gilead science inc equity incentive plan amended and restated may amendment no to gilead science inc equity incentive plan amended and restated may form of employee stock option agreement under equity incentive plan for grant made in through form of employee stock option agreement under equity incentive plan for grant made in form of global employee stock option agreement under equity incentive plan year vest for grant made in form of global employee stock option agreement under equity incentive plan year vest for grant made in form of global employee stock option agreement under equity incentive plan year vest for grant commencing in form of non employee director stock option agreement under equity incentive plan for grant made in through form of non employee director stock option agreement under equity incentive plan for grant made in form of non employee director stock option agreement non under equity incentive plan for grant made in form of non employee director stock option agreement under equity incentive plan for grant made in through form of non employee director stock option agreement under equity incentive plan for grant made in form of non employee director stock option agreement under equity incentive plan for grant commencing in form of performance share award agreement tsr goal under equity incentive plan for grant made in form of performance share award agreement tsr goal under equity incentive plan for grant made in form of performance share award agreement tsr goal under equity incentive plan for grant commencing in form of performance share award agreement revenue goal under equity incentive plan for grant made in form of performance share award agreement revenue goal under equity incentive plan for grant made in form of performance share award agreement revenue goal under equity incentive plan for grant commencing in form of employee restricted stock unit issuance agreement under equity incentive plan for grant made in through form of employee restricted stock unit issuance agreement under equity incentive plan for grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant made in form of global employee restricted stock unit issuance agreement under equity incentive plan year vest for grant commencing in form of non employee director restricted stock unit issuance agreement under equity incentive plan for grant commencing in gilead science inc equity incentive plan amended and restated april gilead science inc employee stock purchase plan amended and restated january gilead science inc deferred compensation plan amended and restated april gilead science inc severance plan amended and restated may gilead science inc corporate annual incentive plan amended and restated january offer letter between registrant and daniel day dated november stock option agreement for daniel day under equity incentive plan performance share award agreement for daniel day for tsr goal in under equity incentive plan performance share award agreement for daniel day for revenue goal in under equity incentive plan form of restricted stock unit issuance agreement for daniel day in under equity incentive offer letter between registrant and johanna mercier dated may letter agreement between registrant and johanna mercier dated may global stock option agreement for johanna mercier in under equity incentive plan restricted stock unit issuance agreement for johanna mercier for performance objective in under equity incentive plan global restricted stock unit issuance agreement for johanna mercier in under equity incentive plan offer letter between registrant and merdad parsey dated september global stock option agreement for merdad parsey in under equity incentive plan global restricted stock unit issuance agreement for merdad parsey in under equity incentive plan form of indemnity agreement entered into between registrant and it director and executive officer form of employee proprietary information and invention agreement entered into between registrant and certain of it officer and key employee form of employee proprietary information and invention agreement entered into between registrant and certain of it officer and key employee revised september agreement dated october between registrant the institute of organic chemistry and biochemistry iocb and rega stichting rega together with the following exhibit the license agreement dated december between registrant iocb and rega the license agreement the license agreement dated october between registrant iocb and rega the october license agreement and the license agreement dated december between registrant iocb and rega the december license agreement agreement between registrant and iocb rega dated december amending the license agreement and the december license agreement amendment agreement to the license agreement between iocb rega and registrant dated august amending the october license agreement and the december license agreement amendment agreement to the license agreement between iocb rega and registrant dated july amending the october license agreement and the december license agreement license agreement by and between registrant successor to triangle pharmaceutical inc glaxo group limited the wellcome foundation limited glaxo wellcome inc and emory university dated may sale agreement by and among registrant emory university and investor trust custodial service ireland limited solely in it capacity trustee of royalty pharma dated july and restated license agreement by and between registrant emory university and investor trust custodial service ireland limited solely in it capacity trustee of royalty pharma dated july and restated evg license agreement by and between japan tobacco inc and registrant dated november agreement by and between registrant gilead science and japan tobacco inc dated november and restated collaboration agreement by and among registrant gilead science ireland uc formerly gilead science limited and janssen ireland dated december agreement by and among kite pharma inc cabaret biotech ltd and dr zelig eshhar dated december license and collaboration agreement by and between galapagos nv and registrant dated july subsidiary of consent of independent registered public accounting power of attorney included on the signature page of this report certification of chief executive officer required by rule or rule of the security exchange act of certification of chief financial officer required by rule or rule of the security exchange act of certification of chief executive officer and chief financial officer required by rule or rule and section of chapter of title of the united state code in xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl sch inline xbrl taxonomy extension schema cal inline xbrl taxonomy extension calculation linkbase def inline xbrl taxonomy extension definition linkbase lab inline xbrl taxonomy extension label linkbase pre inline xbrl taxonomy extension presentation linkbase page interactive data file formatted in inline xbrl included exhibit filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on march and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant current report on form filed on april and incorporated herein by reference filed an exhibit to registrant current report on form filed on december and incorporated herein by reference filed an exhibit to registrant current report on form filed on march and incorporated herein by reference filed an exhibit to registrant current report on form filed on november and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant current report on form filed on september and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended march and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended june and incorporated herein by reference filed an exhibit to registrant current report on form filed on may and incorporated herein by reference filed an exhibit to registrant current report on form filed on december and incorporated herein by reference filed an exhibit to registrant registration statement on form no amended and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended march and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to triangle pharmaceutical inc quarterly report on form filed on november and incorporated herein by reference filed an exhibit to registrant quarterly report on form for the quarter ended september and incorporated herein by reference filed an exhibit to registrant amendment no to annual report on form filed on april and incorporated herein by reference filed an exhibit to registrant annual report on form for the fiscal year ended december and incorporated herein by reference filed an exhibit to kite pharma inc registration statement on form no filed on june and incorporated herein by reference management contract or compensatory plan or arrangement filed herewith furnished herewith certain confidential portion of this exhibit were omitted by mean of marking such portion with an asterisk the mark this exhibit ha been filed separately with the secretary of the security and exchange commission without the mark pursuant to registrant application requesting confidential treatment under rule under the security exchange act of amended certain confidential portion of this exhibit were omitted by mean of marking such portion with the mark because the identified confidential portion are not material and ii would be competitively harmful if publicly disclosed item form summarynone pursuant to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized gilead science inc by daniel day daniel daychairman and chief executive officerpower of attorney know all person by these present that each person whose signature appears below constitutes and appoints daniel day and brett pletcher and each of them true and lawful attorney in fact and agent with full power of substitution and resubstitution for or and in his or her name place and stead in any and all capacity to sign any and all amendment to this report and to file the same with all exhibit thereto and other document in connection therewith with the security and exchange commission granting unto said attorney in fact and agent and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith fully to all intent and purpose might or could do in person hereby ratifying and confirming that all said attorney in fact and agent or any of them or their or his substitute or substitute may lawfully do or cause to be done by virtue hereof pursuant to the requirement of the security exchange act of amended this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated daniel daychairman and chief executive officerfebruary day principal executive officer andrew dickinsonchief financial officerfebruary dickinson principal financial officer diane wilfongsenior vice president and chief accounting officerfebruary wilfong principal accounting officer jacqueline bartondirectorfebruary barton ph jeffrey bluestonedirectorfebruary bluestone ph sandra horningdirectorfebruary horning kelly kramerdirectorfebruary kramer kevin loftondirectorfebruary lofton harish manwanidirectorfebruary manwani javier rodriguezdirectorfebruary rodriguez anthony weltersdirectorfebruary copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next